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Abstract
Investigation of monoclonal antibodies raised to human ovarian carcinoma cell
lines
Allan Blacoe-Masterson
Monoclonal antibodies (MAb) were generated to multidrug resistant (MDR) and 
sensitive variants of the ovarian carcinoma cell line OAW42 which over-express the 
MDR associated protem LRP/MVP MAb 3/B6 was raised to the intrinsically resistant 
variant OAW42-SR Immunofluorescence and immunocytochemical analysis indicated 
that the antigen detected by MAb 3/B6 was expressed primarily on the external surface 
of the plasma membrane but was also found to be expressed in the cytoplasm of a series 
of human MDR cell lmes 3/B6 over-expression was associated primarily with cell lines 
which expressed the LRP/MVP
3/B6 expression was studied in paraffin-embedded normal and malignant adult and in 
foetal tumour tissue There was heterogeneous expression of the 3/B6 antigen and the 
LRP/MVP in normal adult and foetal kidney Low-level LRP/MVP expression was 
observed in 1/10 untreated malignant ovarian tumours while 3/B6 was absent In two 
paired pre- and post-chemotherapy breast tumours sections, 3/B6 expression was 
observed in the post-chemotherapy sections only LRP/MVP expression was also 
observed in these sections
A new commercially available immunoprécipitation protocol based on biotm labelling 
of cellular proteins was extensively modified and improved for this project The MAb 
3/B6 was found to immunoprecipitate a 115 kDa un-glycosylated protein 
Immunoprécipitation experiments with anti-rat vault polyclonal serum, N2 and purified 
rat vault protems mdicated that MAb 3/B6 and LRP-56 (the standard MAb used to 
detect LRP/MVP) did not cross-react Competitive immunocytochemical studies 
confirmed these results Incubation of OAW42-SR cells with MAb 3/B6 did not have 
any effect on adnamycm drug accumulation or cellular proliferation
The antt-OAW42-SR MAb 5/C4 was also characterised by immunofluorescence and 
immunocytochemistry Results from these studies revealed that this MAb recognised a 
cytoplasmic antigen which migrated as 2 protein bands at 110 and 85 kDa by Western 
Blotting Further Western Blotting analysis mdicated that MAb 5/C4 did not cross react 
with purified rat vault particles
The anti-OAW42-S MAb 3/E3 was partially characterised by immunofluorescence and 
immunocytochemistry There did not appear to be any significant difference in 
expression of this antigen m a panel of multidrug resistant cell lines It was not possible 
to determine the molecular weigh of the antigen by Western Blotting or 
immunoprécipitation This suggested that the epitope was destroyed during sample 
preparation
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Introduction
1.1. General introduction
Recent reports have indicated that 7,306 deaths in Ireland could be attributed to cancer 
in 1997 (Irish Cancer Society, 1998). Although a small drop in cancer related deaths has 
been noted in the period from 1992-1994, there has been little change since then. Lung 
cancer accounts for the majority of cancer deaths (20%) while bowel and breast cancer 
were each responsible for about 10% of cancer deaths in 1994 (National Cancer 
Registry, 1997). Although not a significant figure, ovarian cancer accounted for 3% of 
all cancer deaths in Ireland in 1994. World-wide figures indicate an increasing prevalence 
of ovarian malignancies. It is now the fourth greatest cause of cancer death in women 
and the leading cause of gynaecological malignancy in the USA (Boring, 1993; Nahaas, 
1997). Surgery and radiotherapy continue to be the first-line management for ovarian 
cancer, with chemotherapy being the chief follow-up treatment. However, the five year 
survival rate still remains at approximately 20% (Nahaas, 1997). This poor response rate 
is primarily due to the development of primary or recurrent tumours, which are either 
partially, or wholly non-responsive to a broad spectrum of structurally and functionally 
unrelated chemotherapeutic drugs i.e., multidrug resistance, MDR. A number of 
mechanisms of drug resistance have been characterised in multidrug resistant cell lines 
(Section 1.3.) which include the expression of energy dependant transmembrane drug 
efflux pumps such, as P-glycoprotein (Pgp) and multidrug resistance associated protein 
(MRP), (Bellamy, 1996; Clynes, 1993). The role of these proteins in multidrug resistance 
has been greatly enhanced by the use of monoclonal antibodies (MAb) in retrospective 
and functional studies. The recently discovered lung resistance related protein (LRP) has 
been shown to have a significant predictive value in the outcome of ovarian cancer in 
studies with the LRP specific MAb, LRP-56 (Izquierdo et a l, 1995) (Section 1.3.3.1.1). 
LRP is the human homologue of the major vault protein (MVP) a component of 13 MDa 
particles which are highly conserved in a wide variety of species from slime mould to 
man (Section 1.3.3.4.). Although the precise function of these particles has yet to be 
elucidated, they may play an important functional role in multidrug resistance (Section 
1.3.3.13.). The recent isolation and characterisation of MAb to novel proteins expressed 
in multidrug resistant cell lines has revealed a myread of possible candidates for drug 
resistance associated markers (Flens et al., 1997). Similarly the possibility of a non­
functioning form of the LRP/MVP suggested by Moran et al., (1997) indicates that
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multiple forms of these drug resistance proteins may exist, as is illustrated by the recent 
discovery of a number of homologues of MRP (Kool et a l, 1997) Clearly, MAb have a 
role to play in the identification and characterisation of potentially novel multidrug 
resistance mechanisms
1 2. Monoclonal antibodies
The first attempt to isolate homogenous antibodies was undertaken with B cell tumours 
from BALB/c mice where mineral oil was used to induce the tumour (Potter, 1972) The 
cell line derived from this tumour was cloned and found to secrete a homogeneous 
population of antibody, or monoclonal antibodies, (MAb, Honbata and Harris, 1972) 
There was still a major drawback however in that antibodies with a predefined specificity 
could not be produced This problem was solved by Kohler and Milstem (1975) when 
non-secreting B cell tumour cells were fused with splenocytes immunised with a specific 
protem In animals, antibodies are synthesised primarily by terminally differentiated B- 
lymphocytes but due to their limited capacity to grow in culture (not surviving for more 
that a few days) they could not be used as a source of antibody By fusing these cells 
with the immortalised myeloma cells, the antibody producing capabilities of the 
splenocytes could be extended indefinitely From these initial studies, MAb technologies 
have widened to include more sophiciated methods for MAb production These include 
electrofusion, where high voltages are used to physically fuse B-and myeloma cells, 
phage-display where short peptide sequences are expressed on the surface of Ml 3 phage 
In vitro immunisation procedures have become popular over the past number of years 
This method allows the sensitisation of isolated lymphocytes/splenocytes to antigen in 
vitro The two major advantages for in vitro immunisation are the small amount of 
antigen required (as little a 1 ng) and the lack of cellular regulation on the developing 
immune response (Harlow and Lane, 1988) Other developments include advances in 
chimeric and bispecific MAb, which have useful applications in the area of 
immunotherapy and immunoscintigraphy
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1 3 Multidrug resistance
Surgical excision has been the main mode of treatment of solid tumours The basis of 
conventional cancer therapy is the treatment of local or regionalised cancer with surgery 
and/or radiotherapy, and the administration of chemotherapy for disseminated disease 
(Nahaas 1997) With advances in the development of chemotherapeutic drugs and 
treatment regimes, a number of cancers such as acute leukaemias, lymphomas and 
selected solid tumours (including testicular carcinomas and certain childhood 
malignancies) have an increasingly positive prognosis The development of new 
combination therapies have increased the response of other malignancies such as ovarian, 
lung and advanced breast cancer although these cancers remain essentially incurable (de 
Vita, 1989, Izquierdo et a l, 1996b)
One of the major limiting factors in chemotherapy is the existence of drug resistant cells 
which are intrinsically resistant or acquire resistance to chemotherapeutic drugs during 
treatment (Bellamy Dalton and Dor, 1990, Gottesman, 1993) Anticancer chemotherapy 
is essentially based on the capacity to combine a cytotoxic mechanism with a selective 
action of a drug in order to distinguish tumour cells from host cells (Coop, 1993) 
However during chemotherapy the cancer tissues, without modification of their anatomic 
and structural features, are able to change their functional characteristics, becoming 
rapidly resistant to many structurally and functionally unrelated cytotoxic drugs, in this 
way the selectivity of the drug completely vanishes (Clynes, 1993, Coop, 1993) This 
phenomenon is termed multidrug resistance It is not known whether selection of pre­
existing subclones and/or mutation during chemotherapy has occurred in this acquired 
resistance but recent evidence suggests that both modes of development may be in 
operation in ovarian cancer (Moran et a l, 1997, Coley, 1997, Izquierdo et a l, 1996 a,
b)
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Three main changes have been observed in cells that develop the multidrug resistant 
phenotype,
(I) A decrease in cellular accumulation of cytotoxic drug
(II) Changes in cellular physiology affecting the structure of the plasma membrane, 
cytosolic pH and the rates and extent of intracellular transport of membrane as well as 
lysosomal structure and function (Cleary, 1997, Izquierdo, 1998, Gottesman, 1993)
(m) Changes in activity or expression of certain cellular proteins
The dominant feature of MDR cell lines is a decrease in accumulation of cytotoxic drugs 
(Gottesman, 1993) In the laboratory, tumour cell line models have added to the 
knowledge regarding the development of multidrug resistance These cell lines selected 
for resistance to a single cytotoxic drug by repeated exposure to increasing 
concentrations of drug often also display cross resistance to a range of structurally and 
functionally distinct cytotoxic drugs including anthracychnes, vinca alkaloids, 
epipodphylotoxins, taxanes and actynomycin D (Borst, 1991, Biedler, 1992, Clynes,
1993) Frequently the resistance observed in these cell lines is associated with the 
expression of one or more cellular proteins including P-glycoprotein (Pgp), the multidrug 
resistance related protein (MRP) and the lung resistance related human major vault 
protein (LRP/MVP) Over expression of other cellular proteins and mechanisms have 
also been observed such as alterations in topoisomerase II, (Reviewed by Hoffman and 
Mattern, 1993), alterations in the glutathionme system (Reviewed by Moscow and 
Dixon, 1993), and over expression of the T antigen presenting protein (TAP) (Izquierdo 
e ta l, 1997)
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1.3.1 P-glycoprotein
Kessel et al (1968) first reported that anthracycline-drug selected cells appeared to 
accumulate less drug than their unselected parental cell line Further studies indicated 
that this reduction in cellular accumulation of cytotoxic drug was dependent on an ATP 
activated pump which was later identified and named P-glycoprotein (Pgp), (Dano, 1973, 
Julamo and Ling, 1976) Since these initial reports, a wide variety of multidrug resistant 
cell lines have been established in order to study this phenomenon (Clynes, 1993, 
Germann, 1996) It has been observed that many of these cell lines over-express Pgp 
(Beck and Danles, 1991, Hill, 1993, Germann, 1996)
P-glycoprotein (Pgp) has been extensively characterised It is a 170 kDa glycoprotein 
which is primarily associated with the plasma membrane It is comprised of 12 
transmembrane domains and consists of a short highly charged cytoplasmic domain 
followed by 3 additional membrane loops and a second cytoplasmic region (Chen et al, 
1986, Gros et a l, 1986) It has been observed that P-glycoprotein comprises of 2 halves 
of similar structure, the 2 halves are connected by a linker region bridging the amino and 
carboxy halves (van der Blink et a l, 1987) The linker region that conveys drug 
resistance contains sequences for c-AMP and c-GMP dependent protein kinase 
phosphorylation sites and appear to be important for Pgp function (Hsu et a l, 1989)
The functional domains of the Pgp molecule have been analysed by a series of genetic 
and biochemical studies Photoaffinity labelling with drug and drug analogues have 
identified a number of binding sites (Germann et a l, 1993 Germann et a l, 1996) The 
results of these experiments also indicated a major role for the mtracytoplasmic loop and 
transmembrane loop in substrate specificity of the transporter (Bruggerman et a l, 1989, 
1992, Safe et a l, 1989, Busche et a l, 1989)
In humans, 2 closely related genes, mdr-1 and mdr-3 located on chromosome 17q,
encode highly homologous Pgp (Reviewed by Croop , 1993) A number of groups have
observed that the mdr-3 encoded gene product may not be associated with drug
resistance (Chien et a l, 1986, Ueda et a l, 1987, van der Bliek et a l, 1988) However,
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recent evidence suggests that this may now be the case ( Smit et a l, 1993, Larkin et a l, 
1998a) The murine homologue, mdr-2 does, however appear, to be active in transport 
and the secretion of phosphatidylcholine in bile (Smit et al , 1993, Borst and Schinkel, 
1996, El Fannk et a l, 1997) A possible physiological role for Pgp has been 
demonstrated by Schinkel et al (1994, 1995, 1997) where mdr-1 knock out mice which 
appeared phenotypically normal, displayed increased sensitivities to vinblastine, 
dexamethasone and cyclosporin A This sensitivity was attributed to the absence of Pgp 
in the blood brain barrier
Resistance to the vinca alkaloids, anthracyclines, epipodophyllotoxins and taxanes 
observed in human cancer cell lines is frequently caused by the over expression of Pgp 
(Flens, 1997 PhD thesis) Transfection of the mdr-1 gene has shown that Pgp can 
mediate drug resistance directly (Higgins, 1992, Gottesmann et a l, 1993, Endicott and 
Ling, 1989)
The discovery that Pgp belongs to a larger family of ATP-binding cassette transport 
proteins, many of which have clear transport functions has given a better insight into the 
normal physiological role of Pgp (Endicott and Ling, 1989, Gottesman, 1993) The 
mammalian MDR gene family is related to the ATP-binding cassette (ABC) superfamily 
of genes that encode a wide variety of proteins in various species This family of proteins 
is characterised by their 2 ATP-binding sites To date over 50 members have been 
identified (Higgins, 1992) Significant degrees of homology have been demonstrated 
between Pgp and the Hly B protein from Escherichia coh (Juranka et a l, 1989) and the 
leukotoxin secretion protein Ikt in Pasteurella Haemolytica (Strathdee and Lo, 1989) 
Sequence homology has also been observed in humans with the cystic fibrosis trans 
membrane conductance regulator (CFTR) and the TAP 1, TAP 2 and PMP70 proteins 
(Higgins, 1992, Leveille-Webster and Arias, 1995)
Human Pgp is predominantly expressed in the apical membranes of organs with
excretory functions (Georges et a l, 1990, van der Valk et a l, 1990) It is though that
Pgp may play a role in the elimination of exogenous toxins or their toxic metabolites
from the body (Hono et a l, 1989) High levels of mdr-1 mRNA expression has been
observed in the adrenal glands, kidney, liver, small intestine and colon, whereas, low
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levels have been observed in most other tissues (Fojo et a l , 1987)
Immunohistochemically, P-glycoprotein has been detected on the surface of cortical 
cells, the luminal surface of the brush border of the proximal renal tubule, the luminal 
surface of biliary hepatocytes and the mucosal surface of the columnar epithelial cells of 
the small intestine (Thiebaut et a l, 1987, Moran et al 1997b) In human tumours, mdr-l 
expression has been observed in colon, renal carcinoma and adrenocortical heptoma, all 
of which naturally express mdr-l (Goldstein, 1989) Pgp expression has also been 
reported in endometrial and gastric cancers (Schmder et a l, 1993, Robey-Cafferty et a l, 
1991), leukemias, lymphomas and some other tissues which do not normally express the 
mdr-l gene (Rischin and Ling, 1993, Goasguen et a l , 1993) Researchers have also 
observed Pgp expression in breast and ovarian samples (Venerom et a l, 1994, Dixon et 
a l, 1992) Pgp expression is most commonly found in samples from patients who have 
received chemotherapy than from untreated patients (Toffoli et a l, 1992, Dalton et a l, 
1989, Goldstein et a l, 1989) Opinions differ as to the significance of Pgp expression as 
a predictor of poor outcome and survival, many groups have used similar methods but 
have achieved significantly different results (Bater et a l, 1991, Chan et a l, 1991, Favrot 
et a l, 1991) The outcome of the St Jude workshop has suggested the use of more than 
one antibody in an attempt to obtain more consistent results (Beck et al, 1996)
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1.3.2. Multidrug resistance associated protein (MRP)
MRP mRNA was first isolated from H69AR cells by Cole et al, in 1992. Subsequent 
chracterisation revealed that the gene encoding MRP was located on chromosome 16 
position 13.1 and encoded a 1531 amino acid, N-glycosylated integral membrane protein 
with a molecular weight of 190 kDa (Krishnamachary and Centre, 1993; Zaman et al.,
1994). Analysis of the MRP gene reveals that it has similar structural motifs to that of P- 
glycoprotein (Section 1.3.1.), however, it has only 15% homology with Pgp (Zaman et 
al., 1994).
A number of models have been proposed for the membrane topology of MRP (Loe et 
al., 1996) but it is now generally accepted that the transporter contains 12 
transmembrane segments in the amino proximal half and 6 transmembrane segments in 
the carboxy proximal half. The topology of MRP allows it to be classified as a member 
of the ABC superfamily of genes (Section 1.3.1.). This membrane topology appears to be 
unique amongst the currently known ABC transporters (Bakos et al., 1996; Muller et al., 
1996; Tusnady et al., 1997). MRP appears, therefore, to be the first fully characterised 
member of a new sub-family of transporters distinctly related to mdr-1. Three other 
transporters have similar topology to MRP; P cell sulfonylurea receptor (SUR involved 
in insulin regulation), the cMOAT (multispecific organic anion transporter) and the yeast 
cadmium resistance factor (YCF1) (Lauther et al, 1996). Recently, a number of human 
homologues of MRP have been isolated (Kool et al., 1997). Termed MRP-3-MRP-6; 
preliminary characterisation has revealed expression of the different homologues in 
human tissue. MRP-3 is mainly expressed in liver, MRP-4 exhibits low level expression 
in most tissues, while MRP-5 is expressed in almost all tissues assayed. Similarly, 
expression was determined in relation to drug resistance; findings suggest little 
correlation with resistance for the majority of these homologues (Kool et al., 1997). 
Antibodies raised to MRP (Flens et al., 1994), predominantly stain the plasma membrane 
in drug selected and in MRP cDNA transfected cells. Cytoplasmic staining has also been 
observed, usually as a densely stained spot close to the nucleus which may be related to 
the Golgi apparatus or to vesicular sequesterisation which has also been observed in 
some cells (Flens et al., 1994; Hipfner et al., 1994; Zaman et al., 1994).
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The physiological role of MRP has yet to be defined but it has been observed that inside 
out plasma-membrane vesicles isolated from cells over-expressing MRP have shown an 
increase in ATP dependant transport of Glutathione S conjugates including leukotnene 
C4 (Jedhtschky et a l , 1994, Leier et a l, 1994) Photoaffmity labelling has confirmed 
MRP as a leukotnene C4 binding protein (Jedelischly et a l, 1994) Evidence that cancer 
cells require glutathione for MRP drug transport has been demonstrated by the cellular 
depletion of glutathione (Versanvoort et a l, 1995, Zaman et a l, 1995)
MRP mRNA has been detected in total RNA preparations of all human tissue and in cell 
types from peripheral blood (Cole et a l, 1992, Zaman et a l, 1993) Flens et a l, (1994) 
have described the localisation of MRP in normal human tissues Staining (mainly 
cytoplasmic) has been observed in several types of epithelia particularly lung, skin, large 
and small intestine and heart muscle cells and macrophages This have concluded that the 
presence of this protein in these tissues suggests that MRP function in normal tissues is 
associated with the transport of natural xenobiotics (Flens 1994)
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1.3.3. Lung resistance-related protein/human major vault protein (LRP/MVP)
1.3.3.1. LRP
Clinical drug resistance has been found more frequently in tumours where the patient has 
been previously treated with chemotherapy (Bellamy, 1990). Over the past few years, 
emphasis has shifted to the development of low level resistant cellular models which are 
thought to be more clinically relevant (Izquierdo et a l, 1998; Moran et al., 1997a). To 
this end, a number of research groups initiated studies where human cancer cells were 
exposed to lower levels of drug, mainly doxorubicin, typically between 50 to 200 |n 
moles. (Kuiper et al., 1990; Vesemvoot, 1995; Moran et al., 1997a). Investigations by 
Kuiper et a l, and Flens et al, in a series of sublines, revealed a typical multidrug 
phenotype but without the corresponding expression of Pgp. Subsequent investigation 
led to the discovery of a new multidrug resistant related protein, termed the lung 
resistance related protein LRP so named because it was first observed in the non-small 
lung carcinoma cell line SW1573/2R120 (Scheper et al., 1993).
1.3.3.2. Molecular characterisation of LRP
Molecular characterisation of LRP has been undertaken by a number of researchers. 
Scheffer et al, (1995) have mapped the gene encoding LRP to the short arm of 
chromosome 16 position 11.2. The proximity of the LRP gene to that of the other newly 
discovered MDR associated protein, MRP (Section 1.3.2.), posed the question whether 
these two genes were co-over expressed. Evidence from Slovak et al, (1995) have 
shown that, although these genes are located within the same region of the chromosome, 
co-amplification rarely occurs and they are rarely found on the same amplicon. Only one 
incidence of co-amplification was observed, in the fibrosarcoma cell line HT1080/DR4. 
In seven other drug resistant cell lines (with doxorubicin resistance of between 20-300 
fold), this co-amplification was not observed. In the same publication, Slovak et al have 
also demonstrated that over expression of the LRP is not associated with gene 
amplification in 2 LRP over expressing cell lines including the 2R120 subline. This
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research group have concluded that LRP gene amplification is not a common occurrence 
and that other mechanisms such as transcriptional activation or mRNA stabilisation 
appear to be more likely to be responsible for the over expression of the LRP gene 
Recently Komarov et a l, (1997) have mapped the gene encoding protein kinase C (to 
the short arm of chromosome 16) which has been shown to be involved in MDR by the 
activation of the mdr-1 gene (Chambers et a l, 1992) This mechanism may also be 
involved in LRP gene activation Beck et a l , (1998), have recently demonstrated that the 
expression of the protein kinase C isozyme r\ (eta) correlates with mdr-1 and LRP gene 
expression in blast cells from adult AML patients, ascites from aspirates from ovarian 
cancer patients and primary breast carcinoma
1 3 3 3 LRP is the human major vault protein (MVP)
Scheffer et a l, (1995) have constructed an eukaryotic expression system for the 
isolation of the LRP cDNA Purified plasmids containing cDNA from a HT1080/DR4 
cDNA library were transfected into MOP-8 mouse fibroblast cells Cells that transiently 
expressed the LRP protein were selected by immunocytochemistry Successive 
screenings produced a pure clone which was confirmed by immunoprecipitation 
expenments with LRP-56 Sequence analysis has revealed that the LRP gene has a single 
open reading frame of 2,688 base pairs coding for an 898 ammo acid protein with a 
calculated molecular weight of 100 kDa A computer-based search of the LRP cDNA 
versus the gene bank library has revealed that LRP is the human homologue of the rat 
major vault protein (MVP, Kedersha and Rome 1986 a, b) Alignment of the deduced 
ammo acid sequence reveals a 57% homology with the major vault protein from the 
slime mould Dictyostehum discoideum and 87% homology with the MVP of Rattus 
norvegicus
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1 3 3 4 Vault proteins
Vault particles were originally isolated by Kedersha and Rome (1986 (a) (b) as 
contaminants in rat coated vesicle preparations Vault particles appeared a ovoid shapes 
by scanning electron microscopy (EM), having a distinct morphology resembling the 
multiple arches of cathedral vaults, hence the name (Figure 1 3 3 4)
r
Vault particles are large ribonucleoproteins measuring 57 X 32 nM and have an 
estimated molecular mass of 13 MDa, composing of the largest ribonucleoprotein 
reported to date (being three times the size of a ribosome) Vault particles have a 2 fold 
octagonal symmetry, each half of the structure can open out into a flower like structure 
which contains eight petals surrounding a central barrel like ring (Kedersha and Rome, 
1991) Vaults are composed (in rat liver) of a 104 kDa protein, the MVP, which 
accounts for 70% of the total weight of the vault particle, and 3 minor protein species, 
210, 192 and 55 kDa along with a small RNA molecule
Polyclonal antisera prepared against whole vault particles is largely specific for the MVP 
(Kedersha et al, 1990), although there is an increased specificity for the minor species 
with repeated booster injections with purified rat vault preparations Mobility studies 
have shown similarities between coated vesicle components proteins and vault particles 
However, when purified coated vesicles are probed with anti-vault antisera no cross 
reactivity is observed
Vaults have been isolated from various species including the lower eukaryote 
Dictyostehum, amphibians, avians and mammalian (rat, rabbit and cow) (Kedersha et al, 
1990) Vaults are most abundant in epithelial cells and macrophages EM reveals that 
vaults from these diverse species are similar both in dimension, morphology and 
polypeptide composition The MVP of 100 kDa predominated in most species This 
evolutionary conservation is highlighted by the observation that polyclonal antisera raised 
to rat vaults also recognise the MVP in these diverse species (Kedersha et al, 1990)
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Figure 1 3 3.4.1 Proposed model for the folding of vault "flowers" Reproduced, 
with permission, from Kedersha et a l, (1991)
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1.3.3 5 Vault associated RNA
The vault associated RNA (vRNA) has an unusual base composition of adenosine (12%), 
guanosine (29 7%), undine (30 9%) and cytidine (24 4%) (Kedersha and Rome, 1991) 
The vRNA constitutes approximately 4 6% of the entire structure, the large size of the 
vault particle requires that each one contains approximately 9 molecules of vRNA (a 
minimum of 55 copies of the MVP, (pi04) are also present) A structural role for the 
vRNA seems unlikely, removal of the vRNA (by treatment of vaults with RNAse A) 
revealed no differences in mobility on sucrose gradients or on more sensitive agarose 
gels Similarly, there were no observed differences when vaults were viewed by EM 
(Chugani et a l, 1993) vRNA has been found to vary in length and number between the 
species (Kickhoefer et a l, 1993) Mouse and rat vRNA is 141 bases m length while 
bullfrog and humans have 2 forms, in bullfrog the sequences are 89 and 94 bases while in 
humans, the two forms are 80 and 95 bases long Despite the difference in length the 
secondary structure is highly conserved across the species suggesting an important role 
for vRNA in the function of vault particles (Kickhoefer et a l, 1998) One of the genes 
coding for the human forms of vRNA, termed hgv 1 coding for the 95 base vRNA, has 
recently been cloned and has been shown to be a single copy gene Chromosome 
localisation is currently in progress (Kickhoefer et a l, 1998, Rome, personal 
communication), hgv 2, which codes for the 80 base species of vRNA is currently being 
cloned
1 3 3 6 Characterisation of the MVP
Trypsin treatment of vault particles results in the exclusive cleavage of the MVP
resulting in alterations in structure as revealed by EM This change in vault morphology
is consistent with the localisation of the MVP in the petals of the particles (Kedersha and
Rome, 1991) Two mam changes are observed following trypsin treatment, vaults are
either flattened and collapsed suggesting that the loss of the MVP results in the loss of
radial symmetry or, less frequently observed, a reduction in the diameter of the barrel
structure (Kedersha et al, 1990) Studies by Vasu et a l, (1993, 1995) have shown that
the MVP may be important for normal physiological growth in the slime mould
Dictyostelium Dictyostehum contains 2 forms of the major vault protein, MVP A with a
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molecular weight of 94 4 kDa and MVP B, 92 kDa MVP A was the first to be 
sequenced (Vasu et a l, 1993) followed by MVP B (Vasu et a l, 1995) Disruption of the 
MVP A gene results in a mould which retains normal function, it is thought that MVP B 
takes over the function of the A form However the morphology of these mutant vaults 
was not characteristic of normal vault particles Similar results were obtained with MVP 
B mutants Disruption of the MVP B gene in MVP A negative mutants results in 
impeded growth under conditions of nutritional stress Vault particles isolated from these 
mutants are truncated but are still functional under normal growth conditions These 
experiments have allowed the discovery of a third MVP protein in Dictyostelium, MVP 
C, which, like the A and B form m single mutation experiments, takes over the function 
of the other two, although not to the same extent Kickhoefer et a l , (1994) have 
sequenced the cDNA encoding the MVP from rat vaults and shown that it has a57% 
homology with Dictyostelium vault particles
1 3 3 7 Cellular location of vault particles
The majority of vaults are located in the cytoplasm but a small fraction have been 
localised to the nuclear envelope, more specifically the nuclear pore complex, NPC 
(Chugani et a l, 1993) There is evidence to suggest that vault particles may constitute 
the central plug of the NPC as vaults display structural similarities to the central plug of 
the NPC
The NPC are octagonal organelles which span the inner and outer membranes of the 
nuclear envelope providing a channel for nucleocytoplasmic transport (reviewed by 
Gerace and Bourke, 1988, Feldherr and Akin, 1990) Inserted into the centre of the 
channel is the central plug termed the NPC transporter consisting of 2 equivalent halves 
each with an 8 fold symmetry (Akey and Glodfarb, 1989, Akey, 1990) with an estimated 
molecular mass of 13 MDa (Reichelt et a l, 1990) The dimensions, mass and geometry 
of the central plug of the NPC are comparable to those of the vault particle (Chugani et 
a l, 1993) Western blotting and immunofluorescence studies have confirmed that vaults 
are located within the NPC Immunogold EM on isolated nuclei from rat fibroblasts in 
paraffin embedded rat liver has also demonstrated the presence of the vault particles in 
the region of the NPC
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Vault particles have also been localised abundantly in cholinergic nerve terminals in close 
proximity to synaptic vesicles (Herrmann, 1996)
1 3 3 8 Vault function
As yet no precise function can be assigned to vault particles The similarities in molecular 
weight and the symmetry between rat vaults and the NPC (Section 1 3 3 7) suggest a 
function in bi-directional nucleocytoplasmic transport (Chugani et a l, 1993) The 
association of vaults with coated pits indicates a possible role in vesicular transport of 
substrates (Kedersha and Rome, 1986, Section 1 3 3 4) Recently, Herrman et a l , 
(1996) have isolated vault particles from the nerve terminals of Torpedo which also 
points to a role in vesicular transport Vault particles have also been found at the ruffling 
edges of rat fibroblasts and associated with components of the cytoskeletal system 
suggesting a possible role in motility (Rome et al, 1991) Vaults have also been located 
in the developing rat brain and in the microglia (Chugani et a l, 1993) A possible role in 
the growth regulation of Dictyostelium is implied from studies by Vasu et a l, (1993, 
1995, Section 1 3 3 6)
Recently, Kickhofer et a l , (1998), investigated the expression of vault particles in
multidrug resistant cells It has been demonstrated that intact vault particles always
associate with the pellet following centrifugation at 100,000g It has been shown
previously that the human MVP was upregulated in multidrug resistant cells (Scheper et
a l, 1993) It was not certain whether this was an indication of total vault upregulation in
these cells Scheffer et al (1996) demonstrated that MVP cannot confer drug resistance
by itself) Kickhoefer et a l, (1998) have clearly shown that there is a 15 %  increase in
vault synthesis in multidrug resistant cells Probes derived from hgvl cDNA were used to
quantify the level of vault synthesis It has been observed that the amount of vRNA
associated with vault particles is upregulated in the LRP/MVP over-expressing cell line
GLC4/ADR However, the total amount of vRNA is not increased There seems to a
pool of vRNA, a certain fraction of which appears to be associated with the vault particle
at any one time If the level of synthesis of intact vault particles is increased then there is
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also an increase in the portion of the vRNA pool which is vault associated (figure 
1 3 3 8 1 ) This not only suggests a functional role for vRNA but also suggests a role for 
vaults and therefore the MVP/LRP in drug resistance
Kickhoefer et al (1998)also observed that only hgvl was associated with vault particles 
hgv2 is usually found in the supernatant of the 100,000g spin whereas hgvl, like 
LRP/MVP is associated with the pellet Hgvl is only found in the supernatants of cells 
that do not express the LRP/MVP (Kickhoefer et a l, 1998, Rome, personal 
communication)
vRNA (free)
vRNA (vault associated)
Figure 13  3 8 Location of cellular vRNA in MDR cell lines (adapted from 
Kickhoefer et a l , 1998)
17
1 3 3 9 Monoclonal antibody LRP-56 recognises the LRP
Kuiper et a l, (1990) derived a series of subîmes of which the SW1573/2R120/ subline 
was characterised by moderate levels of resistance to doxorubicin, vincristine and 
etoposide, reduced intracellular accumulation of drug and the absence of p-glycoprotein 
expression (Kuiper et a l, 1990) This cell line was used to immunise BALB/c mice the 
resulting hybndoma clones were screened against parental SW1573 (low expression of 
LRP) and SW1573/2R120 (high expression of LRP) cells Clone 56 was chosen for its 
strong immunoreactivity to the 2R120 subline (Scheper et al , 1993) Observations by 
Scheper et al demonstrated that the antigen detected by LRP-56 was predominantly 
located in the peripheral cytoplasm in a granular fashion indication that possible 
association with the endoplasmic reticilum This pattern of staining is characteristic of the 
LRP in a range of multidrug resistant cell lines and normal and malignant tissues (Section 
13 113) A reduction in the level of expression was observed where P-glycoprotein 
expression was predominant which was observed by immunoprécipitation with MAb 
LRP-56 The molecular weight of the LRP has been determined by immunoprécipitation 
to be approximately 110 kDa Scheffer et al (1995) have shown that LRP mRNA is 8 
times higher in the 2R120 subline than in the Pgp positive 2R160 subline and 4 times 
higher than the 2R120 reverent subline, grown in the absence of drug for 9 months
1 3 3 10 Expression of LRP/MVP m multidrug resistant cell lines
Over expression of the LRP/MVP has been observed in a number of drug selected cell 
lines (Moran et a l , 1997a, Scheper et a l, 1993, Versanvoort et a l, 1995, Verovski et 
a l, 1996, Wyler et a l, 1997, Komarov et a l, 1997, Futscher et a l, 1994, Parker et a l, 
1997 and Ikeda et a l, 1997)
Over expression of the LRP/MVP appears to be more closely associated with low level
resistance where it is frequently observed at the early stages of resistance selection It has
also been observed, though less often, in highly resistant cells, (Moran et a l, 1997a,
Scheper et a l, 1993, Wyler et a l, 1997, Vervoski et a l, 1996, Versantvoort et a l,
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1995) The mechanisms of resistance that operate in the low-level resistant cell lines are 
thought to be more clinically relevant (Moran et al , 1997a, Izquierdo 1995, PhD thesis, 
Coley, 1997)
The expression of LRP/MVP and Pgp in drug resistant cell lines appears to be exclusive 
l e the majority of pgp over-expression cell lines are LRP negative and vica versa 
(Moran et a l, 1997a, Versantvoort et a l, 1995, Scheper et a l, 1993) Moran et a l, 
have demonstrated that, in a series of subhnes of the ovarian carcinoma cell line, 
OAW42, LRP/MVP over-expression is seen at the lower levels of resistance in O AW42- 
S, and OAW42-SR cell lines whereas a switch to pgp-over-expression is observed in the 
adriamycin selected OAW42-A1 and OAW42-A lines Similar over-expression at lower 
levels of resistance has been observed by Scheper et a l , in their 1993 study The 
apparent association of LRP/MVP with low level resistance suggests that it could be a 
clinically relevant marker for drug resistance since low level resistance is considered to 
be more clinically relevant (Izquierdo et a l, 1996 a, b, Moran et a l, 1997) Concomitant 
over-expression of LRP/MVP and Pgp has been observed in very few cell lines namely 
the MCF7/D40 breast cancer cell line and certain 8266 myeloma cell lines (Scheper, 
1996, Scheper et a/,1993, Wyler et al, 1997, Shao et a l, 1995) It has been suggested 
that in cell lines with over-expression of both pgp and LRP, the LRP associated 
mechanism of drug resistance may contribute to the MDR phenotype (Izquierdo et a l, 
1998) Evidence by Shao et al, has demonstrated that in 2 subhnes of the myeloma cell 
line 8266 where the Pgp content was similar, the greatest resistance was observed in the 
subline with the higher LRP/MVP content (Shao et a l, 1995)
Many LRP/MVP over-expressing cell lines also appear to over-express MRP (Flens et 
a l, 1994, Moran et a l, 1997a) Whether the LRP/MVP or MRP contributes to MDR 
phenotype in these cell lines is unknown Preliminary evidence from LRP/MVP ribozyme 
and antisense transfected cells of OAW42-SR suggests that the LRP/MVP may play a 
significant role in drug resistance (Byrne, 1998) Moran et a l, (1997a) have also 
observed a passage dependent increase in LRP/MVP expression in the OAW42-SR 
subline with a paralleled increase in drug resistance without any change in MRP 
expression It has also been shown that the non-small lung carcinoma cell line 
GLC4/ADR over-expresses of both LRP/MVP and MRP However, it has yet to be
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established which drug resistance mechanism predominates, it has been suggested that 
resistance is due to the over-expression of LRP/MVP (Kickhoefer et a l, 1998, Flens et 
a l, 1997, Slovak et a l, 1995) Despite the evidence to suggest that the drug resistance 
phenotype of many cell lines is due mainly to LRP/MVP expression, the observation that 
2 and sometimes 3 MDR associated markers being expressed concomitantly suggests 
that several drug resistance mechanisms may be necessary to cause the phenotype of 
drug resistance observed in LRP/MVP positive drug-selected cell lines (Izquierdo et a l, 
1998 in press)
LRP/MVP expression does not appear to be associated with the so-called “classic” MDR 
drugs such as adnamycin A wide range of drugs have been used in the selection of 
LRP/MVP over-expressing drug resistant cell lines (including doxorubicin, mitoxantrone, 
etoposide, vincristine, cytavabine, methotrexate and cisplatin Moran et a l, (1997), 
Wyler et a l, (1997) and Scheper et a l, (1993) have demonstrated that, despite the fact 
that the majority of LRP/MVP cell lines were selected by exposure to doxorubicin, they 
exhibit cross-reactivity to the majority of drugs listed above Studies with a number of 
drug resistant gastnc cell lines have indicated correlation between LRP/MVP mRNA 
expression and resistance to etoposide and a topoisomerase inhibitor SN-38 (Ikeda et a l,
1997)
Generally, the increase in LRP/MVP expression appears to be accompanied by a 
paralleled increase in drug resistance, however, recent observations have shown that in 
the OAW42-S cell line, cloned from the LRP/MVP over-expressing cell line OAW42- 
SR, LRP/MVP is also expressed in a passage dependant manner but without any increase 
in drug resistance (Moran et a l, 1997a) This phenomenon will be discussed in more 
detail in Section 15 3 1
Over-expression of LRP/MVP is not limited to drug resistant cell lines selected with
cytotoxic drugs In a study of a panel of 61 cell lines from the National Cancer Institute
(NCI), many of which are intrinsically resistant (Izquierdo et a l, 1996a), 24% of these
cell lines exhibited Pgp over-expression while LRP (and MRP) were constitutively and
heterogeneously expressed at varying levels in 87% (and 78% for MRP) of cell lines
Statistical analysis indicated that pgp significantly correlated with MDR rank and
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resistance to doxorubicin whereas MRP correlated with resistance to vincristine LRP 
expression correlated with resistance to melphalin, cisplatin vincristine and carboplatin 
Concomitant expression of different MDR mechamsms was also observed in 34% of cell 
lines 18% expressed pgp, MRP and LRP/MVP, 43% MRP and LRP/MVP and 3% Pgp 
and LRP/MVP In 8 of these cell lines, LRP/MVP mRNA expression, but not MRP 
mRNA expression was determined to be strongly correlated with drug sensitivity to both 
MDR and non-MDR related drugs LRP/MVP mRNA estimation appeared to be a 
slightly better indicator of drug sensitivity that LRP/MVP protein expression (Laurencot 
e ta l, 1997)
1 3.3 11 LRP/MVP expression in normal and malignant tissue
The information gamed from in vitro drug selected and intrinsically resistant cell lines 
suggest a possible role for LRP/MVP in the MDR phenotype and as a marker for low- 
level resistance A number of groups have determined the expression of LRP/MVP in 
normal and malignant tissues in an attempt to determine distribution of expression of this 
antigen
Izquierdo et a l, (1996b), found LRP/MVP to be widely expressed in normal tissue
MAb LRP-56 showed strong immunoreactivity with epidermal keratinocytes and
melanocytes with some staining of mesenchimal dermal cells Epithelial cells lining the
bronchioles of the lung also stained strongly with MAb LRP-56 Type I and II
pneumocytes exhibited low level staining while alveolar macrophages were also strongly
positive for LRP/MVP expression In the urinary tract, strong staining was seen in
proximal but not distal tubules of the kidney, while in the endocrine glands, the cortex of
the adrenal gland gave the strongest staimng In the male and female reproductive system
and breast tissue, strongest staining was observed in germ cells of the seminferous
tubules and leydig cells of the testes, in epithelial ovarian cells, placental trophblast and
the duct lining cells of the breast Significant staining was also observed in cells of the
immune system, particularly in macrophages Similar results were obtained by Sugawara
et a l, (1996) but with two notable exceptions, less staimng was observed in epithelial
cells of the ovary and in type I and II lung cells In a more detailed study of the over-
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expression of LRP/MVP in normal lung, Dingemans et a l, (1996) confirmed the 
observations of Izquierdo et al and Sugawara et a l, regarding the general distribution of 
LRP/MVP in lung tissue This also demonstrated that the level of expression in smokers 
was not related to number of pack years smoked but there was a higher a trend for 
higher expression levels in patients who had smoked more that 10 pack years 
The overall trend of LRP/MVP expression in normal tissues appears to suggest that it 
may play a role in defence against xenobiotics Highest LRP expression is seen in tissues 
chronically exposed to xenobiotics 1 e epithelia of the bronchus, digestive tract, 
keratinocytes and in metabohcally active tissue such as the adrenal cortex and 
macrophages (Izquierdo et a l, 1996b, 1998, Sugawara et a l, 1996, Dingesman et a l,
1996) Kedersha and Rome, (1990) have observed similar over-expression of rat vault 
particles in limited studies on animal tissues, particularly in epithelial cells and alveolar
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macrophages The distribution appears to resemble that of other drug resistance related 
proteins such as Pgp and MRP in normal tissue which have been implicated in protection 
against xenobiotics (Flens et a l, 1996, van der Valk et a l, 1990, Cordon-Cardo, 1991, 
Flens, 1997)
Izquierdo et a l, (1996b) have also studied the expression of LRP/MVP in a panel of 174 
tumour specimens comprising 27 tumour types Results from this study indicate that 
LRP/MVP expression appears to reflect the susceptibility to chemotherapy of different 
tumour types Highly chemosensitive cancers such as germ cell tumours and 
neuroblastoma expressed LRP/MVP in the minority of cases, partially chemosensitive 
cancers such as ovarian carcinoma expressed LRP/MVP in the majority of case while in 
highly chemoresistant cancers such colon, renal and pancreatic cancers, all samples 
expressed the LRP/MVP These initial studies were performed on frozen sections 
However Schroeijers et a l, (1997) have recently modified and improved the staining 
protocol for MAb LRP-56 and a new rat MAb LMR-5 (Flens et a l, 1997) for paraffin- 
embedded archival tissue Similarly, den Boer et a l, (1998) have optimised flow 
cytometric analysis for LRP-56 in childhood acute lymphoblastic leukaemia
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1 3 3 12. Clinical significance of LRP/MVP expression
A number of studies have been undertaken to determine the clinical significance of 
LRP/MVP in patient outcome and survival These studies are introduced according to 
tumour type
Neuroblastoma
Neuroblastoma is a relatively chemosensitive tumour type which does not appear to 
over-express Pgp in the MDR phenotype (Gottesman et a l , 1989, Favrot et a l , 1991) 
Neuroblastoma tumours investigated by Izquierdo et a l, (1996b) demonstrated that 
LRP/MVP was not commonly expressed in this neoplasm Ramam et a l , (1995), have 
also demonstrated that LRP/MVP expression was low in untreated tumours, 3 out of 10 
tumours expressed low levels of LRP/MVP This figure increased following 
chemotherapy (9 of 11 samples) In 9 paired samples, 7 that were LRP/MVP negative, 
pre-chemotherapy, LRP immunorecativity was demonstrated post-chemotherapy 
However there was no correlation between survival and LRP/MVP expression
Melanoma
Schandendorf et a l, (1995) have shown that Pgp is rarely expressed in malignant 
melanoma (1 out of 71 lesions), whereas MRP and (primarily) LRP/MVP appeared to be 
more clinically relevant LRP/MVP expression was mainly associated with a subset of 
nervi in nervus cells exhibiting up to 25% positive LRP reactivity In 13 out of 21 
primary melanomas and 23 out of 37 metastases, greater that 25% of tumours cells 
stained with MAb LRP-56 In the metastases group, 50 %  of positive samples came from 
patients previously treated with chemotherapy van der Pole et a l, (1997) have also 
found LRP/MVP expression in a small panel of chronic melanoma tissue samples but 
were unable to determine if this was clinically significant Their results do however 
confirm the observations by Schadendorf et a l, that the highest LRP/MVP expression 
was observed in tumour tissue previously treated by chemotherapy
23
Multiple myeloma
To date only 1 major retrospective study has been initiated to determine the significance 
of LRP/MVP expression in multiple myeloma (Raaijmakers et a l , 1998) LRP/MVP 
expression was assayed in tumours from 70 patients who received varying degrees of 
treatment with Melphalan LRP/MVP expression was found in 47% of patients 
LRP/MVP appeared to be significant prognostic factor in Melphalan/Predmsone treated 
patients, but did not have a significant prognostic value in patients treated intermediate 
high dose melaphalan Results from this study also show that in a subset of untreated 
patients who may receive future treatment with Melphalan/Predmsone there was a poor 
probability of response to these drugs because of high LRP/MVP expression This 
research group has concluded that intensification of the Melphalan treatment could 
overcome LRP/MVP resistance
Breast cancer
Linn et a l, (1997) have shown that 65% of breast tumours assayed expressed LRP/MVP 
but it appears that LRP/MVP has no predictive value in treatment outcome
Lung cancer
Dingesman et a l , , (1996) have studied the expression of LRP/MVP in 36 non-small
lung carcinoma (NSCLC) and 17 tumours (10 NSCLC and 7 small cell lung carcinoma,
SCLC) derived from patients treated with chemotherapy LRP/MVP expression was
found to be significantly higher in NSCLC than SCLC samples All SCLC displayed low
level expression Within NSCLC, squamous cell and adenocarcinoma had higher
expression of LRP/MVP than large cell, undifferentiated and mixed tumours In NSCLC
patients, LRP/MVP expression was a prognostic factor for survival In a recent study be
Volm et al, (1997a), of 87 NSCLC it was observed that there was a significant
correlation between LRP/MVP expression and tumour resistance to doxorubicin There
was no interrelationship between LRP expression and gender, age, stage, lymphnode
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status, proliferation and survival time However, a correlation of borderline significance 
was noticed between LRP expression and patients smoking habits Carcinoma in heavy 
smokers (1 e, more than 30 cigarettes per day) were more frequently LRP/MVP positive 
than carcinoma found in non-smokers
Childhood leukaemia
The molecular basis for drug resistance in childhood leukaemia, particularly acute 
lymphoblastic leukaemia (ALL) is still unclear (Peiters et a l, , 1997) Multivariable 
analysis has shown that analysis of Pgp alone has a limited prognostic significance (Volm 
et a l, , 1997b) It has also been observed that in vitro and in vivo resistance to 
daunorubicin of childhood ALL blast cells is related to prognosis and relapse prior to 
chemotherapy (Pieters et a l , 1997)
Studies by Klumper et a l , (1995) have shown that LRP/MVP but not Pgp was 
significantly associated with increased in vitro resistance of fresh leukaemia cells to 
daunorubicin Recently Veerman et a l , (1997) have determined the LRP/MVP 
expression (as well as Pgp and MRP) in initial and relapse childhood ALL Results from 
this study showed that expression of MRP and Pgp did not correlate with accumulation 
or sensitivity to daunorubicin In contrast, expression of LRP/MVP was significantly 
higher in relapse samples and correlated weakly with in vitro resistance to daunorubicin
In a study of 38 children with initial and 25 children with relapsed lymphoblastic
leukaemia, LRP/MVP expression was found in 18 out of 38 children with initial ALL and
17 out of 25 relapse ALL Children with initial ALL and without LRP/MVP expression
had significantly longer relapse free intervals than patients with LRP/MVP expression
(Volm et a l , , 1997b) den Boer et a l, (1998) have also determined the expression of
LRP/MVP in childhood ALL In a study of 141 children, Pgp, MRP and LRP/MVP
expression did not differ between 112 initial and 29 unrelated relapse samples or between
paired initial and relapse samples from 9 patients In multiple relapse however,
LRP/MVP expression was 1 6 fold higher compared with both initial and first relapse
response which was not observed for Pgp or MRP LRP/MVP was found to be weakly
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response which was not observed for Pgp or MRP. LRP/MVP was found to be weakly 
but significantly related to in vitro resistance to daunorubicin but not to vincristine, 
etoposide, and non-MDR-associated drugs, prednisone and L-asparaginase. The 
expression of Pgp, MRP and LRP/MVP was not higher in initial ALL patients with 
prognostically unfavourable immumotype, white cell count or age.
Adult leukaemia
Intrinsic or acquired resistance to antineoplastics limits the effectiveness of conventional 
treatment in acute myeloid leukaemia, AML (List et a l , 1996). Pgp has been implicated 
as a cellular mechanism contributing to chemotherapeutic resistance in this disease 
although it does not account for the majority of cases (List et al 1993; Broxterman and 
Schuurhus, 1997). A number of studies have shown that, while pgp is over-expressed in 
AML, LRP/MVP appears to be more clinically relevant (List et al, 1996; Borg et al.f 
1996 unpublished; Hart et a l , 1997; Michieli et al., 1997; Filipitus et al, 1997; den Boer
1998).
List et al, (1996) have demonstrated the prognostic significance of LRP/MVP 
expression in 87 patients with AML which included 21 of de novo AML, 27 secondary 
AML and 29 relapse AML and blast phase CML. LRP/MVP. Over-expression was 
observed in 37% of cases and was highest in secondary AML patients. It was noted that 
LRP/MVP expression was associated with an inferior response to chemotherapy, 
remissions were achieved in 35% of cases and appeared to be of independent prognostic 
significance. In this study, LRP/MVP also appeared to be linked with age and previous 
treatment with mitoxanthrone. Filipitus et al, (1998) have observed complete remission 
rates in 80% versus 55% for LRP/MVP positive and negative groups. Overall survival 
rates were much lower for LRP/MVP patients; disease free survival was greatly reduced 
for LRP/MVP positive patients. Contrary to the apparent trend of LRP/MVP expression 
found in adult AML, Hart et al, (1997) found that there is no significant difference 
between presentation and relapse in 8 patients studied sequentially at presentation and 
relapse. These researchers have concluded that LRP is not necessarily predictive of poor 
response to chemotherapy.
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Ovarian cancer
To date, researchers have not agreed on the role of Pgp in ovarian cancer or its 
expression as a predictive marker Although some authors have found elevated levels of 
Pgp before and after chemotherapy, they differ as to the correlation if any with clinical 
resistance (Holzymer et a l, 1992, Arao et a l, 1994, Karvallis et a l, 1996) Others have 
obtained clear results indicating no predictive value for pgp in ovanan cancer (Rubin et 
a l , 1990, Venerom eta l, 1994)
Recently Izquierdo et a l, (1995) determined the prognostic significance of LRP/MVP 
expression in a retrospective study of 57 women with FIGO stage III/IV ovarian cancer 
All patients in the study received platinum or alkylating-based chemotherapy following 
debulking surgery 77% of tumours expressed LRP/MVP This group has shown that 
only LRP/MVP expression (and not Pgp or MRP) correlated with survival and 
chemotherapy response, patients with LRP/MVP positive tumours exhibit poorer 
response to chemotherapy, shorter progression free and overall survival time Recent 
work has also shown a tendency for higher levels of LRP/MVP positivity in fresh tissue 
samples of patients treated with chemotherapy although there was no statistical 
significance associated with LRP/MVP expression (Coley, 1997)
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1.3.3.13. Proposed function for LRP/MVP in MDR
From the large number of studies described, it is clear that LRP/MVP is associated with 
drug resistance in drug selected cell lines, inherently resistant cell lines, normal and 
malignant tissue (where it has been linked to poor prognosis). The expression of 
LRP/MVP in both normal and malignant tissues commonly associated with the transport 
of natural xenobiotics (Izquierdo et al, 1996b) suggests that LRP/MVP, as a component 
of vault particle plays a functional role in transport. The localisation of rat vault particle 
to the nuclear pore complex appears to support this. Based on this evidence Izquierdo, 
constructed a hypothetical model for the functional role of vaults in MDR (Scheper, 
1997; Izquierdo, 1996), Figure 1.3.3.13.
Vault particles have been found associated with components of intracellular transport 
(coated pits), (Kedersha and Rome, 1986 b; Rome et al., 1990). MDR cells have been 
shown to redistribute daunorubicin into the perinuclear region and subsequently relocate 
the drug away from the nucleus in a granular cytoplasmic pattern reminiscent of 
LRP/MVP staining, as opposed to the diffuse nuclear and cytoplasmic localisation of 
drug sensitive parental cells (Gervasconi et al., 1991). This phenomenon has been 
observed in LRP/MVP expressing cell lines notably in samples from AML patients 
(Michieli et al., 1997; Schuurhuis et al. 1989). It has also been observed that in certain 
cell lines, drug redistribution is accompanied by the formation of vesicular structures 
(Dietal et al, 1990). Cleary et al, (1997) also developed and characterised a Pgp over­
expressing cell line that also expresses LRP/MVP. Vesicular sequestration has been 
identified as an important characteristic of drug-resistant cells. Although only 10 %  of 
cells express the LRP/MVP it may play a role in the drug resistance in this cell line since 
it has been clearly shown that these two MDR markers can be co-expressed (Moran et 
al., 1997a; Wyler et al, 1997; Shao et al, 1995). The apparent association of vault 
particles with the nuclear pore complex suggests a functional role for LRP/MVP in 
nucleocytoplasmic transport (Chugai et al, 1991). Vault particles have also been shown 
to associate with the synaptic vesicles in nerve endings but there is as yet no evidence 
that they have a functional role here (Herrmann et al, 1996).
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Although these studies strongly suggest a functional role for vault particles in drug 
resistance there is no direct evidence that they contribute to the MDR phenotype The 
only direct evidence comes from studies by Byrne, (as yet unpublished), which indicate 
that in LRP/MVP ribozyme and antisense transfected cells, down regulation of the LRP 
mRNA is accompanied by a concomitant reduction in drug resistance These 
observations by Byrne have been confirmed in part, in this thesis Transfection of the 
LRP/MVP into drug sensitive cell lines failed to confer drug resistance (Scheffer et a l,
1995) suggests that all of the components of the vault particle are required for vault 
function This point was also demonstrated by Vasu et a l, where the disruption of 
Dictyostehum MVP resulted in growth arrest (Vasu et a l , 1993, 1995, section 1 5 3 6) 
The recent report that vault particles are up-regulated in MDR cell lines, has prompted 
further studies into the interdependency of the vault particle components (Kickhoefer et 
a l, 1998, Scheper, Schroeijers and Rome, personal communication) Co-transfection of 
the cDNA encoding different vault proteins will give a clearer picture into the 
functioning of vault particles and may shed some light onto the possibility of non- 
functionmg particles (Moran et a l , 1997a, section 15 3 1)
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Figure 1 3 3 13 Proposed function for cellular vaults in multidrug resistant cells
(adapter from Izquierdo, 1996 PhD thesis and Scheper, 1996)
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1.4. Ovarian cancer
Ovarian cancer is the 5th leading cause of death in women in the USA and the 2nd most 
common gynaecological malignancy exceeded only by endometrial cancer (Runowicz, 
1992; Naddas, 1997). Statistics for 1994 showed 24,000 newly diagnosed cases with
13,000 deaths from the disease in the same year. Estimates for 1997 indicate that as 
many as 26,800 women could have developed the disease with 14,200 deaths due by the 
end of the year (Parker, 1997). Unfortunately these neoplasms remain asymptomatic until 
massive ovarian enlargement causes compression of the pelvic structures, ascites, 
abdominal distension or distant metastasis (Merino and Jaffe, 1992). Only in a small 
percentage of patients will the tumours be found at an early stage, confined to the 
ovaries (Aure, 1971). The 5 year survival rate for patients with advanced disease FIGO 
stages I, III and IV (Bast and Berchuck, 1992) is 25% to 30% (Runowicz, 1992). This 
rate has changed little in the past 20 years. In a recent US statistical study the number of 
cancer deaths per 100,000 women increased by 8.9%, only lung cancer has surpassed 
this increase (Runowicz, 1992). Ovarian cancer develops in 1 woman in 70, with an 
expected-overall cure rate of 30% (Runowicz, 1992). Ovarian neoplasms are usually 
staged (i.e. description of appearance and malignancy) because of the late diagnosis 
involved. The International Federation of Gynaecology and Obstetrics (FIGO) have 
compiled a guide to the surgical staging ranging from Stage I where growth is limited to 
one ovary to stage IV where growth includes metastases, pleural effusion and associated 
problems (Nahaas, 1997).
Ovarian neoplasms are classified according to their histogenesis. Broadly speaking, they 
can be divided into two main groups; tumours occurring in pre and postmenopausal 
women (Merino and Jaffe, 1992). Germ cell and Sex cord tumours are primarily 
associated with premenopausal women. Marino and Jaffe (1992) have extensively 
reviewed the anatomy and incidence of the constituent tumours of these two groups. 
Neoplasms of the surface epithelium that covers the ovary are the commonest group of 
ovarian neoplasms (Godwin, 1993), Tumours affecting these two main age groups are 
outlined briefly below.
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14  1 Anatomy of the normal ovary
Gross Anatomy
The ovaries are two nodular bodies located on either side of the uterus, attached to the 
broad ligament, and situated close to the pelvic wall in a shallow depression known as 
the ovanan fossa The anterior margin of the ovary is thin, straight and attached to the 
posterior surface of the broad ligament The postenor is rounded, convex and 
unattached Beside attachment to the broad ligament, the ovary is held in place by two 
ligaments one attached to the lateral angle of the uterus and the other, the suspensory 
ligament that extends form the rounded end of the ovary to the wall of the fallopian tube 
The ovary is covered by a layer of surface cells that are a modified form of peritoneal 
mesothehum It covers the whole surface but is separated form the rest of the pelvic 
peritoneum by a distance line of demarcation known as the Farre-Waldymer line 
(Blaustein, 1988) Surface cells are separated from the cortex by the tunica albugines 
The cortex houses the functional components, namely the oocytes, follicles and corpra 
lutea, in varying stages of development and regression The stroma is composed of a 
surface layer of compact fibrous connective tissue
Surface epithelium
Epithelial cells that cover the surface of the ovary can vary from cubidol to columnar and 
squamoid although cuboidal type predominates It is not until the 3rd or early in the 4th 
month of gestation that they become separated from the cortical stroma by the basement 
membrane, until then they are indistinguishable (Blaustein, 1979) During the maturity of 
the foetus the epithelium become separated from the tunica albuginea Surface epithelia 
follow the contours of the ovary and extend into crypts Some of the crypts may be 
sealed off from the surface forming inclusion cysts The surface epithelia tend to have 
microvilli as well as cilha and are attached by desmosomes and lateral integration 
processes Nuceoli and mitocondna are abundant
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Anatomy of the cortex
The appearance of the cortex is age dependant, in the new-born the cortex is packed 
with oocytes and primary follicles, during the reproductive years it contains follicles and 
corpora lutea in varying stages of maturation while in postmenopausal women the cortex 
is composed mainly of scarred remnants (Baker, 1963) The cells of the cortex are 
spindle-shaped and round fibroblast elements They form the matrix in which the 
structures mentioned above are found
14  2 Functions of the normal ovary
The surface epithelia of the adult human ovary has been described as a non-descript layer 
of cells that vary from squamous to cubidal and low columnar (Nicosia and Nicosia, 
1988, Blaustein et a l, 1979) The overall unremarkable appearance of this layer of cells 
suggests that it lacks any particular function, however this does not appear to be the 
case The ovary has two major functions, production of steroid hormones and the timed 
releases of ova Blaustein et a l, (1979)believe that the surface epithelia play a significant 
role in the latter In the preparation for ovum release, production in lysosomal bodies has 
been observed in surface epithelial cells These lysosomal bodies are secreted/excreted 
from the cells' basal surface before ovulation These groups believe that the lysosomal 
bodies aid in the breakdown of the tugesia albugema by exposure to specific lysosomal 
enzymes and thus aid in follicular rupture The resultant wound is repaired by growth of 
ovarian surface epithelia, a supposed source of mutation in epithelial ovarian cancer 
(Section 14 5 1)
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1.4.3. Tumours occurring in young, pre-menopausal women
Germ cell neoplasms
Germ cell neoplasms account for 40% of ovarian lesions and 15-20% of all ovarian 
cancers (Merino and Jaffe, 1992). These neoplasms arise from germ cells that 
embryonically originate in the yolk sac. These neoplasms are more common in pre­
pubertal children and young women accounting for 90% of tumours found in this age 
group and 60% of all tumours in women under the age of 20 years (Scully, 1979).
Dysgerminomas
These neoplasms arise from undifferentiated germ cells that have lost their capacity to 
differentiate. The average age of patients with this form of ovarian cancer is 20 years the 
majority of sufferers being under the age of 30 years. Tumours as large a 40-cm have 
been observed. Disgerminomas usually disseminate through the lymphatic system very 
early, to the lymph nodes, lung and bone. However the prognosis is excellent with a 5 
year survival rate of 90 % (Merino and Jaffe, 1992).
Yolk sac tumours
These tumours are rare, constituting 1% of ovarian cancers, usually occurring in women 
under 20 years of age. They are usually highly malignant and have a poor prognosis. 5 
year survival rates have yet to be established (Granai, et al.,., 1994).
Stromal tumours
These tumours are rare and usually secrete sex hormones. Associated neoplasms such as 
childhood granulosa cell tumour can cause precocious puberty although most stromal 
tumours are begin or of low grade malignancy. Of those neoplasms that are malignant, 
10-15 % of cases present with metastasis. The 5 year survival rate has been calculated at 
80 % (Granai et al., 1994).
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14  3 1 Tumours affecting post-menopausal women
Epithelial tumours are the most common histological types found in post-menopausal 
women Although tumours of the surface epithelium can occur in younger women, they 
are usually rare before menarche (Merino and Jaffe, 1992) Incidence of epithelial 
tumours increase after the age of 55 years, the most progressive forms predominating in 
elderly, postmenopausal women Younger women tend to have benign lesions, borderline 
tumours, tumours of low malignant potential or low-grade adenocarcinomas These 
neoplasms arise from the surface epithelia that cover the ovary and have the potential to 
undergo metaplastic changes to resemble to various types of epithelium, which cover the 
gynaecological tract The various histological types are briefly outlined below,
Serous tumours
Serous tumours account for 42% of all epithelial carcinomas (Blend and Ostrowiski, 
1994) Histologically, these neoplasms resemble the lining of the fallopian tube Serous 
cystadenocarcinoma account for approximately 65% of all serous neoplasms and is the 
most malignant histological type of epithelial ovarian cancer As many as two thirds of all 
neoplasms of this subtype present as bilateral at the time of diagnosis The overall 
prognosis for this type of tumour is poor with a 20-30% survival rate The prognosis 
depends heavly on the FIGO stage of the disease and the grade of the tumour Treatment 
for this tumour usually involves total abdominal hysterectomy and tumour debulking 
followed by chemotherapy (Merino and Jaffe, 1992)
Mucinous tumour
Mucinous tumours account for approximately 15% of all epithelial malignancies and 5% 
of all ovarian neoplasms Blend and Ostrowiski, 1994) Tumours are characterised by tall, 
columnar mucin-producing cells which resemble the lining of the intestine or endocervex 
(Czarnobilisky, 1988) Mucinous adenocarcinoma accounts for 10% of all mucinous 
carcinoma These tumours are highly malignant and metastasise early As with the 
previous malignancy, the prognosis is heavily dependent on the FIGO stage of the lesion
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but survival rates are still less that 60%, treatment is identical to serous carcinoma 
(Merino and JafFe, 1992)
Endometroid tumour
These histological types are characterised by resemblance to cells of the endometrium 
Endometroid tumours are almost always malignant and account for 20% of all ovarian 
neoplasms (Blend and Ostrowiski, 1994) The mean age for patients with this form of 
epithelial ovarian cancer is 50 years and at the time of surgery, 30-50% of patients have 
bilateral disease Histologically, the tumours are composed of glands lined by columnar 
cells with large nuclei and scanty cytoplasm The tumours may produce mucin but the 
mucin is concentrated within the gland (Czarnoblisky, 1987, Merino and Jaffe, 1992) 
Prognosis is similar to that previously described
Clear cell carcinoma
These neoplasms comprise of 5% of all ovarian tumours They are rarely bilateral and 
mainly affect older post-menopausal women
Malignant Brenner tumours
One of the rarer histological types, Brenner tumour is also associated with older post­
menopausal women Lesions are usually destructive to the surrounding stromal tissue 
and have a typical infiltrating pattern Metastasis usually occurs to the omentum, 
peritoneum and distant visera (Merino and Jaffe, 1992)
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14  4 Epithelial ovarian cancer
In theory, all cells that comprise to human ovary have the potential for malignant 
transformation (Godwin et a l , 1992) The vast majority of malignant ovarian tumours 
arise from the surface epithelium (Nahaas, 1997) The surface epithelia are thought to 
play an important function in follicular rupture and accompanying wound repair 
Epithelial tumours are known to disseminate primarily by surface shedding, lymphatic 
spread and occasionally hematogenous spread (Blend and Ostrowiski, 1994) 
Intrapentoneal spread is thought to occur when malignant cells are shed from the surface 
of primary tumour material These exfoliated tumour cells attach to peritoneal surface 
and form micrometastases (carcamatosis or peritoneal studding), which in turn shed cells 
These free-floating cells are thought to be captured by the lymphatic channels in the 
diaphragm It has been observed that clearance of cells occurs more extensively on the 
right side, overlying the liver (Blend and Ostrowiski, 1994) Obstruction of the 
lymphatics of the diaphragm then allows for the implantation of cells in the omentum and 
on other sites in the peritoneal area It has been shown that ovarian cancer can spread by 
direct extension and it has been found in the bladder, colon and pelvic peritoneum 
(Young eta l, 1989)
1.4.4.1 Monoclonal nature of epithelial ovarian cancer
The colonahty of disseminated ovarian cancer is controversial, histopathological
examination alone cannot distinguish malignant material of monoclonal and multicentnc
origin (Kupryjanczyk et a l, 1996) The question of monoclonality arises particularly
where other anatomic sites are involved such as the omentum, pentonem endometrium
etc In most tumours with identical bilateral disease there is no criteria to discriminative
between a primary unilateral tumour and metastasis from bilateral primary carcinomas
Previous cytogenetic and molecular genetic studies support the hypothesis of
monoclonality in stage III ovarian carcinomas with bilateral involvement (Mok et a l,
1992, Jacobs et a l, 1992) These studies revealed that ovarian cancer may not be
multifocal but that lesions identified in multiple sites were denved from a single origin
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More recent evidence has supported the hypothesis of monoclonal origin of ovarian 
cancer Bilateral stage III ovarian cancer was assayed for known mutations in the p53 
gene It was found that p53 patterns were identical In one patient, a p53 mutation in 
exon 5 was present in the malignancy in both of the ovaries and a metastatic tumour of 
the omentum (Kupryjanczyk et a l , 1996) Pejoue et a l , (1996) have found similar 
results in a study of 11 patients with Stage III bilateral carcinoma with identical genetic 
and cytogenetic abnormalities in each ovary
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14  5 Causes of ovarian cancer
As epithelial cancer of the ovary accounts for the majority of ovarian neoplasms, 
discussion will be limited to this histological subtype Table 14 5 1 lists a number of 
possible causative factors that may be relevant in epithelial ovarian cancer
*Number of ovulation years
* First pregnancy>30 years 
*Late onset of menopause 
*First degree family member 
*Exposure to asbestos and talc 
*Diet high in red meat and animal fat
* Obesity
* Genotype changes
9Table 14  5. Suggested causative factors of epithelial ovarian cancer 
1 4 5.1 Multiple ovulation
Ovarian epithelia, unlike most epithelial cells, behave as generative stem cells, (Hamilton,
7 1992) Thus, the division of 1 epithelial cell is thought to yield two daughter cells with 
the equivalent potential for further growth This contrasts with replicative stem cell 
which yield two daughter cells, one of which has a loss of growth potential l e one cell 
will terminally differentiate In the case of ovarian surface epithelia, a single destructive 
mutation could easily be inherited by an exponentially expanding progeny (Godwin et 
a l, , 1992) Therefore, the larger the number of cells that are available for additional 
mutations, the more likely it is that the mutation which may cause transformation will 
occur Thus, continual ovulation may play a role in the development of epithelial ovarian 
cancer Observations have shown that tumours in animals are rare This may be due to 
the fact that animals ovulate seasonally and usually become pregnant shortly after the 
onset of ovulation begins, therefore the number of ovulations is low The only animal
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with a high incidence of epithelial ovarian cancer is the
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development Studies have also shown oestrogen receptor expression in malignant 
surface epithelial cell lines and tissues to varying degrees There is limited evidence to 
suggest that oestrogen is a strong mytogen (Langdon et a l , , 1990, Sawada et a l , , 
1990) These groups have also shown that oestrogen can influence substrate dependant 
growth, these findings suggest that the uncoupling of the control mechanisms involved in 
oestrogen stimulation of growth could have an effect in cancer
1 4 5 3 Peptide hormones
Transforming growth factors (TGFs) are potent mitogeruc peptides (Chow et a l, ,
1996) Two classes of TGF have been isolated the alpha (a) and beta (3) forms (Anazno 
eta l, , 1983) Mature TGF a is an acid and heat stable 50 ammo acid peptide of 55 kDa 
(Derynck et a l, , 1986) TGF a has been found to be secreted by a number of 
transformed cells and tumours (Todaro, 1983) TGF a has been shown to be an 
autocrine growth promoter by the incorporation of [3H] Tymidine TGF a has been 
shown to share 80% homology with epidermal growth factor (EGF) and functions by 
binding to the EGF receptor (EGFR) TGF a was initially discovered in malignant cells 
as an EGF like factor binding to the EGFR It has been speculated that it may play a role 
in malignant transformation of epithelial ovarian cells, high levels have been reported in 
ascites and urine of patients with ovarian cancer (Arteaga et al, , 1988)
TGF P, on the other hand acts as an autocrine inhibitor of proliferation, being secreted as 
an inactive molecule bound to a precursor molecule which must be cleaved to release its 
activity (Chow, 1996) TGF P interacts with a cell surface receptor senne/threomne 
kinases (Berchuck and Carney, 1997) While normal cells produce active TGFP and are 
growth inhibited by it, most ovarian cancer cell lines are not, having lost the ability to 
produce, activate or respond to TGF P (Berchuck and Rodriguez, 1992, Berchuck et a l , 
1990, Zhou and Leung, 1992) It is thought that the loss of TGFp and the up-regulation 
of TGFa may play a role in ovarian cancer development (Berchuck and Carney, 1997)
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1 4 5.4. Cellular oncogenes and tumour suppressor genes in ovarian cancer
The possible involvement of cellular oncogenes in ovarian cancer has been studied by a 
number of groups Chromosomal translocations during mitosis can lead to the relocation 
of cellular proto-oncogenes affecting the normal function of these genes and leading to 
changes in cellular proliferation (Chow, Chien and Chow, 1996) Similarly the loss of 
one allele of a tumour suppressor gene can lead to increased chances of the subsequent 
loss of the other allele resulting in the loss of control of proliferation To date, a number 
of oncogenes and tumour susppressor genes have been identified as being involved in the 
development of ovarian cancer
Mutations in the gene coding for the ras gene product leads to changes in the normal 
GTPase activity which may lead to alterations in control of cell growth Amplification 
and/or mutation/over-expression of the ras genes have been detected by a number of 
investigators Studies by Chien et a l, have shown amplification of the K-ras gene in 33% 
of samples assayed Over-expression of the H-ras gene was detected in 12% of tumours 
The c-myc gene codes for a DNA -binding protein that appears to play an important role 
in cellular proliferation In a study by Zhou et al „ (1988) 25% of ovarian 
adenocarcinomas displayed c-myc gene amplification Baker et a l, , (1990) have 
reported similar findings with 29% of ovarian samples assayed displaying c-myc over- 
expression as have Although c-myc over-expression has been detected in a number of 
studies, these does not appear to be any correlation between c-myc amplification, tumour 
grade and prognosis in ovarian cancer patients (Chow, Chien and Chow, 1996)
Over-expression of c-erb2 (a DNA binding protein) has been linked with poor survival in 
breast cancer patients (Salmon et a l, , 1989) Slamon have found similar results in 
ovarian cancer patients, HER-2/neu the gene coding for c-erb2 was reported to be over­
expressed in 33% of ovarian tumours in the study Expression also appeared to be linked 
to poor prognosis and survival Berchuck et a l, (1990) have also reported expression of 
c-erb2 in a series of archival ovarian tissue specimens Patients with normal HER-2/neu 
expression were found to be less likely to require a second look laoparotomy compared 
to patients with amplification of the gene, those patients with HER-2/neu over-
expression had a lower survival rate that those with normal expression
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Tumour suppressor genes code for proteins that normally control proliferation at times 
when it is inappropriate The majority of tumour supressor genes encode nuclear proteins 
involved in cell cycle control It has been observed that in the majority of cancers, the 
incidence is due to the inheritance of a mutant copy of one of the tumour suppressor 
genes (Berchuck and Carney, 1997)
Loss of P53 function appears to be the most common genetic event described thus far in 
human cancers P53 usually acts as an inhibitor of proliferation by binding to 
transcriptional regulatory elements in DNA P53 function is thought play an important 
role in cancer prevention Mutation in the gene coding for P53 is usually accompanies by 
a deletion in the other allele resulting in mutant P53 Because mutant P53 is not 
degraded as rapidly as normal or "wild -type" P53, nuclear build up of the mutant form is 
seen Mutant p53 has been detected m half of advanced cancers, 15% of early stage and 
4% of borderline tumours (Marks et a l, , 1991, Koler et a l, , 1993, Berchuck et a l, , 
1992)
Approximately 5-10% of epithelial ovarian cancers are thought to be due to inherited 
mutations in cancer susceptibility genes (Berchuck et a l, , 1996) The BRCA1 gene is 
located on chromosome 17q and has been linked to the majority of inherited (familial) 
epithelial ovarian cancers It has been observed that the lifetime risk of the development 
of breast and/or ovarian cancer is approximately 90% in BACR carriers BACR1 is likely 
to be a tumour suppressor gene although its exact function remains unknown Although 
allelic deletion in the region 17q occurs frequently in sporadic ovarian cancer patients, 
acquired mutations in B ACR1 appear to be relatively rare
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1 4  5 Diagnosis of ovarian cancer
The advances in the diagnosis and screening methods have, unfortunately, only a small 
effect on the overall ability to predict incidence of this disease Patients are rarely 
diagnosed until they are in the late stages of the disease (FIGO stage III-IV, Nahaas, 
1997) To date, three main screening/diagnostic methods are employed for the detection 
of ovarian neoplasms,
(I) bimanual recto-vaginal examination
(II) trans-vaginal ultrasonography
(III) radio-immunoassay for serum markers
Anatomical methods are far from ideal due to their inability to detect micro-metastases in 
the peritoneal cavity Serum markers associated with ovarian cancer have also found to 
be unregulated in other diseases particularly in the gastrointestinal tract (Nilof 1984) 
However, they are considered to be an integral part of ovarian cancer diagnosis and are 
certainly a good indicator of problems in the pelvic region Radioimmunoscintography 
has been used more extensively in the diagnosis of ovarian cancer (Section 1 6 ) This 
method of diagnosis appears to be very promising at catching malignancies at an early 
stage The major use of radioimmunoscintography in patients with ovarian cancer 
appears to be in the diagnosis of intra-abdominal and, particularly, peritoneal spread of 
the disease (Goldenberg and Larson, 1992)
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14  6 Tumour markers in ovarian cancer
Primary ovarian cancer is usually treated by debulking surgery followed by 
chemotherapy The efficacy is routinely evaluated by repeated viginal examination and 
trans abdominal ultrasonography However, these methods are unreliable for monitoring 
as aggressive and recurrent disease often remains hidden until the patient presents with a 
large tumour mass Over the last few decades, a variety of serological tumour markers 
have been proposed as a supplement to other non-aggressive diagnostic methods A 
number of monoclonal antibodies have been generated to ovarian and non-ovarian cells 
expressing potentially useful antigens Table 14 6 1 lists serological antigens that are 
now routinely used, in the diagnosis of these neoplasms
Table 1 4  6 Serological markers routinely used in ovarian cancer monitoring
Tumour marker Reference
CA125 Bastia/,, 1981
CA72 4 Gadducci et a l, 1989
CA15 3 Larbre et a l , 1990De
CA195 de Bruijn et a l , 1993
CA19 9 Larbre et al, 1993
CA50 Gadducci et a l, 1990
OS A = Ovarain serum antigen McGuckin et a l, 1992
MSA = Mammary rerum antigen McGuckin ef a/, 1992
90K Panici et al, 1989
Sialyl-Tn Inou se t al, 1992
Sialyl-Lewis Xi Inou e et al, 1992
PLAP = Placental alkaline phosphatase Epenetos et al, 1985
HCG= Human chorionic gonadotropin Donaldson et a l , 1980
AFP= Alpha-feto protein Donaldson et a l , 1980
LASA-P = lipid associated sialiac acid Bernstein e/ al, 1991
Ferritin Negishie/a/, 1987
SP1 Pulay et a l , 1987
IAP = immunosuppressive acidic protein Negishieia/, 1987
PHI = phosphohexose isomerase Pauhcke/a/, 1985
HMFG2 = Human milk fat globule 
membrane antigen
Taylor-Papadimitnou et a l , 1981
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1 4.6.1. CA125
CA125 has been the most widely used tumour marker for the investigation and 
management of ovarian cancer, therefore, the discussion on the uses of tumour markers 
will deal primarily with this antigen CA125 is an antigen expressed on many histological 
subtypes of ovarian carcinoma The antigen was first studied by Bast et a l , (1981) who 
developed the first monoclonal against OVCA433 cells which over-expressed the CA125 
antigen CA125 is a glycoprotein, aggregated to high molecular weight complexes larger 
that 200 kJDa, but different subunit sizes have been reported (O’Brien et a l, , 1991, 
Nagata et a l, , 1991, Nustad et a l, , 1994) The carbohydrate content is 24% lower than 
for typical mucins, sugar chains are both N-and O-hnked (Nagate et a l, 1991, Davis et 
a l, 1986) CA125 appears to carry two major antigenic determinants, A, recognised by 
MAb OC125 (Bast et a l, , 1981), and B, recognised by a new generation MAb Mil 
(Nustad Et a l, 1996) CA125 is primarily expressed on the cell surface which has been 
demonstrated by electron microscopy (Blaustein et a l , 1984) while some
mtracytoplasmic staining has also been reported (Shishi et a l, 1985, de Bruijn et a l ,
1997) In the original study by Kabawat et a l, (1983), CA125 was found to be expressed 
in amnion and derivatives of foetal coelomic epithelium and in the epithelium of the 
fallopian tube, endometrium, endocervex, and in mesothelial cells of the adult pleura, 
pericardium and peritoneum, particularly in areas of inflammation and adhesion Initially 
these studies revealed that CA125 was not expressed in the adult normal ovary but on 
subsequent examination staining was seen on the normal ovary, colon, bladder, stomach, 
lung and kidney Radioimmunoassay has fixed the normal serum concentration at 35 
units per ml (Kenemans et a l, 1993) In healthy subjects, elevated CA125 levels have 
been seen during menstruation, early pregnancy m begin diseases of the unnogemtal 
tract, and in non-gynaecological conditions such as peritonitis, liver cirrhosis, cancer of 
the breast, pancreas, liver and lung (de Bruijn et a l , 1997) Serum levels of CA125 
appear to correlate with FIGO staging of ovarian cancer (Tuxen et a l, 1995) 
Markowska et a l, (1990), have show elevated serum levels in 51% of Stage I and 98% 
of Stage IV CA125 appears to be expressed in all histological types but is higher in 
tumours classified as non-mucinous than in mucinous types Despite the large body of
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knowledge which has been amassed about CA125, its exact function is still unknown as 
the gene or cDNA sequences have yet to be isolated (de Bruijn et a l, , 1997)
1 4 6.2 Measurement of CA125 during chemotherapy
Measurement of CA125 levels is now widely applied to follow the response to 
chemotherapy It has been found that CA125 levels correlates with the course of the 
disease in about 90% of patients Regression gives declining levels in 97% of cases, 
progression gives increases in 83% of patients and in stable disease, the levels remain 
unchanged in 71% of patients (Kenemans et a l, , 1993) Gallon et al t (1992) have 
shown that serum levels of 20-35% were related to residual disease in 12/13 patients 
This group has suggested resetting the upper limit of what is considered normal CA125 
levels following hysterectomy to a lower level A number of trials have included CA125 
levels in the evaluation of results from chemotherapy trials (Long et a l, 1994, Rustin et 
a l, 1996) However at least 1 study has reported the failure of CA125 to correlate with 
radiographically measurable disease m cases where patients received salvage 
chemotherapy (Morgan et a l, 1995) Attention has also focused on CA125 as a 
prognostic predictor of remission and survival Following initial studies, CA125 half life 
measurements have now been documented as an important, independent indicator of 
survival (Buller, 1996, Gaddicci et a l, 1992, Yedema et a l, 1993) Values of less than 
35 units/ml were associated with 50% survival at 24 months, 60% survival at 48 months 
(Gadducci et a l, 1992, Marker et a l, 1993) de Bruijn et a l, (1996) have suggested that 
with elevated CA125 levels before the 3rd course of chemotherapy and a half life of 
more than 20 days, a change in the chemotherapy regime is warranted
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1.5. Primary culture of ovarian tumour tissue and ascites
Primary culture or, the establishment of permanent human ovarian tumour cell lines in 
continuous culture, has proven to be one of the most useful techniques towards 
understanding these cells. The establishment of tumour cell lines serve as a valuable 
resource for multiple investigations. Ovarian cell lines have been used extensively in the 
identification of growth factors, receptors and oncogene expression. They have also been 
used to study the methods of steroid action, characterisation of tumour and the 
generation of specific monoclonal antibodies with the potential application in tumour 
diagnosis, monitoring disease progression and the development of treatment strategies 
(Hung, Sayaswaroop and Tabizadeh, 1994). These cell lines have also been useful in the 
development of experimental in vitro model systems for a range of disorders including 
MDR.
1.5.1. Sample preparation of ovarian tumour material
Since the mid-1970’s, several permanent ovarian cancer cell lines have been established 
in culture. The literature contains descriptions of over 70 ovarian tumour cell lines the 
majority representing reports of one to three cell lines. However, a number of groups 
have reported the isolation of 5 or more cell lines (Fogh et al., 1977, Wilson et al., 1984, 
1996; Hamalton et al., 198;, Hill et al., 1987, van Niekerk et al., 1988 and Mobus et al., 
1992, 1994). More recent reports have detailed various techniques which my improve 
the success rate in cell line establishment such as transplantation to nude mice or 
isolation of cells from ascites (Hurteau et al., 1994; Buller et al., 1995; Gorai et al., 1995 
Gambona et al., 1995; Kim et al., 1997 and Codegoni et al., 1998).
A review of the literature in this area reveals a range of commonly used standard 
techniques for the desegregation of solid tumour material. In general, tumours are 
minced into 1 -2mm3 pieces and sieved to produce a cell suspension with relatively few 
cell clumps. Two researchers have reported the use of proteolytic enzymes (trypsin and 
collagenase) to aid dissociation of the tissue sample (Hill at a l 1987; Gorai at al, 1995),
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A number of researchers have transplanted solid tumours directly into nude mice in an 
attempt to improve the chances of establishing permanent cell cultures (Codegom et a l, 
1998, Kim et a l, 1997) However this technique does not appear to be any more 
successful than standard cell culture methods Tissue explants (1 e small tissue pieces 
approximately 1mm3 are cultured until epithelial cells form outgrowths) have also been 
used as a source of epithelial cells however this method increases the risk of 
contamination and over growth by fibroblasts (Wilson et a l, 1997)
Investigators have also established permanent cultures from ascites Due to the difficulty 
in diagnosis of ovarian malignancies, tumour growth is usually accompanied by 
considerable malignant ascites (Hung, Satyaswaroop and Tabibzadeh, 1994), section
14 1 The apparent easy with which researchers are able to successfully establish lines 
from ascites may be due to the culture conditions which the cells have become 
accustomed to i e growth in a free floating or partially attached state in a liquid 
environment (Wilson et a l, 1997, O'Sullivan et a l, 1998)
1 5  2 Isolation of pure epithelial cells for primary culture
Epithelial cells account for only a small percentage of the total cellular content of the 
human ovary As a result, contamination from other cell types is common in ovarian 
primary culture Fibroblast contamination appears to be a significant problem in most 
cultures derived from solid tumours and some ascitic samples (Wilson et a l, 1997) 
Removal of fibroblasts is mainly achieved by differential trypsmization i e fibroblasts 
detach from cell culture flasks before epithelial cells on treatment with trypsin-versene 
therefore they can be completely removed from epithelial cultures over a number of days 
or weeks (O'Sullivan et a l, 1998, Gorai et a l, 1995, Gamboa et a l, 1995, Mobus et a l, 
1994 and Hill et a l, 1987)
Wilson et a l, (1997) employed differential incubation with cell free ascites for the
removal of mesothelial cells from epithelial cultures Cell free ascites was found to
produce a fibrin mesh on exposed cells Brief exposure to trypsin-versene produced
complete detachment of the mesothelial sheet of cells that attached specifically to the
fibrin mesh without removing epithelial cells which do not attach to the fibrin
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15  3 Studies with variants of the ovarian carcinoma cell line OAW42 as an in vitro 
model for MDR in ovarian cancer
Expression of Pgp, MRP and LRP/MVP in clinical samples has been discussed 
previously in section 1 3 3 12 A review of the literature suggests that clinical MDR is 
rarely associated with the expression of a single MDR-linked protein Instead, it is more 
likely that a number of MDR associated proteins may work in tandem giving rise to the 
MDR phenotype in ovarian cancer, ( Izquierdo et a l, 1995, Karvalhs et a l, 1996,Coley
1997) Analysis of the expression of these MDR markers in established ovarian cell 
cultures can mirror the in vivo case and therefore serve as suitable in vitro models 
(Moranza/, 1997a)
It has already been suggested that epithelial ovarian cancer is monoclonal in nature, that 
is, bilateral tumours arise from a common primary tumour (section 14 6) However, it 
has also been demonstrated that within monoclonal epithelial tumours there can exist a 
certain degree of heterogeneity (Bar et a l, 1994) Wolf et a l, (1987) has demonstrated 
that 2 cell lines derived from the same tumour sample had different degrees of drug 
sensitivity and growth characteristics This he assigned to the possible clonal selection of 
a drug resistant population of cells evolving from the minor to major population within a 
given tumour Similar observations have been made by Moran et a l, (1997a) with 
respects to the expression of the LRP/MVP in variants of the ovarian carcinoma cell line 
OAW42
The OAW42 cell line was derived from ascites of a patient with serous
cystadenocarcinoma of the ovary (Wilson, 1984) Moran et al (1997a) have derived a
series of variants with exhibit increasing resistance to adnamycin OAW42-SR is a
heterogeneous cell population that was derived by serial subculture of the OAW42 and
appears to be intrinsically drug resistant i e exhibits resistance to adnamycin without to
the drug in vitro OAW42-S is a drug-sensitive clonal sub-population of the OAW42-
SR The OAW42-A1 and OAW42-A were derived by prolonged exposure to adnamycin
Immunocytochemical analysis of these four variants revealed that a number of drug
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resistance mechanisms were co-expressed in the OAW42-SR, Pgp, MRP and LRP/MVP. 
Further analysis of this variant revealed that following continuous subculture, LRP/MVP 
positive cells within the OAW42-SR population appeared to evolve form being a minor 
to the major cell population. This suggests clonal variation of this particular cell type 
may have occurred. This phenomenon is similar to observations by Izquierdo et al 
(1995), who observed distinct heterogeneity in LRP expression in frozen archival 
specimens. Mobus et al., (1992) have also demonstrated clonal selection of CA125 
negative cells in vitro.
In the drug selected variants, OAW42-A1 and OAW42-A, there appeared to be a shift in 
the mode of resistance with increased expression of Pgp and a reduction in LRP staining. 
This may also reflect the in vivo development of tumour resistance from low and possibly 
intrinsic resistance where pgp is undetectable, to higher levels where Pgp is detectable 
(e.g. in post chemotherapy situations). This phenomenon has also been observed in other 
cell line models such as the SW1573/2R series (Scheper et al., 1993).
I.5.3.I. Expression of the LRP/MVP in OAW42-SR and OAW42-S
The increase in LRP/MVP over-expressing cells within the OAW42-SR was associated 
with an increase in drug resistance to adriamycin (Moran et al., 1997a), similarly 
LRP/MVP over-expression has also been demonstrated in the OAW42-S, the sensitive 
clonal sub-population of the OAW42-SR. The OAW42-SR variant displayed a passage 
dependant increase in the expression of the LRP/ MVP with an associated increase in 
drug resistance (an increase in IC5o values). This observation suggested a direct role for 
the LRP/MVP in drug resistance in the OAW42-SR variant (see section 1.3.3.12.). The 
increase in LRP/MVP expression in the OAW42-S variant was not accompanied by an 
increase in drug resistance. Moran et al., (1997a) have postulated that the LRP/MVP 
present in the OAW42-S may have a non-functioning component.
Another alternative may also be possible. Rome et al., (personal communication) have
failed to isolate vault particle from cells in culture. This group suggest that these changes
in vault conformation may be due to the vault particles being in a state of "flux” i.e.
continually changing shape to suit its proposed function Therefore alternative
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conformational states may account for the lack of vault function in the OAW42-S cell 
line
The development of ovarian cancer is therefore, a complex group if interactions between 
a wide variety of cellular antigens In order to understand the mechanisms by which these 
neoplasms form and develop resistance to chemotherapeutic drugs it is necessary to fully 
understand the cellular processes and identify the antigens involved in these mechanisms
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The aims of this thesis were to raise monoclonal antibodies to a sensitive OAW42-S and 
a resistant OAW42-SR variant of the ovarian carcinoma cell line OAW42, and to use 
these monoclonal antibodies to identify antigens which may play a role in resistance.
Work undertaken previously in this laboratory (discussed below) had indicated that the 
LRP/MVP may play a role in chemo-resistance in these cell lines and might exist in 
multiple alternative active or inactive forms. It was hope that some of these anti- 
OAW42SR and OAW42-S MAbs might recognise antigens related to LRP/MVP, or 
other resistance-related proteins.
Following isolation these antibodies could be characterised by a range of immuno- 
analytical methods including ELISA, immunocytochemistry, immunofluorescence and 
Western Blotting.
In the characterisation of monoclonal antibodies, not all antibodies recognise their target 
antigens by conventional Western Blotting procedures. Other methods such as 
immunoprécipitation can be used in their characterisation.
In order to characterise the antigens detected by such antibodies, the objective of the 
work in the next phase was to modify a pre-existing non-radioactive method for labelling 
of cellular proteins with biotin derivatives. This would allow estimation of molecular 
weight and confirmation of distribution of the antigen in cell lines by 
immunoprécipitation coupled to Western Blotting.
The results from these studies revealed similar but not identical patterns of expression 
and molecular weight between the antigen detected by the anti-OAW42-SR MAb 3B6 
and the LRP/MVP.
The aim of the final part of the project was to determine whether,
(i) these two antigens differed in glycosylation, and/or,
(ii) shared sequence homology.
1.6. Aims of thesis
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This latter question was approached by amino sequencing of internal peptides of the 
3/B6 antigen and subsequent protein data base searches to determine the degree of 
homology, if any, between these two proteins
Two other monoclonal antibodies were also chosen for further study The aim in this part 
of the study was to partially characterise these antibodies to determine whether there 
were any similarities in the staining characteristics between these antibodies and the anti- 
LRP/MVP monoclonal antibodies LRP-56 and LMR-5 This could be undertaken in 
cross-reactivity experiments with purified rat vault particles
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Materials and Methods
2 1 Water
Ultrapure water was used in the preparation of all media and solutions This water was 
purified by reverse osmosis system (Milipore Milli-RO 10 Plus, Elgastat UHP) to a 
standard of 12-18 megaohms/cm resistance
2 2 Glassware
Most solutions pertaining to cell culture and maintenance were prepared and stored in 
sterile glass bottles All glassware including these bottles, used for cell culture work were 
soaked in a 2% (v/v) solution of RBS (AGB Scientific) fort at least one hour after which, 
they were scrubbed and rinsed several times in tap water They were then washed by 
machine using Neodisher detergent (an organic, phosphate-based acid detergent) rinsed 
twice in distilled water, once in ultrapure water and sterilised by autoclaving
2 3. Sterilisation
Water, glassware and all thermostable solutions were sterilised by autoclaving at 120°C 
for 20 min under pressure of 1 bar Thermolabile solutions were filtered through a 0 22 
|im sterile, low protein binding filter (Milipore)
2.4 Media preparation
The base media used during routine cell culture were prepared according to the 
formulations shown in table 2 4 1 10X media were added to sterile ultrapure water, 
buffered with HEPES and NaHC03 and adjusted to a pH of 7 45-7 55 using sterile 1 5M 
NaOH and 1 5M HC1 The media was then filtered through a sterile 0 22 jam bell filter 
(Gelman G1423S) and stored in 500 ml bottles at 4°C up to the expiry date specific for 
each individual 10X medium container Prior to use, 100 ml aliquots of basal media were 
supplemented with 2mM L-glutamine (Gibco 043-0503) and 5-15% foetal calf serum 
This was then used as routine culture medium This was Stored for up to 2 weeks at 4°C 
after which time fresh culture medium was prepared Hybndoma and Sp/2 myeloma cells
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were grown in a basic basal media of commercially available DMEM, DMEM with 
Glutamax I (Glutamax I is L-Alanyl-Lglutamine Gibco BRL, Pasiley, Scotland, 61965- 
026) supplemented with 10% heat inactivated FCS (Myclone, Gibco 10082-147) This 
was further supplemented for the hybridoma growth and cloning (section 2 8 2 and 
2 8 5 )
Table 2 4 1 Preparation of basal media
DMEM
(Gibco 042-02SOM)
Hams-F12
(Gibco04201430M)
10X Medium 500 ml 500 ml
Ultrapure H20 4300 ml 4700 ml
1M HEPES
(Sigma H9136)
100 ml 100 ml
7.5 % NaHC03 
(BDH 30151)
45 ml 45 ml
2 5 Sterility checks
Sterility checks were routinely carried out on all media, media supplements and reagents 
used m cell culture The various solutions were inoculated onto Columbia (Oxid CM331) 
blood agar plates, Saburaud (Oxid CM217), Dextrose and Thioglycollate (Oxid CM173) 
broths and incubated for 2 days to 3 weeks Media was sterility checked for at least 2 
days pnor to use by incubating samples at 37°C
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2.6. Cell lines
All cell culture work was earned out in a class II down-flow re-circulating laminar flow 
cabinet (Nuaire Biological Cabinet) and any work which involving toxic compounds was 
carried out in a cytoguard (Gelman) Stnct aseptic technique was adhered to at all times 
The laminar flow cabinet was swabbed with 70% industnal methylated spirits (IMS) 
before and after use, as were all items used in the cabinet Each cell line was assigned 
specific media and waste bottles and only one cell line was worked with at a time in the 
cabinet which was allowed to clear for 15 mm between cell lines The cabinet itself was 
cleaned weekly with industnal disinfectants (Viron, Antec International TEGO, TH 
Goldschmidt) as were all incubators used in the culture of cell lines and hybndomas Cell 
lines were maintained in 25 cm2 (Coster 3035) 75 cm2 (Coster 3075) or 175 cm2 
(Nunclon, NUNC) tissue culture flasks at 37°C and fed every 2-3 days Cell lines were 
cultured through 7-10 passaged before they were discarded and new cultures grown 
from frozen stocks Section 2 5 4 The cell lines used during the course of this study, their 
sources and growth media requirements are listed in Table 2 6 11 and 2 6 12
2 6.1 Subculture of adherent cells
During routine subcultunng or harvesting of adherent cell lines, cells were removed from 
their flasks by enzymatic detachment Waste medium was removed from the cells which 
were then rinsed with pre-warmed trypsin-versene/EDTA (TV) solution (0 25% trypsin 
(Gibco 043-05090), 0 01% EDTA (Sigma) solution in PBS (Oxoid BR14A) This 
ensured that any naturally occurring trypsin inhibitor in residual serum was deactivated 
Fresh TV was then placed in the flask and incubated until the cells were seen to have 
detached (2-10 min) The TV solution was deactivated by the addition of pre-warmed 
basal medium containing serum The entire solution was then transferred to a 30 ml 
sterile universal tube (Stenlin 128a) and centrifuged at 1,000 rpm for 5 min The 
resulting pellet was then resuspended in pre-warmed growth medium, cells counted and 
tissue culture flasks re-seeded at the required density
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2 6 2. Subculture of cells in suspension
Hybridoma and Sp/2 cells are partially adherent and mainly grow in suspension Cells 
were passaged by tapping the flask lightly and/or gentle pipetting with a 9 ml sterile 
pipette (Elkay, Ireland lOOstr) Cell suspensions were pooled and centrifuged at 1,000 
rpm for 5 nun Cell pellet was then resuspended in culture medium and a cell count 
performed (section 2 6 3 ) and the cells resuspended at the desired density Cells were 
grown in 5% CO2
2 6 3 Cell counting
Cell counting and viability were carried using trypan blue (Gibco, 15250) dye exclusion 
technique An aliquot of trypan blue was added to a single cell suspension ant a ration of 
1 2 After 3 min incubation at room temperature, a sample of the mixture was applied to 
the chamber of a haemocytometer over which a glass cover slip had been placed Cells in 
the 4 outer corner grids of the chamber were counted microscopically, an average per 
corner grid was calculated with the dilution factor taken into account and the final 
number multiplied by 104 to determine the number of cells per ml Non-viable cells were 
those which stained blue while viable cells excluded the trypan blue dye and remained 
unstained
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Table 2.6.1.L Cell line used in this study
:; Soil rcc’ Growthriiiediuiiiif
Ovarian
Carcinoma
ATC1
OAW42-SR ETCC3 ATC
OAW42-S U Gilvarry, NCTCC4 ATC
OAW42-A1 Dr A Redmond, NCTCC ATC
OAW42-A Dr I Cleary, NCTCC ATC
OAW42-SR RZ2 D Byrne, NCTCC ATC
OAW42-SR RZ4 D Byrne, NCTCC ATC
OAW42-SR AS1 D Byrne, NCTCC ATC
A2780 Prof R Scheper, Amsterdam DMEM
A2780/AC12 Prof R Scheper, Amsterdam DMEM
A2780/AC16 Prof R Scheper, Amsterdam DMEM
Lung carcinoma
DLKP Dr G Grant, NCTCC ATC
DLKP-A Dr G Grant, NCTCC ATC
DLKP-A10 Dr I Cleary, NCTCC ATC
COR-L23 S Dr P Twentyman RPMI 1640
COR-L23R Dr P Twentyman RPMI 1640
Nasal carcinoma
RPMI 2650 ATCC5 MEM2
]ATC consists of 1 1 mixture of DMEM and HAMS F12, this was supplemented with 2mM 1-glutamine, 
FCS and 1 mM sodium pyruvate for OAW42 cell lines
2MEM was supplemented with 1% (v/v) MEM Non-essential ammo acids (NEAA) (Gibco, 043-01140)
2 mM 1-glutamine, FCS and 1 mM sodium pyruvate
3ETCC European Tissue Culture Collection
4NCTCC National Cell and Tissue Culture Centre
5ATCC American Type Culture Collection
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Table 2 6 12. Animal cells used in this study
Cell line Source Growth medium
Rat kidney
NRK 3a t c c *ACT
African Green Monkey 
Kidney
BS-C-1 ATCC 2MEM
Hamster kidney
BHK ATCC MEM
Bovine Kidney *
MDBK ATCC MEM
Canine kidney
MDCK ATCC MEM
Mouse fibroblast
MOP-8 Prof R Scheper Amsterdam ATC
1ATC consists of 1 1 mixture of DMEM and HAMS F12. this was supplemented with 2mM 1-glutamine, 
FCS and 1 mM sodium pyruvate for OAW42 cell lines
2MEM was supplemented with 1% (v/v) MEM Non-essential amino acids (NEAA) (Gibco, 043-01140) 
2 mM 1-glutamine, FCS and 1 mM sodium pyruvate 
3ATCC American Type Culture Collection
6 0
2 6 4 Cell freezing
Cells of various passage numbers were frozen and cryo-preserved to serve as master 
stocks Vials could then be thawed and cultured for study
Cells to be frozen were harvested in the log phase of growth and counted as described in 
Section 2 6 3 The pellets were re-suspended in foetal calf serum (pre-cooled to 4°C) and 
equal volumes of freezing medium (DMSO/serum 1 9 (v/v) was added dropwise to the 
cell suspension to give a final concentration of at least 5xl06 cells per ml 1 5 ml of the 
cell suspension was quickly placed in a cryovial (Greiner 122278) which was placed in 
the vapour phase of liquid nitrogen container for 2 5-3 5 hr After this, the cryovials were 
stored in liquid nitrogen until required
2 6 5 Cell thawing
Immediately prior to removal of a cryovial from the liquid nitrogen, a sterile universal 
tube containing growth medium was prepared for the rapid transfer and dilution of 
thawed cells (thus reducing the exposure time to DMSO which is toxic at room temp ) 
Following the addition of the thawed cell suspension to the growth medium, the 
suspension was centrifuged at 1,000 rpm for 3 mm after which the pellet was re­
suspended in fresh growth medium A viability count was earned out (Section 2 6 3 ) 
and the thawed cells were placed in tissue culture flasks and allowed to attach over 
night, The following morning the cultures were re-fed with growth medium to remove 
any residual DMSO
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2 7 Mycoplasma analysis
Mycoplasma examinations were carried out routinely (every 3 months) on all cell lines 
used in this study
2 7 1 Indirect staining procedure
Mycoplasma negative NRK cells (Normal Rat Kidney fibroblasts) were used as the 
indicator cells These cells were cultured with supernatant from test cell lines , fixed and 
stained with Hoescht fluorescent stain which binds specifically to DNA, thus it would 
stain the nucleus of the cell and any Mycoplasma infection which can be seen as small 
fluorescent bodied outside the cell
NRK cells were seeded onto sterile coverslips at a density of 2x103 cells per ml and 
allowed to attach over night at 37°C and 5 % CO2 1 ml of cell free test supernatant was 
then inoculated onto each coverslip and the cells incubated as before until the culture 
reached 30-50% confluency Following this, the medium was removed and the coverslips 
rinsed twice in PBS and once in PBS/Carnoys (50 50) and fixed in Carnoys solution 
(acetic acid, methanol 1 3) for 10 min After the solution was removed the coverslips 
were allowed to air dry for 10 min The coverslips were then washed with twice with 
sterile water and stained with Hoechst 33258 stain (BDH) for 10 min Following 3 rinses 
with PBS the coverslips were mounted in 50% (v/v) glycerol in 0 05 M citric acid, 0 1 M 
disodium phosphate and examined using a Nikon phase contrast microscope fitted with a 
UV filter Positive controls consisted of NRK cells infected with Micoplasma enriched 
supernatants
6 2
2 7.2. Direct staining
The direct stain for Mycoplasma involved inoculating test samples onto an enriched 
Mycoplasma culture broth to optimise the growth of any contaminants and incubated at 
37°C for 48h Samples of this broth were then streaked onto plates of Mycoplasma agar 
base and incubated for 3 weeks at 37°C and 5% CO2 Plates were checked 
microscopically every 7 days for the growth of "fried egg" like colonies, which was 
indicative of Mycoplasma infection
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2 8 Monoclonal antibody production
2 8 1 Immunisation procedure
2 Balb/C mice were injected 3 times in 6 weeks with 2xl06 OAW42-SR cells A further 
pair of Balb/C mice was injected with 2xl06 OAW42-S cells
2 8 2 Fusion Procedure
The fusion procedure was a modification of the protocol outlined by Koler and Milstein 
(1974) Prior to the removal the spleen from the sacrificed mouse, Sp/2 myeloma cells 
were prepared for cell fusion by harvesting from 75 cm2 flasks and centrifuging at 1,000 
rpm for 5 min in HEPES free serum free medium This step was repeated twice A ceil 
count was then performed (Section 2 6 3 ) and the cells kept at 37°C Balb/C mice were 
then sacrificed by cervical dislocation The animal was swabbed with 70% IMS and the 
spleen removed in a laminar flow cabinet with sterile dissection instruments Single cells 
were obtained by forcing the spleen through a sterile falcon cell strainer (Becton 
Dickinson 2360) using the plunger from a 10 ml syringe into serum free DMEM (the 
DMEM referred in this section is DMEM with Glutamax I (Gibco 61965-026) 
containing pyndoxine and without sodium pyruvate or HEPES, Glutamax is L-Amyl-L- 
Glutamine) This cell suspension was placed in a 50 ml centrifuge tube and the volume 
adjusted to 20 ml Large clumps of cells were allowed to pellet by standing at room 
temperature for 2-3 mm The supernatant was then transferred to a fresh centrifuge tube 
and centrifuged at 1,000 rpm for 5 min A cell count was performed as before (Section 
2 6 3 ) Splenocyte and Sp/2 myeloma cells were mixed in a 50 ml universal tube at a 
ratio of 10 1 (a minimum of lxlO7 Sp/2 are required for this procedure), centrifuged at
1,000 rpm for 5 min and resuspended in serum free medium This step was repeated 
twice Following the final washing step, 1 ml of PEG (polyethylene glycol, Boehringer 
Mannheim, 783641 pre-warmed to 37°C) was added to the cell pellet with a Pasteur 
pipette using a gentle swirling and aspirating action for 30 sec After 30 sec the 
aspiration was discontinued After 75 seconds 0 5 ml of plating medium (DMEM with 
Glutamax I, 10 % heat inactivated FCS, 5 % Bnclone and 1% HAT (Hypoxanthine,
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Aminopterin, Thymidine, Boehringer Mannheim, 644579) was added slowly down the 
side of the 50 ml centrifuge tube while continuing to swirl gently 8 ml of plating medium 
was added over the next 5 min (3 ml at 1 mm intervals followed by the addition of 5 
m l) Following this step, the cell suspension was centrifuged at 500 rpm for 5 min The 
supernatant was removed and the cells were resuspended in 10 ml of plating medium and 
incubated at room temperature for 15 mm 0 5 ml of plating medium was dispensed into 
each well into each well of 8x48 well plates (Coster, 3548) 1 drop of fused cells was 
added to each well and the plates were incubated for 12 days at 37°C, 5% C 0 2 for 12 
days
2 8 3 Screening of hybndomas
OAW42-SR and OAW42-S cells were seeded at 3x104 cells per 100 [i\ of ATCC growth 
medium per well in 96 well tissue culture treated microtitre plates (Falcon, 3072, Becton 
Dickinson) and allowed to grow for 48 hour or until confluent The culture medium was 
discarded and the wells were washed with PBS Cells were then fixed with 0 5% 
glutaraldehyde (v/v), 150 |il per well, (Sigma, G6257) and incubated for 10 mm at 4°C 
to fix the cells The glutaraldehyde was then discarded and the wells were washed 3 
times with PBS If the plates were not required immediately, they were stored in 
blocking buffer (1% w/v BSA, Sigma 3803, 0 1% sodium azide, BDH, in PBS, 150 |il 
per well) at 4°C otherwise, plates were incubated at 37°C for 1 5 hr in 0 1% (w/v) 
gelatine in PBS When large hybridoma colonies were observed in the 48 well plates 
lOOjul of supernatant was aseptically removed, added to the cell coated plated and 
incubated at 37°C for 1 hr This solution was then discarded and the plates washed with 
wash buffer (0 1% (v/v) Tween 20 (Merk) in PBS) 50 \i\ of secondary antibody, alkaline 
-phosphatase-linked rabbit anti-mouse immunoglobulins, IgG, IgM (Dako, diluted 
1/10,000 in PBS 0 1% (v/v) Tween 20) was added to each well and incubated at 37°C 
for 1 hr The secondary antibody was removed and the plated washed with wash buffer 
as before Plates were then incubated with the substrate solution (1 mg/ml p-mtrophenyl 
phosphate (PNPP, Sigma 104-0) in 0 1M glycine, 0 001% MgCl2, 0 001 M ZnCl2, pH 
10 4) at 37°C for 0 5-1 hr or until a yellow colour appeared in the wells The reaction 
was stopped by the addition of 1M NaOH which also enhanced to colour Absorbencies
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were read on an Titerex ELISA plate reader at 405 nm Positive reactivity was 
determined by comparing supernatant containing wells with those which had been 
incubated with PBS instead of supernatant
2 8 4 Subculture of Hybndomas
Positive clones were further cultured to 6 well plates (Costar) and gradually transferred 
into medium containing HT ( Hypoxanthine, Thymidine, Boehringer Mannheim, 
623091) Eventually hybndoma clones were weaned off HT containing medium into 
DMEM supplemented with 5% Bnclone and 10 % heat inactivated FCS
2.8 5 Single cell cloning by limiting dilution
Using a mulit-channel pipette (eppendorff) 100 \i\ of DMEM growth medium was 
pipetted into each well of a sterile 96 well tissue culture treated plate 100 |il of cell 
suspension from rapidly growing hybndomas at a concentration of lxlO4 cells was added 
to the top left hand well and mixed by pipetting 1 in 2 doubling dilutions were 
performed down the left hand row of the plate (8 wells, 7 dilution steps) and mixed by 
pipetting ensuring to change t pipette tip each time 1 in 2 dilutions were also performed 
across the plate using a multi-channel pipette Plates were then incubated for 7-10 days 
at 37°C, 5 C 0 2 Wells with a single colony were chosen Hybndomas were cultured to 
25 cm2 flasks and the procedure repeated The selected clones were screened by 
immunocytochemistry (Section 2 9 5 ) and frozen stocks made of positive clones
2 8 6 Propagation of hybndomas by ascitic tumour production
Prior to introducing the hybndoma cells into the peritoneal cavity, Balb/C mice were 
primed with 0 5 ml of Freunds incomplete adjuvant (Sigma P5506) into the peritoneum 
24 hours later, 5x10s hybndoma cells were aseptically resuspended in PBS (Oxide, 1 
tabled dissolved in 100ml dH20  yielding PBS pH 7 4 ), and injected inraperitoneally 
Tumour growth was evident 7-10 days post-injection The mice were sacrificed and the 
ascitic tumour fluid drained under sterile conditions by insertion of a sterile 21-gauge
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needle into the peritoneal cavity The ascitic fluid was centrifuged at 3,400 rpm for 10 
minutes and the supernatant carefully removed, aliquoted and stored at -20°C 
Hybndoma cells were re-cultured in DMEM growth medium
2 8 7 Isotype analysis
Isotype analysis was carried out using the ELISA Isotyping Kit (Biorad) and the Isostnp 
mouse monoclonal antibody isotyping kit (Boehringer Mannheim, 1493027)
For the ELISA method, ascites was diluted 1/100 and 1/1000 in carbonate buffer pH 9 5 
100|il of the ascites solution was added to each well of a chosen column and plates were 
incubated for 1 hr at 37°C and then over night at 4°C Mouse immunoglobulins were 
included as a positive control Plates were washed with wash buffer (0 1% (v/v) Tween 
20 in PBS Non-specific sites were blocked with 1% (w/v) BSA in PBS for 1 hr at 37°C 
The blocking buffer was then discarded and washed as before 100 jil of appropriate 
rabbit-anti-mouse immunoglobulin (l e anti-IgG 1, 2a, 2b, 3, anti-IgM, anti-kappa, and 
anti-lambda chain etc ) from the kit was added to each row (each column containing 
immobilised test antibody or standards) Plates were incubated at 37°C for 1 hr Plates 
were then washed as previously described 100 \i\ of goat anti-rabbit immunoglobulin- 
alkaline phosphatase-conjugated antibody diluted in blocking buffer was then added to 
each well and incubated at 37°C for 1 5 hr Following the washing step, PNPP in 
substrate solution was added to each well and incubated for 5-1 5 hr at 37°C Colour 
enhancement was achieved by the addition of 0 2 M NaOH Plates were read o an 
ELISA plate reader at 405 nm
Isotype analysis was also carried out using the Isostnp method The isotyping strip bears 
immobilised bands of goat anti-mouse antibodies corresponding to the common mouse 
antibody isotypes and to kappa and lambda light chain The development tube also 
contains anti-mouse lambda and kappa light chain antibodies immobilised on latex beads 
which bind to all mouse monoclonal antibodies regardless of isotype Upon addition of 
the test strip to the development tube containing the teat antibody/latex bead complex, 
the complex travels up the strip until it binds to the goat anti-mouse antibody specific for 
the monoclonal isotype Results appear as a blue band in two sections corresponding to
6 7
the subclass and light chain type.
Hybridoma supernatants were diluted 1/100 and ascites 1/20,000 in PBS and incubated 
for up to 10 min at room temperature. Once the positive control bands were suitably 
developed, the black strip ant the base of the isotyping strip was removed to prevent any 
further band development.
2.8.8. Antibody purification
Monoclonal antibody was purified from ascitic fluid using the Immunopure (A/G) IgG 
Purification Kit (Pierce 44902). The protein A/G column was first equilibrated with 10 
ml of binding buffer. Ascites was diluted 1:1 in binding buffer. The diluted sample was 
applied to the column and allowed to flow completely through the column and washed 
with 20 ml of binding buffer. The bound IgG was the eluted by the addition of 10 ml of 
elution buffer. The elute was collected as a 7 ml fraction. The column was regenerated 
by running thorough 8 ml of elution buffer followed by 10 ml of dH20  with 0.02% (w/v) 
sodium azide and the column stored in this way. The pH of the elution buffer was raised 
to approximately 7.5 with the addition 3 ml of binding buffer. Elutes were then 
transferred to Slid-a-lyzer dialysis cassettes (Pierce 66406) and dialysed against 2 
changes of PBS overnight on a stirring platform at 4°C.
2.8.9. Determination of Protein concentration
Protein concentration was determined by the BCA method (Pierce, 23225). Protein 
samples (cell lysates or purified IgG) were diluted to a final volume of 100 jllI in PBS. 
BSA protein standards of known concentration were also prepared from a 2mg/ml stock 
solution in PBS in borosicilliate test tubes. Negative controls consisted of PBS. 100 \i\ of 
the BCA reagent (prepared according to the manufacturers instructions) was added to 
each protein sample, mixed and incubated at 60°C for 30 min. Following a brief cooling 
period, samples were transferred to plastic cuvettes (Elkay) and the absorbencies read on 
spectrophotometer at 540 nm. A standard curve of absorbance vs protein concentration
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of the BSA standards was constructed The protein concentration of the test samples was 
then estimated
2 8 10 Determination of IgG concentration
IgG concentration was determined by radial immuno-diffusion RID (The Binding Site)
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2 9 Immunological studies
2 9.1. Coating slides with poly-L-lysine
Washed microscope slides were coated with poly-L-Lysine hydrobromide (Sigma P I274) 
following the procedure of Huang et al (1983) Slides were stored at room temperature 
for up to 1 month
2 9 2 Preparation of cytospins
Cells from actively growing cultures were trypsimsed (Section 2 6 1), washed 3 times in 
10 min in PBS and diluted to a final concentration of lx l0 6 cells/ml in PBS 100 |il of 
the cell suspension was then applied to modified eppindorf component of a cytofuge and 
spun onto poly-L-lysine coated glass slides at 400 rpm for 4 mm Cytospins, consisting 
of 2 "sections" were allowed to air dry over night Slides were dipped in ice cold acetone 
at -20° C, allowed to air dry and stored wrapped in tin foil at -20° C until required
2 9.3 Immunofluorescence analysis on live cells
When immunofluorescence is carried out on live cells only cell surface components are 
detected All reagents were kept at 4°C Cell suspensions at lxlO6 cells/ml were prepared 
in PBS 100 |al of cell suspensions was placed in an eppindorf tube mixed and incubated 
at 4°C for 30 min Negative controls consisted of cell suspension incubated with mouse 
immunoglobulins (Vector Labs, 1-2000), diluted 1/10,000 in PBS Cells were washed 3 
times in 12 mm in PBS by centrifuging at 2,000 rpm in a microfuge Cell pellets were 
resuspended in 100 \x\ of anti-mouse IgG FITC-labelled secondary antibody, diluted 1/50 
in PBS, (Boehringer Mannheim 814385) and incubated in the dark for 30 min at 4°C 
Cell suspensions were washed as described and following the final washing step the 
supernatant was removed Cells were then aspirated in 1 drop of Vectashield Mounting 
Medium (Vector Labs Ltd UK H I000) 20 \i\ of the suspension was placed on a 
microscope slide, covered with a coverslip and the edges sealed with nail polish Slides 
were viewed using a Nikon phase contrast microscope fitted with an FITC filter
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For cytoplasmic antigens, cells were fixed with Facslyse (Becton-Dickinson) diluted 
according to the manufacturers instructions Cells were incubated for 1 min in the 
Facslyse solution
2 9 4 Immunofluorescence analysis on fixed cells
Indirect immunofluorescence on fixed cells was carried out on cytospin preparations 
(Section 2 9 2 )  Cytospins were fixed in ice-cold acetone (BDH) for 1,2,4,'7 and 9 min 
and allowed to air dry at room temperature The test antibody was applied to one 
cytospin section on the cytospin while mouse IgG diluted 1/10,000 in PBS was applied 
to the other section The cytospins were incubated for 30 min at room temperature in a 
humidified chamber Slides were then washed in PBS 0 1% (v/v) Tween 20 3 times in 10 
mm 50 jil of an anti-mouse FITC-labelled secondary antibody diluted 1/50 in PBS was 
applied to each section and incubated at room temperature for 30 min Slides were 
washed as before 1 drop of Vecta Shield mounting medium was applied to the centre of 
the slide and mounted as described in Section 3 9 3
2 9 5 Immunocytochemical analysis using the StrepAB complex/HRP method
All immunocytochemical studies on cytospins or formalin fixed paraffin-embedded 
archival material were performed following the method of Hsu et a l , (1981) using an 
avidin-biotin (ABC) horseradish peroxidase (HRP) conjugated kit The use of 
diaminobenzidine (DAB) as a substrate for the peroxidase enzyme produced an insoluble 
brown precipitate, which was indicative of primary antibody activity
Frozen cytospin preparations were allowed to equilibrate to room temperature 
(approximately 10-15 min) Slides were then fixed in ice cold acetone for 4 to 10 m in, 
depending on the antibody, and allowed to air dry A wax pen (Dako S2002) was used to
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encircle each "section" to contain the various solutions involved Cytospins were then 
incubated with 0 3% (v/v) hydrogen peroxide (BDH) in methanol (BDH) to quench 
endogenous peroxidase activity followed by a brief rinse in dH20  and incubation in 
lxTBS for 5 mm Following this cytospins were incubated in 20% (v/v) normal rabbit 
serum (Dako X0902), in lxTBS for 20 min at room temperature to block any non­
specific binding of the secondary antibody (a rabbit host) The excess serum was tapped 
off and the optimally diluted primary antibody was applied to one of the cytospin 
sections while mouse immunoglobulins diluted 1/10,000 in lxTBS served as a negative 
control Slides were placed in a humidified atmosphere and incubated at room 
temperature for 2 hr or at 4° C over night Following primary antibody incubation, 
cytospins were washed 3 times in 15 min in lxTBS, 0 1% (v/v) Tween 20 (TBS/Tween) 
and then incubated with a biotinylated rabbit anti-mouse IgG secondary antibody (Dako 
E345) diluted 1/300 in TB S/Tween, for 30 mm at room temp Following this cytospins 
were washed as before in TB S/Tween The Strep AB complex (Dako K337 prepared 
according to manufacturers instructions) was applied to the cytospin and incubated at 
room temperature for 30 min Following the washing steps, liquid DAB (Dako K3565 
prepared according to the manufacturers instructions) was applied to each "section" of 
the cytospin for 7-10 min at room temp Cytospins were rinsed in tap water, terminating 
the reaction, counterstained in Coles haemotoxyhn (Sigma HHS-1S, 15 sec), 
differentiated in 1% (v/v) hydrochloric acid in methanol (15 sec) and differentiated in 
Scotts tap water (10 sec) nnsing in water between each step Cytospins were then 
dehydrated in graded alcohols (2 x 3  min in 70 %, 90% and 1005 (v/v) IMS in dH20  and 
cleared in xylene (BDH, 2 changes of 5 mm each) Cytospins were mounted in DPX 
mounting medium (BDH) and allowed to dry over night Cytospins were viewed under a 
light microscope
For 3/B6/LMR-5 competition experiments, cytospins were incubated with either 3/B5, 
LMR-5 or the anti-vault polyclonal antibody N2 for 2 hours at room temperature 
followed by 3 washed m i x  TB S/Tween and a second with MAb 3/B6 LMR-5 or N2 
polyclonal antibody overnight at 4°C To determine the specificity of species-specific 
secondary antibodies, the mouse primary antibody, 3/B6 was incubated with the rabbit 
anti-rat specific (Dako E0468) and the goat anti-rabbit specific (E0432) specific 
biotinylated secondary antibodies This experiment was repeated for the rat primary 
antibody LMR-5 (cytospins were probed with an anti-mouse secondary (Dako E0464)
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and the anti-rabbit secondary biotinylated antibody) and the rabbit polyclonal antibody 
N2 (cytospins were probed with the anti-rat and anti-mouse specific biotinylated 
secondary antibodies) Cytospins were then processed as outlined above 
A modified protocol was use for formalin-fixed paraffin-embedded histological material, 
slides were de-waxed in 2 changes of xylene (4 min each, BDH) and cleared in graded 
alcohols (IMS, 100%, 90% and 70%, 2 X 4  min each), washed briefly m ultrapure and 
then in 1 X TBS for 5 mm Slides were then incubated for 5 min in 0 3% (v/v) hydrogen 
peroxide in ultrapure water to quench endogenous peroxidase activity Following all 
antibody incubations, sections were first washed gently with 1 X TBS 0 1% (v/v) Tween 
20 from a wash bottle before standard wash procedures Slides were then viewed by Dr 
Peter Kelehan, Dept of Pathology, The National Maternity Hospital, Holies St Dublin)
Table 2 9 5 Antibodies used in îmmunocytochemical analysis
Antibody Source Concentration
Cytospins Paraffin-embedded 
tissue sections
3/B6 4-6 ng/ml 10-15|ag/ml
LRP-56 Prof Rik Scheper 5 ng/ml lOjig/ml
LMR-5 Prof Rik Scheper 2(ig/ml 4-6ng/ml
MRP-rl Prof Rik Scheper 2|ig/ml 5|ig/ml
UIC-2 commercial ND 2[xg/m\
MDR-1 (clone BioResearch Ireland ND 1/50 dilution of
6/1C) mouse ascites
Anti-vault poly Prof L Rome 1/100 dilution of ND
clonal antibody rabbit serum
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2 10 Protein analysis by Western Blotting and immunoprécipitation
2 10 1 Sample preparation for gel electrophoresis
Cells were prepared in PBS as outlined in section 2 9 3 Protein inhibitors were also 
added to the cell suspension (protease inhibitor cocktail tablets, Boehringer Mannheim 
1697498) Cells were lysed by somcation Complete lysis was confirmed by viewing 
under an inverted microscope Protein concentration was determined by the BCA 
method (Section 2 8 9) Protein samples were prepared in loading buffer (2 5 ml 1 25M- 
Tns/HCL pH 6 8, 1 Og SDS, 2 5 ml mercaptoethanol (Sigma M6250), 5 8 ml glycerol 
and 0 1% bromophenol blue (Sigma B8026) and boiled for 3 min Samples were stored 
at -20 until required for a maximum of 1 month
2 10.2 Gel electrophoresis
Proteins for Western blotting were separated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE, Laemmli et al, 1970) Gels were prepared as outlined in table 2 10 1 and 
poured into clean 10cm x 8cm gel casting cassettes (Mighty Small II, Hoefer) which 
consisted of 1 glass plate and 1 aluminium plate separated by 0 75cm2 plastic spacers 
The resolving gel was poured flat and allowed to set A layer of saturated isopropyl 
alcohol was gentle layered over the resolving to prevent drying out The stacking gel was 
then poured and a comb was fitted allowing the formation of wells for sample loading 
Once the gels had set (at room temperature), they were immediately wrapped m tinfoil 
and stored at room temperature or at 4°C if not used immediately 10-15 jj.g of protein 
was applied to each well of the polyacrylamide gel Empty wells were loaded with 1 x 
loading buffer to ensure even running of the gel Pre-stained molecular weight markers 
(Sigma, SDS-6H) were also loaded onto the gel for he determination of the molecular 
weight of unknown protein samples Gels were run at 250 volts and 45 mih-amps (Atto 
power pack, Atto Corp , Japan) for 1-15 hr (values were halved if only one gel was 
being run) When the bromophenol dye front had reached the end of the gel,
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electrophoresis was stopped, the gel removed and equilibrated in transfer buffer (Tris- 
Glycine, 10X, BDH) for 15 mm
Table 2 10 2 Preparation of electrophoresis gels
Stock solutions Resolving gel (7 5% 
acrylamide
Stacking gel (5% 
acrylamide)
“Acrylamide/ 
bis-Acrylamide stock
3 8 ml 0 8 ml
dH20 9 1 ml 4 0 ml
b8X Tris-HCl pH 8 8 1 88 ml
C16X Tris-HCl pH 6 8 0 3 ml
d10% SDS 150 pi 50 Ml
e10% Ammonium 
persulphate
60 Ml 17 Ml
fTEMED 10 Ml 5 jul
a 30% Acrylamide/ 1 034% bis-Acrylamide (Scotlab, Anachem SL-9232) 
b PAGE resolving gel buffer (BDH 444092L) 
c PAGE stacking gel buffer (BDH 444102T) 
d 10% SDS (BDH) (W/V) in DH20
e 10% Ammonium persulphate (Sigma A-3678) (w/v) in dH20  
f TEMED [ N, N, N, N-T etr am ethyl ethyl enediam i ne ] (Sigma T-9281)
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2 10 3. Western Blotting
Western Blotting was carried out according to the protocol of Tobwin et al (1979) 8-10 
sheets of Watman filter paper (Grade I) were soaked in transfer buffer (Tris-glycine, 10X 
BDH 444145H diluted 1 in 10 in dH20) and placed on the anode of a semi-dry blotting 
apparatus (Biorad Transblot SD) taking care to remove all bubbles by rolling a glass 
pasteur pipette across the sheets PVDF membrane (Boehnnger Mannheim, 972206, pre­
soaked according to the manufacturers instructions) was placed over the filter paper and 
the gel laid on top of this A further 8-10 sheet of filter paper were paced over the gel 
and any air bubbles removed The cathode was carefully laid on top of the stack and the 
proteins transferred form gel to PVDF membrane at 15 volts and 34 mili-amps for 25 
min
2 10 4 Development of western blots by enhanced chemiluminescence (ECL)
Following Western Blotting, the filter paper was removed and the membrane blocked for 
non-specific binding by incubating for 2 hr on a rocking platform with non-fat milk 
(Marvel, Cadbury) After the blocking step was complete, the blot was rinsed once in 
TBS (0 05 M  Tns-HCl pH 7 5 ), cut into strips (if required) and incubated with the 
primary antibody optimally diluted in TBS/Tween over night at 4° C on a rocking 
platform Mouse IgG diluted 1/5,000 in TB S/Tween served as a negative control The 
following day blots were washed 3 times within 30 min with TBS 0 5% (v/v) Tween 20 
Blots were then incubated with a rabbit anti-mouse HRP-conjugated secondary antibody 
(Dako, P0447) diluted 1/4,000 in TB S/Tween for 1 hr at room temperature on a 
rocking platform The Blots were washed as before, laid out on a glass plate covered in 
parafilm and incubated with ECL reagents (Amersham RPN 2109) for 1 min at room 
temp Super Signal Ultra (Pierce) was mixed according to the instructions and applied to 
the blots for 5 min at room temperature Following this the solution was tapped off, the 
blot laid between two sheets of cling film and exposed to LUMI film, chemiluminescence 
film (Boehringer Mannheim 166657) for various time periods and processed using 
standard x-ray developing procedures Dried film was aligned with prestained molecular 
markers for molecular weight determination
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This protocol was modified for biotin-labelled immunoprecipitates PVDF were 
incubated in 1 5% BSA as it had been demonstrated previously that non-fat milk contains 
endogenous biotin, which caused non-specific bands to appear, (Section 2 10 5) 
Following the blocking step, blots were rinsed once in lxTBS and placed in an anti- 
biotin secondary antibody diluted 1/4,000 in TB S/Tween for 1 hr at room temperature 
on a rocking platform and processed as above
2.10 5. Immunoprécipitation
Immunoprécipitation of specific proteins was carried out using a new cellular labelling 
and immunoprécipitation kit (Boehringer Mannheim 1647652) The protocol was 
extensively modified for the purposes of this study (Masterson, Moran, Scheper and 
Clynes, in press)
The principle of this procedure is based non-radioactive labelling of proteins or 
glycoproteins on intact cells (or in cell lysates) with D-biotinoyl-e-aminocarporic acid-N- 
hydroxysuccmimide ester (biotin-7 NSH) which covalently binds free ammo groups 
(mainly lysine residues) These labelled proteins can then be immunoprecipitated and 
detected using a biotin specific antibody
Unless stated otherwise, all reagents were supplied in the immunoprécipitation kit The 
modified procedure was earned out as follows, whole cell lysates were prepared from 
cell pellets containing a maximum of 5xl07 cells/ml Cell lysates were prepared in lysis 
buffer and sonicated as outlined in Section 2 10 1 Following a 20 min incubation penod 
in lysis buffer (to solubilise membrane protein), cell lysates were labelled with biotin-7- 
NHS for 15 mm at 4° C This reaction was stopped by the addition of stop reagent for a 
further 15 mm at 4° C Cell lysates were then diluted 1 1 with dilution buffer and pre­
cleared by incubating with 2 changes of Protein A-linked Agarose beads (2x4 hours) 
following the final incubation step, the primary antibody was optimally diluted in the cell 
lysates (anti-OAW42-SR MAb 3/B6 final concentration of 40 |!g/ml, LRP-56, 15 (ig/ml, 
mouse immunoglobulins at a concentration of 15 [ig/ml served a negative control) and 
incubated at 4° C for 1 hour to over night on a rocking platform These incubation times
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were based on the protocol of Scheper et al (1993) The following day 50 |il of protein 
A/G-linked agarose beads were added to the cell lysates and incubated for various time 
periods at 4° C on a rocking platform to precipitate the antibody-antigen complex 
Pelleted beads were then washed with two changes of wash buffer 1, one changes of 
wash buffer 2 or 2 changes of a low salt buffer (100 m M  NaCl) and two changes of wash 
buffer 3 Following the removal of any remaining supernatant, pellets were resuspended 
in 60 |al or loading buffer and prepared for gel electrophoresis as outlined in section 
2 10 2 followed by western blotting, section 2 10 3 and blot development using ECL 
section 2 10 4
For competitive immunoprécipitation experiments, supernatants from over-night 
precipitations were carefully removed concentrated to 1/5 of their original volume 
(section 2 10 6), and subjected to SDS-PAGE (section 2 10 2) and Western Blotting 
(2 10 4 )
For glycosylation studies, OAW42-SR and SW1573/2R120 cells were seeded in 75 cm2 
tissue culture flasks and allowed to attach for 4 hours at 37°C Following this incubation 
penod, Tumcamycin (preventing N-glycosylation Sigma T3843) was added to the flasks 
at a final concentration of 8 jag/ml of growth medium PNAG (preventing O- 
glycosylation was added to different flasks at a final concentration of 2 5 mM/ml of 
growth medium Negative controls consisted of OAW42-SR and SW1573/2R120 cells 
grown without glycosylation inhibitors Flasks were incubated for 16 hours at 37°C 
Following this incubation penod, the growth medium containing the glycosylation 
inhibitors was removed and the monolayers washed three times with sterile PBS Cells 
were then prepared for immunoprécipitation as outlined above
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2 10 6 Immunoprécipitation experiments with OAW42-SR culture medium
To determine whether the 3/B6 antigen or the MVP/LRP was shed into culture medium, 
10 ml of spent medium was taken from cell cultured for 6 days in 75 cm2 tissue culture 
flasks Samples were concentrated 1/10 in Ultrafree 15 concentrators (Milipore 
UFV2BGC10, ) MAb 3/B6 and LRP-56 were added at a concentration of 40 ¡ig/ml and 
15 |ig/ml respectively and incubated overnight at 4°C on a rocking platform Samples 
were then processed as previously described (Section 2 10 5)
2 10 7 Micro-sequencing of 3/B6 protein samples
3/B6 immunoprecipitates of OAW42-SR cells were prepared as previously descnbed 
(Section 2 10 5) and applied to polyacrylamide gels (Section 2102) Following this 
procedure, the gel was halved and one half was stained with Instaview SDS rapid stain 
(BDH 444313F) When the staining procedure was complete, the 2 halves of the gel 
were re-aligned The area of unstained gel corresponding to the stained 3/B6 band was 
excised, minced, placed in 0 5 ml of elution buffer (2 38% (w/v) Hepes, 0 1% (w/v) SDS 
pH 8 0, adjust pH with 1 N NaOH) and incubated over night at room temperature The 
following day, the gel pieces were centrifuged in a microfuge at 13000 rpm for 5 nun 
The supernatant was saved and a further 0 25 ml of elution buffer added to the gel 
pieces, and microfuged as before The protein concentration of the sample was 
determined as previously described (Section 2 8 9) From this method, excised bands 
consistently yielded a minimum of 15jng of the 115 kDa 3/B6 protein 
Gel fragments were prepared for sequencing in the following manner Following gel 
electrophoresis, gels were stained with Coomassie Brilliant-Blue solution [0 025% (w/v) 
Coomassie Brilliant Blue (Sigma), 40% (v/v) Methanol (BDH), 7% (v/v) acetic acid 
(BDH)] for 10 min at room temperature on a stirring platform The gel was then 
destained (2 changes) to remove background staining with destains solution (10% (v/v) 
acetic acid 30% (v/v) ethanol (BDH) for 30 mm The 3/B6 band was removed and stored 
at sent to Eurosequence qv (Groningen, The Netherlands) for internal sequencing
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Following trypsin protein digestion of the eluted band, peptides were purified be high 
performance liquid chromatography (HPLC) Purified peptides were then subjected to 
Edman degradation (Edman 1956 Ilse and Edman 1963) Phenylisocyanate (Edman's 
reagent) reacts with the N-terminal amino acid groups of proteins under alkaline 
conditions to form their phenylthiocarbamyl adduct This produce was then treated with 
anhydrous hydrofluoric acid which cleaves the N-terminal residue as its thiazolinone 
derivative but does not hydrolyse other peptide bonds These residues were then 
selectively denvativised to more stable phenylthiohydantion derivatives and sequenced in 
an automated pulsed-liquid sequencer (Applied Biosystems model 477A) Stepwise 
released phenylthiohydantion amino acids were identified by on-line RP-HPLC on the 
basis of their elution times Calibrations were in the form of known denvatised amino 
acids
2.11 Effect of MAb on cultured cells
This experiment was carried out according to the protocol of Yang and Page (1995) 
Heat inactivated FCS was used in the culture medium (heat inactivation was achieved by 
incubating aliquots of FCS at 50 °C for 30 min) OAW42-SR cells were seeded at 
densities of 1 X 104/well and cultured overnight at 37°C, 5% C02 in 96 well tissue 
culture plates The following day, growth medium was removed and fresh growth 
medium containing varying concentrations of MAb 3/B6 were added to each column of 
the plate Controls consisted of OAW42-SR cells grown in the absence of MAb and in 
the presence of mouse IgG control antibody (Pierce) diluted over the same range of 
concentrations as MAb 3/B6 Plates were prepared in duplicate and incubated for 6 days 
as before Cell density was determined using acid phosphatase end-point assay (Martin 
and Clynes, 1991) 100 fil of assay substrate (10 m M  p-mtrophenyl phosphate (Sigma 
pi04) in 0 1 M  sodium acetate (Sigma S-2889), 0 1% Triton X-100 (Sigma XI00) was 
added to each well The assay substrate was prepared just before use with the pH 
adjusted to pH 5 5 The plates were incubated for 2 hours at 37°C in 5 % CO2 and read 
in a dual beam ELISA plate reader at a wavelength of 405 nm (reference wavelength 620
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snm) Colour enhancement was achieved by the addition of 50jli1 of 1 5 N NaOH
2 12 Drug accumulation studies with MAb 3/B6 and LRP-56
The accumulation of adnamycin in the presence of monoclonal antibodies was measured 
by a modification of Ganapathi and Grabowski (1983) and Versantvoort et al (1992) 
OAW42-SR cells were grown in 75cm2 flasks until approximately 80% confluency was 
achieved Cells were then trypsimsed and 1 ml was added at a concentration of 4 X 105 
cells/ml to each well of a 6 well cluster plates (Costar 3616) A further 3 ml of complete 
medium was added to each well and the cells incubated at 37° C, 5 %  C02 over night 
The following day the medium was decanted and 1 ml ofDMEM containing lOOjag/ml of 
MAb 3/B6 or LRP-56 for 30 min at 37° C This medium was then decanted and 4 ml of 
complete medium containing \0\xM adnamycin or adnamycin/cyclosponn A, lO^ ig/ml 
was added to the plate and incubated at 37° C in 5 %  C02 A senes of controls were used 
where cells were grown in the absence or presence of monoclonal antibody, adnamycin 
or the circumvention agent, cyclosporin A or combinations of these reagents After 
specific time intervals, the drug-containing medium was decanted and the cells were 
nnsed twice in ice-cold PBS 2 ml of ice-cold ultrapure water was added to the wells and 
left for approximately 5 min to facilitate lysis of the cells The adnamycin was the 
extracted from the cells by the addition of 2 ml of 0 6 N HCL-Methanol solution for 
approximately 5 min The resulting solution was transferred to a universal container and 
centrifuged at 4,000 rpm for 10 min at 4°C The supernatant was collected and the 
fluorescence of each solution determined using a Perkin-Elmer LC50 luminescence 
spectrometer with an excitation wavelength of 470 nm and an emission wavelength of 
585 nm Slit widths for excitation and emission were 10 nm and 15 nm respectively The 
concentration of adnamycin present in each sample was quantified from a linear standard 
curve prepared form the fluorescence of known adnamycin concentrations
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Results
3 1 Production and purification of monoclonal antibodies
3 1.1 Production of monoclonal antibodies
Using whole cell preparations of the resistant cell line OAW42-SR and its resistance 
clone OAW42-S, an immunisation schedule was carried out as described in section 2 8 2 
of Materials and Methods The fusion rate for both immunisations was approximately 
95%
Following three preliminary screenings of hybndoma supernatants 6 appeared to 
consistently reacted with the OAW42-SR cells while 5 reacted with the OAW42-S cells 
Of the 6 anti-OAW42-SR clones, 2 clones designated 3/B6 and 5/C4 were chosen for 
further characterisation while 1 anti-OAW42-S clone, designated 3/E3 was also chosen 
for characterisation In initial experiments MAb 3/B6 did not cross react with OAW42-S 
cells, subsequent experiments showed that it did cross react This suggests that there may 
have been low concentrations of MAb in the initial test supernatants Longer culture 
times would have increased the amount of MAb being secreted by the hybndoma clones
3 12  Isotyping of monoclonal antibodies
Supernatants from hybndoma clones 3/B6 5/C4 and 3/E3 were used to determine the 
class and subclass of the MAb using an antibody isotyping kits as described in section
2 8 7 of Materials and Methods Results indicated that the isotype of the of the 3 MAb
was IgG class, subclass 1
3 13  Cloning of Hybndomas by limiting dilution
Following cloning by limiting dilution, four 5/C4 clones were isolated and further 
characterised by immunocytochemistry Each clone gave similar granular outer 
cytoplasmic staining therefor it was decided to choose clone 5/C4 E9B for further 
characterisation based on absorbance results by ELISA, (immunocytochemistry results 
not shown)
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Nine 3/B6 clones were isolated and characterised in the same manner Clone 3/B6 1E3 
was chosen for further study and recloned, (immunocytochemistry results not shown)
3 14  Propagation of hybndomas by ascitic tumour production
Ascitic fluid and hybndoma cells were removed from the peritoneal cavity of Balb/C 
mice after 7 days as outlined in section 2 8 6 of Materials and Methods Hybndoma cells 
were successfully separated from the ascitic fluid and re-cultured Approximately 5 ml of 
ascites was obtained from clones 3/B6 and 3/E3
This technique proved unsuccessful for clone 5/C4 Approximately 4 days after the IP 
injection the mice became unhealthy and were sacnficed immediately 2 ml of ascitic fluid 
was obtained from the mouse which reacted weakly with OAW42-SR cell by ELISA 
This may have been a problem with the mice however mice are generally in a suitably 
healthy state prior to ascites production Hybndoma cells may have been carrying 
bacterial or fungal infections which may have affected the health of the mice Cells 
recovered from the ascitic fluid did not survive in culture It was decided therefore to use 
culture supernatant from the 5/C4 hybndoma in subsequent experiments There appeared 
to be sufficient quantities of MAb in these culture supernatants and it was not necessary 
to concentrate them
3 15  Determination of antibody concentration
Antibody concentration in the ascites was determined using RID plates (section 2 8 10 
materials and methods) Results showed that 3/B6 ascites contained approximately 2 5 
mg/ml IgG while clone 3/E3 contained an antibody concentration of 2 7 mg/ml Culture 
supernatant from clone 5/C4 was not assayed by this method
3 16  Purification of ascites from hybndoma clone 3/B6
MAb was punfied on protein A/G sepharose mini-columns as outlined in section 2 8 8
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Initial purification steps resulted in a low yield of IgG concentration, approximately 80
fig/ml Yields were increased in subsequent purification procedures by omitting the 
desalting column and dialysing the buffered antibody solution against 1 X TBS (0 5 M
pH 7 5) This resulted in yields of between 200 and 210|ig/ml IgG concentration The
loss of MAb could have been due to incorrect elution from the desalting column
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3 2 Characterisation of MAb 3/B6
3 2.1. Indirect immunofluorescence on live cells with MAb 3/B6
Immunofluorescence studies were carried out on live cell preparations of OAW42-SR 
with MAb 3/B6 and LRP-56 (section 2 9 3 matenals and methods) Results are 
illustrated in Figure 3 2 11
MAb 3/B6 recognised a cell surface antigen, indicated by a fluorescent ring around the 
cell No staining was observed when OAW42-SR cells were incubated with the anti- 
LRP/MVP antibody LRP-56 Similarly, no plasma membrane staining was observed in 
the negative control (OAW42-SR cells incubated with mouse control IgG) These results 
indicated that MAb 3/B6 recognised a surface antigen while confirming previous 
observations that the LRP/MVP is not expressed on the cell surface
A series of multidrug resistant/sensitive cell lines were screened with MAb 3/B6 in order 
to further examine the staining pattern of this antibody, results are outlined in figures 
3 2 12 and 3 2 13 and table 3 1 2
It appeared from these studies that MAb 3/B6 detected a cell surface antigen which was 
expressed primarily in low level resistant cell lines of different histological origins 
Heterogeneous staining was observed on the OAW42-SR, DLKP, DLKP-A, A2780, 
SW1573/2R120, OAW42-A1 and OAW42-A cell lines Approximately 80% of OAW42- 
SR cells had strong plasma m em brane staining while a greater degree of heterogeneity in 
staining was observed on the DLKP and DLKP-A cell lines with 30% and 10% of cells 
stained Similar results were observed with the SW1573-2R120 cell line The A2780 line 
exhibited weak membranous staining on approximately 20% of cells The OAW42-A1 
and OAW42-A cell lines also had mainly weak staining with approximately 10% of cells 
staining intensely Examination of the COR-L23R cell line revealed intense membranous 
fluorescent staining on all cells This was also observed on the negative control All other 
negative controls had negligible staining
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Table 3 2 1 Expression of the antigen detected by anti-OAW42-SR MAb 3/B6 on 
a panel of human MDR human sensitive and resistant cell lines by 
indirect immunofluorescence on live cells
C tlU m t % of pm iiivt cells
OAW42-SR
OAW42-S
80% of cells stained positive, 60% of cells with strong plasma 
membrane staining -
90% of cells with weak plasma membrane staining
OAW42-A1
OAW42-A
10% with weak plasma membrane staining 
10% have weak plasma membrane staining
DLKP
DLKP-À
30% of cells had plasma membrane staining
10% of cells stained, 5% had strong plasma membrane staining
A2780
SWT573/2RÎ20 ~
20% of cells were stained with weak plasma membrane staining 
30% of celis stained, 10% have strong plasma membrane staining
COR-L23R all cells had strong plasma membrane staining including the negative 
control
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Figure 3.2.1.1. Immunofluorescence studies on live cells (section 3.2.1.). OAW42- 
SR cells probed with MAb 3/B6 and LRP-56 detected using an FITC-linked 
secondary antibody, (a) OAW42-SR probed with MAb 3/B6, (b) OAW42-SR 
probed with MAb LRP-56, (c) negative control, OAW42-SR probed with mouse 
IgG. Photographs taken at 40X.
(a)
(b)
(ej
OAW42-SR
(f)
OAW42-A1
OAW42-A
(d)
- ,V, BBÊmMMÊËirSÊ0$iiÿm  M
(g)
DLKP
Figure 3.2.I.2. Indirect immunofluorescence studies on live cells with MAb 3/B6 
(section 3.2.1.). MAb 3/B6 was detected with a FITC-labelled secondary antibody. 
(a)-(d) were taken with FITC filter, (g)-(h), were taken under normal light (40X).
8 8
SW1573/2R120
Figure 3.2.I.3. Indirect immunofluorescence studies on live cells with MAb 3/B6 
(section 3.2.1.). MAb 3/B6 was detected with a FITC-labelled secondary antibody. 
(a)-(f) taken with FITC filter, (e), (f) and (h) are negative controls, cells probed with 
mouse IgG (g) was taken under normal light, (40X).
3 2.2 Indirect immunofluorescence on fixed cells
Acetone fixed cytospins of OAW42-SR and OAW42-S cells were probed with MAb 
3/B6 to investigate if the antigen recognised by this antibody was also expressed 
intracellularly MAb LRP-56 was included as a control (section 2 9 4 materials and 
methods) The optimum fixation time was found to be 4 min in ice cold acetone
Granular cytoplasmic and plasma membrane staining was observed when OAW42-SR 
cells were probed with MAb 3/B6, Figure 3 2 2 The staining appeared to be evenly 
distributed throughout the cytoplasm No staining was observed on the negative control 
In contrast, there appeared to be a greater degree of plasma membrane staining when this 
antibody was used to probe the OAW42-S cells but similar fluorescent staining was also 
observed on the OAW42-S negative control The anti-LRP MAb LRP-56 stained 
OAW42-SR and OAW42-S cells, with fluorescent staining localised mainly to the 
peripheral cytoplasm These results appeared to correlate with those observed in section 
3 2 1 for live cell preparations of OAW42-SR and OAW42-S Similarly, it was also 
confirmed that MAb LRP-56 did not stain the plasma membrane of the OAW42 variants
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Figure 3.2.2. Immunofluorescence studies on OAW42 variants with MAb 3/B6 and 
LRP-56 (section 3.3.2.). (a) OAW42-S probed with 3/B6, (b) OAW42-S probed 
with LRP-56, (c) OAW42-SR probe with 3/B6, (d) OAW42-SR probed with LRP- 
56, (e) and (f) are negative controls, OAW42-S and OAW42-SR respectively 
probed with mouse IgG. Photographs were taken at 40X.
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3.2.3. Immunocytochemical analysis of MDR cell lines using the ABC method
3.2.3.1. OAW42 variants
OAW42-SR and OAW42-S cell lines were re examined with MAb 3/B6 and LRP-56 
using the ABC/HRP method (outlined in section 2.9.5.). Results are illustrated in Figure
3.2.3.1
Approximately 80% of OAW42-SR cells stained positively with MAb 3/B6. The 
majority of cells exhibited granular cytoplasmic staining which appeared to be evenly 
distributed in the cytoplasm, plasma membrane staining was also observed on these cells. 
MAb 3/B6 also stained approximately 80% of OAW42-S cells. Clear plasma membrane 
staining was observed in this cell line with diffuse granular cytoplasmic staining in some 
cells.
MAb LRP-56 stained the cytoplasm of OAW42-SR and OAW42-S cells. In OAW42-SR 
cells, the staining was mainly located in the periphery whereas in the OAW42-S cells, the 
staining was more diffuse. No plasma membrane staining was observed with this 
antibody. There was no significant staining observed in the negative controls. These 
results were similar to those observed in the previous section.
3.2.3.2. Screening of other cell types
To further investigate the expression of the antigen recognised by MAb 3/B6, a panel of 
multi-drug resistant human and murine tumour cell lines were examined with MAb 3/B6 
and LRP-56 by immunocytochemistry (which was included for comparison). Results are 
outlined in table 3.2.3.2. and Figures 3.2.3.2.1-3.2.3.2.4. MAb 3/B6 reacted positively 
with the majority of cell lines in this panel but with different degrees of intensity.
Strong granular cytoplasmic and plasma membrane staining was observed in the LRP 
positive cell line SW1573/2R120 with 90% of cells showing positive staining, while the 
parental SW1573 and 2R160 variant were stained to a lesser degree when these cell lines 
were probed with 3/B6. In the A2780 series of variants, 3/B6 stained 90% of the LRP 
cDNA transfected line AC 16 whereas the AC 12 variant (transfected with a partial cDNA
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sequence) only 30% of cells were stained The staining was predominantly located in the 
plasma membrane which differed from the parental (untransfected) A2780 cell line where 
10% of cells showed low level granular cytoplasmic staining GLC4/S and GLC4/ADR 
cells also displayed predominantly plasma membrane staining with 30% of GLC4/ADR 
and 5% of GLC4/S cells staining positively with 3/B6 No3/B6 reactivity was observed 
in the MRP over-expressing cell line COR-L23R but some , mainly cytoplasmic, staining 
was seen in the sensitive COR-L23S variant 3/B6 staining was also absent from the LRP 
negative MOP-8 mouse fibroblast line Low level cytoplasmic staining was observed in 
DLKP and DLKP-A10 cells with 20% of cells staining positively with 3/B6 Similar 
staining was also seen in the RPMI 2650 line but to a lesser degree, (approximately 5% of 
cells)
A reduction in staining was seen when one LRP antisense and two LRP transfected 
clones of OAW42-SR were probed with this antibody The greatest reduction was 
observed in the nbozyme clone, OAW42-SR RZ4 where 5% of cells had faint, mainly, 
cytoplasmic staining A reduction in LRP staining was also seen in the A/S 1 and RZ2 
(Antisense 1 and Ribozyme 2 clones) but not to the same extent The staining pattern in 
these two clones was more heterogeneous with a large variation in staining
The LRP staining pattern was generally similar to that observed with MAb 3/B6 A 
lower level of staining was observed in the SW1573, SW1573/2R160,A2780/AC12 and 
OAW42-SR RZ2 cell lines Similar levels were seen on the SW1573/2R120, COR-L23S, 
DLKP, and A2780 cell lines No plasma membrane staining was observed with LRP-56 
Staining was primarily localised to the peripheral cytoplasm and was granular in nature 
In certain cell lines namely, COR-L23S and RPMI 2650, the staining was more diffuse in 
the cytoplasm There was no significant staining on the negative controls
These results illustrated the general pattern of co-expression of the 3/B6 and LRP/MVP 
antigens in these cell lines which was evident in the LRP/MVP cDNA transfected 
A2780/AC12 and AC 16 clones which over-express the LRP/MVP compared to the 
parental A2780 cell line Whereas, there was less co-expression observed in the 
SW1573, SW1573/2R160, GLC4 and GLC4/ADR Significant reduction in the 
LRP/MVP ribozyme transfected OAW42-SR cells suggested that the expression of these
93
proteins were closely linked Subsequent experiments were undertaken to determine the 
relationship between these two proteins
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Table 3 2 3 2. Immunocy to chemical analysis of a panel of human and murine 
multidrug resistant/sensitive cell lines with MAb 3/B6 
and LRP-56
Cell M t Antibody
3/B6 LRP-56
OAW42-SR +++ +++
OAW42-S +++ +++
SW1573 ++ +
SW l573/2RÌ2Ò" +++ +++
SW1573/2R160 ++ +
A2780 + +
A2780-AC12 ++ +
A2780-ACÌ6 +++ +++
MOP-8 - -
GLCÌ/S" + +
GLC4/ADR ++ +++
q ^ 4 2 -S R /R Z 2 ++ +
O AW 42-SR/RZ4 + ++
O A W 4^^R /A Sl^ +
COR-L23R - -
COR-L23S + +
DLKP ++ ++
dlicp^a + +/-
DLKP-A10 +/- +/-
+ +
This staining index is based on the number of cells showing positive staining for each particular 
antibody ranging from +, approximately 5% of cells to +++, 90-100% of cells
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Figure 3.2.3.I. Immunocytochemical analysis of OAW42 variants with MAb 3/B6 
and L5P-56 (section 3.2.3.1.) (a) OAW42-S probed with 3/B6, (b) OAW42-S probed 
with LRP-56, (c) OAW42-SR probed with 3/B6, (d), OAW42-SR probed with LRP- 
56, (40X). (e) and (f) are negative controls, OAW42-S and OAW42-SR respectively 
probed with mouse IgG. Photographs were taken at 20X.
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OAW42-SR
OAW42-SR RZ4
A2780
Figure 3.2.3.2.I. Immunocytochemical analysis of MDR cell lines with MAb 3/B6 
(section 3.2.3.2.) using the DAB/ABC method (section 2.9.5. materials and 
methods). Photographs were taken at 40X.
OAW42-SR RZ2
MOP-8
A2780/AC16
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OAW42-SR
OAW42-SR RZ4
A2780 A2780-AC16
Figure 3.2.3.2.2, Immunocytochemical analysis of MDR cell lines with MAb LRP- 
56 (section 3.2.3.2.) using the DAB/ABC method (section 2.9.5. materials and 
methods). Photographs were taken at 40X.
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Figure 3.2.3.2.3. Immunocytochemical analysis of MDR cells lines with MAb 3/B6 
(section 3.2.3.2.) using the DAB/ABC method (section 2.9.5. materials and 
methods). Photographs were taken at 40X.
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SW1573/2R120
COR-L23R COR-L23R
DLKP DLKP-A
Figure 3.2.3.2.4. Immunocytochemical analysis of MDR cell lines with MAb LRP- 
56 (section 3.2.3.2.) using the DAB/ABC method (section 2.9.5. materials and 
methods). Photographs were taken at 40X.
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3 2 3 3. Competition studies with MAb 3/B6 and LMR-5 and the anti-vault 
polyclonal antiserum N2
To determine whether MAb 3/B6 cross reacted with the MVP/LRP cytospins of 
OAW42-SR were probed with anti-LRP/MVP/ MVP and anti-OAW42-SR antibodies 
(section 2 9 5 matenals and methods) A series of controls were designed to determine 
whether species specific biotinylated secondary antibodies recognised their target 
primary antibodies OAW42-SR cytospins were probed with (a) MAb 3/B6 and 
incubated with the anti-rat and anti-rabbit-specific secondary antibodies, (b) MAb LMR- 
5 (a rat primary antibody) and probed with the anti-mouse and anti-rabbit-specific 
secondary antibodies and (c) N2 (a rabbit primary antibody) and probed with the anti­
mouse and anti-rat-specific secondary antibody Results are illustrated in figure 
3 2 3 3 1 c, d No staining was observed when MAb 3/B6 was incubated with the anti­
rat and anti-rabbit specific secondary antibodies compared to the positive control, 
OAW42-SR probed with MAb 3/B6 and detected with the anti-mouse specific secondary 
antibody, 3 2 3 3 1 b Similarly, there was no significant staining observed on cytospins 
probed with MAb LMR-5 and incubated with the anti-mouse and anti «rabbit specific 
secondary antibodies There was also a lack of significant staining on cytospins probed 
with the polyclonal antibody N2 and incubated with the anti-mouse and anti-rat-specific 
secondary antibodies
Cytospins of OAW42-SR were pre-incubated with MAb 3/B6 and probed with MAb 
LMR-5 to determine if MAb 3/B6 blocked the epitope recognised by MAb LMR-5 
Similarly, cytospins of OAW42-SR were also pre-incubated with MAb LMR-5 and 
probed with MAb 3/B6 There did not appear to be any reduction in 3/B6 staining on 
OAW42-SR cytospins pre-incubated with LMR-5 when compared to the positive 
control, OAW42-SR cytospins probed with MAb 3/B6 alone figures 3 2 3 3 1 b and 
3 2 3 3 2 b Similarly, there was no significant reduction in the levels of staining with 
MAb LMR-5 when OAW42-SR cytospins were pre-incubated with MAb 3/B6 and 
probed with MAb LMR-5 (figures 3 2 3 3 1 a and 3 2 3 3 2 a) These experiments were 
repeated with the anti-vault polyclonal antibody N2 There did not appear to be any 
reduction in staining when OAW42-SR cytospins were pre-incubated with MAb 3/B6
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and probed with the N2 polyclonal antibody compared to the positive control (figures 
3 2 3 3 1 c and 3 2 3 3 3 a), levels of staining were unchanged when cytospms were 
pre-incubated with N2 and probed with MAb 3/B6 (figure 3 2 3 3 3 b) Reduced levels 
of LMR-5 staining were observed when cytospins were pre-incubated with the N2 
polyclonal antibody and probed with MAb LMR-5 (figure 3 2 3 3 4 a), this reduction in 
staining was not observed when cytospms were pre-incubated with MAb LMR-5 and 
probed with N2 (figure 3 2 3 3 4 b)
These studies indicated that MAb LMR-5 and the polyclonal antibody N2 did not 
recognise the same epitope and possible the same protein as MAb 3/B6 Further 
biochemical characterisation of the 3/B6 antigen were undertaken to clarify this point
P r i in ary-i;; j; ail t i body;;
lililllllliiSi
: Fri riiairy& Sian ti body ih!Secondary: a n tibody . Staining intensity.
LMR-5 3/B6 anti-mouse +++
3/B6 LMR-5 anti-rat +++
N2 3/B6 anti-mouse +++
3/B6 N2 anti-rabbit +++
LMR-5 N2 anti-rabbit +++
N2 LMR-5 anti-rat +
3/B6
-
anti-rat
-
3/B6
-
anti-rabbit
—
LMR-5
-
anti-mouse
—
LMR-5
—
anti-rabbit
—
N2
-
anti-mouse
—
N2
-
anti-rat -
Table 3 2 3 3 Results from competition and secondary antibody species specificity 
experiments with MAb 3/B6, LMR-5, the anti-vault polyclonal antibody N2 and 
biotinylated anti-mouse, -rat and -rabbit specific secondary antibodies.
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Figure 3.2.3.3.I. Competition studies with MAbs 3/B6 and LMR-5 and the anti-rat 
vault polyclonal antibody N2 using the DAB/ABC method (section 2.9.5. materials 
and methods). Positive control slides. OAW4-SR cytospins probed with, a. LMR-5, 
b. 3/B6, c. N2 and d. mouse IgG (negative control). Photographs were taken at 20X.
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Figure 3.2.3.3.2. Competition studies with MAbs 3/B6 and LMR-5 using the 
DAB/ABC method (section 2.9.5. materials and methods). OAW42-SR cytospins 
probed with a. 2 hour incubation with MAb 3/B6 followed by an overnight 
incubation with MAb LMR-5 and b. 2 hour incubation with MAb LMR-5 followed 
by an overnight incubation with MAb 3/B6. Photographs were taken at 20X.
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Figure 3.2.3.3.3. Competition studies with MAb 3/B6 and the anti-vault polyclonal 
antibody N2 using the DAB/ABC method (section 2.9.5. materials and methods). 
OAW42-SR cytospins probed with a. 2 hour incubation with MAb 3/B6 followed by 
an overnight incubation with polyclonal antibody N2 and b. 2 hour incubation with 
polyclonal antibody N2 followed by an overnight incubation with MAb 3/B6. 
Photographs were taken at 20X.
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Figure 3.2.3.3.4. Competition studies with MAb LMR-5 and the anti-vault 
polyclonal antibody N2 using the DAB/ABC method (section 2.9.5. materials and 
methods). OAW42-SR cytospins probed with a. 2 hour incubation with MAb LMR- 
5 followed by an overnight incubation with polyclonal antibody N2, and b. 2 hour 
incubation with polyclonal antibody N2 followed by an overnight incubation with 
MAb LMR-5. Photographs were taken at 20X.
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3.2.4.I. Optimisation of Immunoprécipitation protocol
A new cellular labelling and immunoprécipitation kit based on biotin labelling of cellular 
protein was extensively modified in the development of a non-radioactive method for the 
characterisation of the 3/B6 antigen (section 2.10.5 materials and methods).
Cell lysates of OAW42-SR were incubated with MAb 3/B6 for various time periods 
ranging from 1 hour to over night. Antibody-antigen complexes were 
immunoprecipitated with protein G coated sepharose beads for time periods ranging 
from 1 to 6 hours at 4°C. These initial incubation times were chosen on the basis of work 
carried out previously with MAb LRP-56 by other researchers (Scheper et al, 1993). 
Results of these experiments are illustrated in Figure 3.2.4.1.1.
There appeared to be low level immunoprécipitation with antibody and 
immunoprécipitation incubation times of 1 hour Figure 3.2.4.1.1. The quantity of 3/B6 
antigen appeared to increase with extended incubation times with the primary antibody . 
There was a second reduction in immunoprecipitates when the antibody antigen complex 
was washed with a high salt buffer. Levels were restored when the washing buffer was 
changed to either (a) a low salt buffer or (b) 1 wash with the high salt buffer. These 
results indicated that extended incubation times were more suitable for this antibody.
To determine the most suitable method for blocking non-specific binding and detection 
of biotin labelled proteins, Western Blots of 3/B6 immunoprecipitates were initially 
developed using Strepavidin/biotin HRP in conjunction with non-fat milk for the 
detection of biotin labelled proteins which was suggested in the kit protocol. It was not 
possible to clearly distinguish immunoprecipitate bands when blots were blocked with 
non-fat milk and developed using ABC/HRP reagents (figure 3.2.4.1.2.) There appeared 
to be less background staining when blots were blocked with biotin free BSA and probed 
with ABC/HRP (b) It has been demonstrated that non-fat milk can contain high levels of 
endogenous biotin therefore causing high background in this experiment. It was still 
difficult to interpret the blots with this method therefore an anti-biotin secondary
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antibody coupled with biotin-free BSA was eventually chosen as the reagents which 
produced the cleanest blots
3 2 4 2 Immunoprécipitation and Western Blotting studies with MAb 3/B6
Initial attempts to determine the molecular weight of the antigen recognised by MAb 
3/B6 by western blotting were unsuccessful The antibody was then used to 
immunoprecipitate cell lysate preparations labelled with D-biotinoyl-s-aminocarproic 
acid-N-hydroxysuccimmide ester (biotin-7-NHS)
Results indicated that the antigen detected by 3/B6 has a molecular weight of approx 
115 kDa, figure 3 2 4 2 The secondary antibody also appeared to detect a range of 
bands in the negative control lane The molecular weight assigned to the 3/B6 antigen 
was similar to that determined for the LRP/MVP (110 kDa) which prompted further 
investigation
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Figure 3.2.4.I.I. Optimisation of immunoprécipitation protocol (section 3.2.4.1. 
and section 2.10.5. materials and methods). All lanes are OAW42-SR cells 
immunoprecipitated with MAb 3/B6. Negative control is OAW42-SR 
immunoprecipitated with mouse IgG detected with a horseradish peroxidase- 
labelled secondary antibody and enhanced chemiluminescence (section 2.10.4. 
materials and methods).
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Figure 3.2.4.I.2. Optimisation of biotin labelling and immunoprécipitation protocol 
(section 3.2.1.). Blots were blocked for non-specific background with (a), 5% non­
fat milk, (b) biotin free BSA. Biotin labelled proteins were detected with ABC/HRP 
and enhanced chemiluminescence (2.10.4. materials and methods).
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Figure 3 2.4.2 Immunoprécipitation experiments with MAb 3/B6 (section 3 2 4) 
Immunoprecipitates were detected by an anti-biotin horseradish peroxidase-labelled 
secondary antibody and enhanced chemiluminescence (section 2 10 4 materials and 
methods) (A), test lane, (B), negative control, OAW4-SR cell lysates precipitated 
with mouse IgG
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3 2 5 Determination of protein glycosylation
To determine if the 115 kDa protein recognised by MAb 3/B6 was glycosylated, 
OAW42-SR cells were grown in the presence of tumcamycin (preventing N- 
glycosylation) and phenyl-acetyl-a-D-Galactosammide (PNAG, preventing 0- 
glycosylation) LRP immunoprecipitates from cells grown in glycosylation inhibitors 
were included as a control Results are illustrated in figure 3 2 5 (a) Lanes 1 and 2 
contain OAW42-SR immunoprecipitates precipitated with 3/B6 and grown in the 
presence of tumcamycin (8|ig/ml) and Phenyl-N-acetyl a D Galactosamrmde (PNAG) 
respectively There was no detectable shift in the molecular weight of the 115 kDa band 
(or in the band size) when compared to precipitates of OAW42-SR grown without 
glycosylation inhibitors, lane 3 This suggested that N or O linked carbohydrates are not 
attached to this protein A second band was detected at 60 kDa but since this band is 
also present in the LRP and negative controls it was considered to be background due to 
mouse IgG and therefore not significant
There was no shift in the band at 110 kDa l e the LRP immunoprecipitate, in OAW42- 
SR cells (lanes 4 and 5 ) or in LRP precipitates of SW1573/2R120 cells (lanes 6 and 7) 
when these cells were grown in the presence of the same glycosylation inhibitors Lanes 
8 and 9 contain SW1573/2R120 and OAW42-SR controls l e , cells which were grown 
without glycosylation inhibitors
There was a detectable shift in the positive control DLKP-A (a Pgp over-expressing cell 
line, Pgp is a known glycosylated protein), cell line when these cells were grown in the 
presence of tumcamycin, figure 3 2 5 (b) MAb C219 (which recognises the MDR-1 gene 
product, p-glycoprotein) detected 2 bands at 170 and approximately 140 kDa
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Figure 3.2.5. Glycosylation studies with MAb 
3/B6, LRP-56 and C219. (a) biotin labelled 
protein samples detected with an anti-biotin 
horseradish peroxidase labelled secondary 
antibody and enhanced chemiluminescence 
(section 2.10.5.materials and methods), lanes 1,
2 and 3 were precipitated with 3/B6, lanes 4-9 
were precipitated with LRP-56, lanes 10-11 
were precipitated with mouse IgG. (b), Crude 
cell lysates of DLKP-A probed with MAb 
C219, visualised with an anti-mouse house 
horseradish peroxidase labelled secondary 
antibody and enhanced chemiluminescence.
PNAG is Phenyl-N-Acetyl-a-5-Galactosanimide
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3 2 6 Immunoprécipitation studied on purified rat vault proteins
3/B6 and LRP-56 immunoprecipitates of OAW42-SR and SW1273/2R120 cells were 
probed with an anti-biotin secondary antibody to detect biotin-labelled protein in the 
immunoprecipitates These precipitates were also probed with the polyclonal serum N2 
which was raised to rat vaults and detects the MVP Supernatants from overnight 
precipitation experiments were also probed for the presence of LRP That is, following 
the final incubation step where protein G coated spharose beads were used to precipitate 
the antibody-antigen complex, the supernatant which is usually discarded was retained, 
concentrated (section 2 10 5) and applied to the SDS-PAGE gel, any remaining un- 
precipitated LRP would be detected by Western Blotting using the anti-MVP antibody 
N2 If 3/B6 was an anti-vault antibody then there would be a reduction in the amount of 
LRP detected in 3/B6 supernatants
In figure 3 2 6 1 (A), the molecular weight of the antigen detected by MAb 3/B6 (lane
a) is slightly higher than the LRP/MVP precipitated by MAb LRP-56 The pi 15 band is 
expressed at much lower amounts in the SW1573/2R120 cell line, lane 3 MAb 3/B6 and 
MAb LRP-56 both appeared to detect a protein at a molecular weight of 192 kDa and a 
range of bands between approximately, 50-30 kDa
Figure 3 2 6 1 (b) shows the same immunoprecipitates probed with the anti-vault 
polyclonal antibody, N2 There is no corresponding band at 110 or 115 kDa in 
immunoprecipitates precipitated with 3/B6, lanes a and c When the supernatants of these 
immunoprecipitates were probed with the N2 polyclonal antibody there was no 
significant reduction in the level of LRP, in those cells lines precipitated with LRP-56 
there was a significant reduction in LRP levels, Figure 3 2 6 2
These results indicated that the antigen detected by the MAb 3/B6 was not the 
LRP/MVP This study also suggested that the 3/B6 antigen was probably not a modified 
form of the LRP/MVP This conclusion agreed with the results of the competition 
studies already discussed in section 3 2 3 3
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(A)
(B)
Figure 3.2.6.I. Immunoprecipitates of OAW42-SR and SW1573/2R120 cells 
probed for the MVP/LRP (section 3.2.6.). (A), immunoprecipitates were probed with 
an anti-biotin horseradish peroxidase labelled secondary antibody and enhanced 
chemiluminescence, (a) OAW42-SR precipitated with 3/B6, (b) OAW42-SR 
precipitated with LRP-56, (c) SW1573/2R120 precipitated with 3/B6, (d) 
SW1573/2R120 precipitated with LRP-56 and (e) negative control, OAW42-SR 
cells precipitated with mouse IgG. (B) the same immunoprecipitates probed with the 
anti-rat vault polyclonal antibody N2 detected using a horseradish labelled anti­
rabbit secondary antibody and enhanced chemiluminescence (section 2.10.4. 
materials and methods).
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Figure 3.2.6.2. Supernatants from immunoprécipitation studies with MAb 3/B6 and 
LRP-56 probed with an anti-rat vault polyclonal antibody N2 detected using a 
horseradish labelled anti-rabbit secondary antibody and enhanced 
chemiluminescence (section 3.2.6 and section 2.10.5.materials and methods).
3 2 7. Immunoprécipitation studies on a panel of multidrug resistant/sensitive cell 
lines
A panel of multidrug resistant and sensitive cell lines were assayed to confirm the 
expression of the antigen detected by MAb 3/B6 observed immunocytochemical analysis 
of MDR cell lines The results are illustrated in Figure 3 2 7 1, Levels of expression 
were compared with the positive control, OAW42-SR cells DLKP cells exhibited low 
level expression as did the COR-L23R cells (lanes 1 and 5 Low level expression was 
observed in the Pgp over-expressing cell line DLKP-A and the COR-L23S (lanes 2 and
6) Expression of the antigen detected by MAb 3/B6 was also seen in the LRP 
transfected cell line, A2780/AC16 while it was absent from the parental, A2780 cell line 
A band at approximately 50 kDa which appears in all immunoprecipitates including the 
negative control (OAW42-SR cells precipitated with control mouse IgG ) was also 
observed Figure 3 2 7 2 illustrates the results of studies with MAb LRP-56 which was 
used in immunoprécipitation studies with the same panel of cell lines Low levels of 
LRP/MVP expression were observed in the DLKP and A2780 cell lines Increased levels 
of expression were observed in the COR-L23R , COR-L23S cell lines and in the 
SW1573/2R120 cell line, the LRP/MVP positive control, LRP/MVP expression was 
absent from the DLKP-A
There appeared to be some unequal loading of lanes in the DLKP and DLKP-A cell lines 
This may account for differences in the levels observed however these results appear to 
correlate with those obtained by immunofluorescence and immunocytochemistry Results 
with MAb LRP-56 did not correlate with immunocytochemical studies in the COR-L23 
variants These differences may have been due to the fixation of the antibody in the 
immunocytochemical analysis
Figure 3 2 71. Immunoprécipitation studies with MAb 3/B6 on drug resistant and 
sensitive cell lmes (section 3 2 7) Immunoprecipitates were probed with an anti- 
biotin horseradish peroxidase labelled secondary antibody and enhanced 
chemiluminescence (section 2 10 4 materials and methods)
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Figure3.2.7.2. Immunoprécipitation studies with MAb LRP-56 (section 3.2.7.). 
Immunoprecipitates were probed with an anti-biotin horseradish labelled secondary 
antibody and enhanced chemiluminescence (section 2.10.4. materials and methods).
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3 2 8 Immunoprécipitation studies with LRP nbozyme and antisense transfected 
OAW42-SR cells
Immunoprécipitation of LRP nbozyme and antisense transfected OAW42-SR cells was 
earned out in order to confirm observations of reduced 3/B6 staining by 
immunocytochemistry Results are illustrated in figure 3 2 8
There did not appear to be a significant reduction in the LRP/MVP expression in the 
antisense 1 clone (lane 1) Similarly, there did not appear to be any reduction in the levels 
of the 3/B6 antigen (lane 5), when compared to the control, OAW42-SR precipitated 
with MAb 3/B6 (lane 8) In the nbozyme clone 2, (lane 3), there was a significant 
reduction in LRP expression compared to the positive control OAW42-SR cells 
precipitated with MAb LRP-56 whereas only s small reduction in the band of the antigen 
detected by MAb 3/B6 was observed (lane 6) In the nbozyme 4 clone (lane 7), levels of 
the antigen detected by MAb 3/B6 appeared to be greatly reduced, only a slight 
reduction in LRP/MVP levels was observed in this nbozyme treated clone (lane 2) Non­
specific binding of the secondary antibody detecting bands at 90 and 50 kDa was 
observed in all îmmunoprecipitates including the negative control
Although it appeared from previous studies that the LRP/MVP and the 3/B6 were 
different antigens, these studies indicated that LRP/MVP may contribute to the control 
of the expression of 3/B6
120
o>
%to
g2
co
o o O o
> > > >
V V to toI
s
CO&
5
à73
*-0
</}
£
N Nto GO
O>
<zt7*
p85Trtoo3*O
107 kD ^
1 2  3 4 5 6  7 8 9
Figure 3.2.8. Immunoprécipitation experiments on ribozyme and antisense 
transfected OAW42-SR cells (section 3.2.8.). Immunoprecipitates were probed with 
an anti-biotin horseradish peroxidase labelled secondary antibody and enhanced 
chemiluminescence (section 2.10.4. materials and methods). Lane 9 is OAW42-SR 
cells precipitated with mouse IgG.
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3 2 9 Immunoprécipitation experiments with OAW42-SR spent culture medium
Conditioned medium from OAW42-SR cells grown for 6 days was immunoprecipitated 
with MAb 3/B6 and LRP-56 to determine whether these antigens were shed into the 
growth medium (section 2 10 6 materials and methods) The results are illustrated in 
figure 3 29 There was no detectable band at 115 kDa in OAW42-SR conditioned 
medium immunoprecipitates (lane 1) The 115 kDa band was detected in 
immunoprecipitated of OAW42-SR whole cell lysates Similarly the 110 kDa LRP/MVP 
band was absent in the conditioned medium immunoprecipitates compared to whole cell 
lysates (lanes 3 and 4) 2 Bands at approximately 85 and 55 kDa were observed in the 
negative control (OAW42-SR conditioned medium immunoprecipitated with mouse IgG, 
lane 5) These results confirm the cytoplasmic location of the LRP/MVP however the 
results for 3/B6 are more surprising m that many antigens expressed on the cells surface 
are excreted into the growth medium including Pgp and many ovarian associated 
antigens
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Figure 3.2.9. Immunoprécipitation of spent medium from OAW42-SR cells 
(section 2.10.5. materials and methods). Lanes 1-2, cells were precipitated with 
MAb 3/B6, lanes 3, 5-6, cells were precipitated with MAb LRP-56. Lane 4, cells 
was precipitated with mouse IgG. The blot was probed with an anti-biotin 
horseradish peroxidase-labelled secondary antibody and enhanced 
chemiluminescence (section 2.10.4. materials and methods).
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3 2 10 Immunohistochemical studies in normal human and foetal tissues
The distribution of the 3/B6 antigen was investigated in a series of formalin fixed 
paraffin-embedded normal adult and foetal tissues (section 2 9 5 materials and methods)
In adult kidney, 3/B6 staining which was cytoplasmic in nature, was predominantly 
localised in the distal collecting tubules with some low level staining m the proximal 
collecting tubules MAb LRP-56 stained the proximal tubules with characteristic 
cytoplasmic reactivity No staining was observed in the distal tubules with this antibody, 
(Figure 3 2 10 1 (a) (b) There was no significant staining on thyroid tissue sections with 
MAbs 3/B6 or LRP-56 (Figure 3 2 10 1 (c) (d)
A series of foetal formalin fixed paraffin-embedded foetal tissues were also probed with 
the MAb 3/B6 and LRP-56 Results are illustrated in figure 3 2 10 2 and 3 2 10 3 
3/B6 staining, which was cytoplasmic in nature, was observed primarily in the distal 
tubules of the kidney There did not appear to be 3/B6 expression in the proximal 
tubules Cytoplasmic staining was observed in the trophoblasts of the placenta and in the 
enterocytes of the small intestine No staining was observed in the foetal liver or adrenal 
gland Low level LRP-56 staining was observed in the distal but primarily in the proximal 
tubules where strong cytoplasmic staining was observed Staining was also seen in the 
cytoplasm of placental trophoblasts and enterocytes of the small intestine In the foetal 
liver, bile ducts exhibited low level staining while the adrenal gland did not exhibit any 
reactivity when probed with MAb LRP-56 There appeared to be some co-expression of 
the LRP/MVP and 3/B6 antigens in foetal tissues excluding the foetal liver however this 
co-expression was absent from the adult tissues surveyed The difference in expression 
amongst normal tissues indicated that 3/B6 and LRP/MVP may have independent control 
mechanisms m theses tissues The shift in the expression of LRP/MVP in foetal kidney 
(distal and proximal tubules) to distal tubules only m the adult kidney might indicate a 
change in function in human adult kindey
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Figure 3.2.10.1. Immunohistochemical studies on normal tissue sections with MAb 
3/B6 and LRP-56 (section 2.9.5. materials and methods), (a) and (b), kidney section 
stained with 3/B6 and LRP-56 respectively, (c) and (d), thyroid section stained with 
3/B6 and LRP-56 respectively. Photographs were taken at 10X.
125
Figure 3.2.10.2. Immunohistochemical studies on human foetal tissue sections with 
MAb 3/B6 (section 3.2.10.), (a) foetal kidney, (b) foetal liver, (c) foetal adrenal, (d) 
foetal small intestine, (e) placenta. Photographs were taken at 20X. (f) negative 
control, foetal kidney probed with mouse IgG, photograph taken at 10X.
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Figure 3.2.10.3. Immunohistochemical studies on human foetal tissue with MAb 
LRP-56 (section 3.2.10.), (a) foetal kidney, (b) foetal liver, (c) foetal adrenal, (d) 
foetal small intestine, (e) placenta, (f) negative control, small intestine probed with 
mouse IgG. (a), (d) and (e) were taken at 20X, (b), (c) and (f) at 10X.
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3 2 11 Immunohistochemical investigation of ovarian and breast tumour tissue 
sections
Two normal ovary and ten pre-chemotherapy ovarian tumour blocks were probed with 
MAb raised to Pgp, MRP and LRP Two paired pre- and post-chemotherapy tissue 
blocks were also screened with MAb 3/B6 (section 2 9 5 materials and methods)
LRP/MVP was expressed at low levels in both normal ovary blocks (1604/97 and 
1313/98) exhibiting diffuse cytoplasmic staining Some staining of blood vessels was also 
observed 3/B6 staining was absent on both of these tumour blocks (figure 3 2 11 1 ) 
LRP/MVP appeared to be expressed at low levels in 1/10 ovarian tumour blocks, block 
1793/95 (figure 3 2 111) 3/B6 staining showed no reactivity on all pre-chemotherapy 
tumour blocks screened Some non-specific binding of both LRP-56 and LMR-5 was 
observed in the majority of tumour sections
The anti-Pgp MAb MDR-1 clone 6/1G and JSB-1 did not react with any of the tumour 
blocks assayed Low level MRP positivity was observed in 1/10 tumour blocks, block 
2079/93 (figure 3 2 11 1 ) One post-chemotherapy ovarian tissue block was probed with 
MAb 3/B6 and LRP-56 to determine whether the 3/B6 antigen or the LRP/MVP were 
over-expressed in this tumour type Results from this experiment proved inconclusive in 
that there did not appear to be any areas of specific staining
The expression of the 3/B6 antigen was also examined in 2 ductal breast tumours as 
outlined above MAb 3/B6 did not appear to stain the pre-chemotherapy blocks (figure 
3 2 112 (a) and (c) Whereas, in the post chemotherapy blocks, distinct cytoplasmic 
staining was evident in the infiltrating cells of the tumour This was particularly evident in 
block 1644/94 (d) Some low level background straining was also observed
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Table 3 2.11 Immunohistochemistry results for normal, pre- and post 
chemotherapy ovarian tissue samples and pre- and post-chemotherapy breast 
tissue sections
Block Niim befe;:ii Antibody staining i l i l s
3/B6 LRP-
56
LMR-5 MDR-1 UIC-2 M RP r l
Normal Ovary ND ND ND ND
1604/97 - +/-
1313/98 - +/- ND ND ND ND
Pre-
chemotherapy
2966/93 - - - - -
1797/93 - + + - -
2079/93 - - - - +
2122/93 - - - - -
2527/93 - - - - -
1994/94 - - - - -
2472/94 - - - - -
2664/94 - - - -
1/95 - - - - -
5/97 - - - - “
Post­
chemotherapy
3069/92 inconclusive inconclusive ND ND ND ND
Breast tumour 
Pre­
chemotherapy
”1423/92
(Larkin et 
a l1998b)
ND ND ND ND
”1418/86 - -(Larkin et 
al 1998b ND ND ND ND
Breast tumour 
Post­
chemotherapy
ND ND
“1664/94 ++ +(Larkin 
et al 1998b ND ND ND
b9987/86 ++ -(Larkin et 
al 1998b ND ND ND
This staining index is based on the number of cells staining positive for 5/C4 ranging from 
approximately 5-10% of cells (+), to 90% of cells (+++) (a) and (b) are paired pre-and post­
chemotherapy samples
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Nomai ovary 1604/97
Pre-chemotherapy 1797/95
Pre-chemotherapy 2079/93 Negative control
Figure 3.2.11.1. Immunohistochemical analysis of normal and pre-chemotherapy 
ovarian histological tissue sections (section 3.2.11.) (a) and (c) were probed with 
MAb 3/B6, (b) and (d) were probed with MAb LRP-56. (e) was probed with MAb 
MRPrl. (f) was probed with mouse IgG. Photographs were taken at 10X
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Figure 3.2.11.2. Immunohistochemical studies with MAb 3/B6 on paired pre- and 
post-chemotherapy breast tumour sections (section 2.9.5. materials and methods), 
(a) and (c), pre-chemotherapy treatment, (b) and (d), post-chemotherapy treatment 
(a) and (c) were taken at 10X, (b) and (d) were taken at 20X.
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<3.2 12 Investigation of species cross-reactivity with MAb 3/B6 and LRP-56
A series of rodent and primate kidney cell lines were investigated to determine the 
expression of the 3/B6 antigen by immunoprecipitation Results indicate that 3/B6 
expression was confined to the African Green Monkey kidney cell line B-SC-1, figure 
3 2 12 1 lane 5 These results suggested that 3/B6 may be a human protein homologue 
which was not expressed in the lower mammals
These cell lines were also assayed for the expression of the LRP/MVP Results from 
these experiments indicated that the LRP/MVP was expressed in the bovine kidney cell 
line MDBK and at very low levels in the green African monkey cell line BS-C-1, figure 
3 2 12 2 This suggests that the 3/B6 antigen and the LRP/MVP are differentially 
expressed in these animal cell lines
3 2 13 Addition of MAb 3/B6 to OAW42-SR cells in culture
OAW42-SR cells were grown in the presence of MAb 3/B6 and LRP/MVP to determine 
whether these antibodies had any effect on cellular proliferation (section 2 11) Results 
from this experiment indicated that the addition of MAb 3/B6 and LRP-56 did not have 
any significant effect on the proliferation of OAW42-SR cells These results suggested 
that the 3/B6 antigen was not involved in cellular proliferation
3 2 14 Drug accumulation studies with MAb 3/B6
OAW42-SR cells were incubated with adnmycin in the presence of MAb 3/B6 and or 
cyclosporin A (an agent which is known to enhance drug accumulation by inhibiting 
Pgp) This experiment was carried out to determine whether 3/B6 had any effect in 
blocking drug efflux and thereby imply a role for the 3/B6 antigen in drug resistance and 
transport (section 2 12)
Incubation of OAW42-SR cells with MAb did not appear to have any effect on the 
accumulation of adnamycin over a 3 hour time period (Table 3 2 14 and Figure 3 2 14 ) 
A maximum of 375 n moles of adnamycin was accumulated after a 3 hours Similar
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accumulation values were observed in the negative control (OAW42-SR cells incubated 
with adnamycin but without MAb 3/B6 Increased adnamycin accumulation (to a 
maximum level of 995 pmoles/million of cells) was observed in the positive control 
sample, OAW42-SR cells incubated with 10 m M  adnamycin and 10 [ig/ml cyclosponn 
A Despite this lack of effect by the MAb 3/B6 , it did not imply that 3/B6 did not have a 
direct role in drug resistance, simply that this MAb had no direct effect on the function of 
the protein
Table 3 2 14 Drug accumulation in OAW42-SR with MAb 3/B6
i : imei pip in t s | (ho u is j i D r II g y i: i| i: i! !Fa c c u hiiii 1 a t i 011 i!
(pnioles/millioh cells)
OAW42-SR + Adr 0 0
1 295
2 320
3 375
OAW42-SR + Adr + 3/B6 0 0
1 290
2 305
3 370
OAW42-SR + Adr J 
+ cyclosporin A
0 0
1 576
2 895
3 995
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Figure 3.2.12.1. Species cross reactivity studies with MAb 3/B6. Blots were probed 
with an anti-biotin horseradish labelled secondary antibody and enhanced 
chemiluminescence (section 2.10.4. materials and methods).
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Figure 3.2.12.2, Species cross-reactivity studies with MAb LRP-56. All cell lines 
were immunoprecipitated with MAb LRP-56 (section 3.2.12.). Blots were probed 
with an anti-biotin horseradish labelled secondary and enhanced chemiluminescence 
(2.10.4. materials and methods).
135
1000
8cau
• 9M
0 . 5  1  1 . 5  2  2 . 5Time (hours)
Figure 3.2.14. Drug accumulation studies with MAb 3/B6 (section 2.12. materials 
and methods). Time course of adriamycin drug accumulation in OAW42-SR cells, 
section 3.2.14.
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Figure 3.2.14. Drug accumulation studies with MAb 3/B6 (section 2.12. materials 
and methods). Time course of adriamycin drug accumulation in OAW42-SR cells, 
section 3.2.14.
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3 2 15 Micro-sequencing of 3/B6 peptides
3/B6 immunoprecipitates were separated by SDS-PAGE (section 2 10 2 materials and 
methods) and the 3/B6 band excised from the gel Gel fragments were then sent to 
Eurosequence (Groningen, The Netherlands) for internal peptide sequencing Following 
elution, protein samples were subjected to trypsin digestion The resultant peptides were 
punfied by reverse phase HPLC (RP HPLC) These peptides derived from the 3/B6 
protein were then subjected to N-terminal sequencing by Edman degradation and 
sequencing on a pulsed liquid sequencer (section 2 10 7 materials and methods) 
Sequence analysis of the 3/B6 protein yielded a 14 amino acid peptide with the following 
ammo acid sequence,
S-T-V-S-L-T-C*-M-V-T-S-F-W-P
5 10 14
Ser-Thr-Val-Ser-Leu-Thr-(Cys?)-Met-Val-Thr-Ser-Phen-Tyr-Pro
There was a tentative assignment of a cysteine residue at position 7 Cystine residues 
form disulfide bonds which must be cleaved before the proteins can be sequenced Unless 
specifically requested from the company, cysteine residues are not denvativised and 
therefore cannot be sequenced In this case, this option was not requested, (cysteine is 
usually converted to a stable derivative by 4-vinylpyndine) Processing of the peptide for 
sequencing can lead to modification of the cysteine residues e g carboxy-methylcystine 
HPLC analysis identified a peak at an elution time point which was similar to cystine and 
therefore, there was a tentative assignment of a cysteine residue at position 7 A protein 
database search revealed homology with the following proteins,
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Table 3 2.15 Sequence homology results for 3/B6 antigen
H OiïiÔ 1 Ôgy :'H
Blood Coagulation Factor XII a Inhibitor 57%
MHC class I alpha fragment 47%
Rat IG gamma-1-chain C region 47%
MHC class I alpha 2 fragment3 47%
MHC class I alpha 2 fragmentb 46%
a and b are fragments of the same protein and constitute individual entries to the data base
Appendix 2 contains the high performance liquid chromatographs for the 14 cycles which 
yielded the peptide illustrated above The aspartic acid residue at time point 3 91 minutes 
was incorrectly assigned, this peak originates from ammonia which is a by-product of 
phenylthiocarbamyl denvitisation of amino acids and is present in all peptide sequencing 
results Dmp, dptu, dpt and mptc are also by-products of the Edman process, dptu and 
mptc are always present at these quantities A number of amino acids appeared at low 
levels in the chromatograph The relatively low level amounts of these residues present in 
each cycle originated from a general background present during the sequence analysis 
Glycine was found to be present at higher amounts in the early cycles, reducing in 
concentration in later cycles Glycine is generally found at these levels in internal peptide 
sequencing When glycine is an amino acid in the sequence, a substantially larger peak is 
observed
These results implied sequence homology with these proteins however 3/B6 may not 
necessarily be a member of these protein families particularly since it has been 
demonstrated that 3/B6 recognises an un-glycosylated protein whereas both of these 
protein families are glycosylated
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3 3 Characterisation of MAb 5/C4
3 3 1 Immunofluorescence on live cells with MAb 5/C4
MAb 5/C4 was raised to the OAW42-SR cell line Immunofluorescence studies were 
earned out on live cell preparations of OAW42-SR and OAW42-S, (section 2 9 3 
matenals and methods) Results are illustrated in Figure 3 3 1
MAb 5/C4 did not detect its antigen on the surface of OAW42-SR or OAW42-S cells 
l e there was no fluorescent ring observed around the cells When these cells were 
incubated with a glutaraldehyde based fixative (FacsLyse solution), for 1 minute, faint 
cytoplasmic staining was observed in OAW42-SR cells only The negative controls, 
consisting of cells incubated with mouse control IgG, did not exhibit plasma membrane 
or cytoplasmic staining These results indicated that the antigen recognised by MAb 5/C4 
was expressed exclusively in the cytoplasm of OAW42 variants
3 3 2 Immunocytochemical analysis of a panel of multidrug resistant/sensitive cell 
lines
This panel of cell lines contained a series of cell lines with varying degrees of drug 
resistance and were assayed using the AB/HRP complex method (section 2 9 5 materials 
and methods), results are outlined in table 3 3 1 and illustrated in Figure 3 3 2
Immuno-reactivity was observed in all of these cell lines There appeared to be little 
difference in the intensity of staining although differences in the number of cells stained 
was observed Approximately 90% of OAW42-SR and OAW42-S cells were stained 
positive with MAb 5/C4 There was no variation in the intensity of staining in the cell 
lines Approximately 50% of A2780/AC12 and A2780/AC16 exhibited immuno- 
reactivity with MAb 5/C4 while 10% of A2780 cells were positive Low level staining 
was also observed in the MOP-8, COR-L23R and COR-L23S cell lines Negligible 
staining was seen in the DLKP, DLKP-A and DLKP-A 10 lines Some variation in 
staining was observed in the LRP nbozyme and antisense transfected OAW42-SR cells
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with a reduction in staining in the RZ2 and A/S 1 clones These results suggested that, 
unlike the MAb 3/B6, MAb 5/C4 did not appear to be associated with any particular 
resistance associated mechanism
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Table 3 3 2 Immunocytochemical analysis of a panel of drug resistant/sensitive cell 
lines with MAb 5/C5
Cell line Antibwly positmty
OAW42-S +++ ......................................
OAW42-SR +++
SW1573 ■c+
SW1573/2R120 +
SW1573/2R160 <+
A2780 +
A2780/AC12 •!++
A2780/AC16 ++
MOP-8 ■C+
GLC4 +
GLC4/ADR <+
OAW42-SR A/Sl i
OAW42-SR RZ2 i++
OAW42-SR RZ4 +++
COR-L23R | <1 +
COR-L23S +
DLKP
DLKP-A +/-
DLKP-AIO !+/-
This staining index is based on the number of cells stained positive for 5/C4 ranging from 
approximately 5-10% of cells (+), to 90% of cells (+++)
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(a)
Figure 3.3.1. Indirect immunofluorescence on live cells with MAb 5/C4 (section 
3.3.1.), (a) OAW42-SR cells treated with facs-lyse fixative for 1 min. at room 
temperature, (b) OAW42-SR cells untreated and probed with MAb 5/C4 for 0.5 
hours at 4°C. MAb 5/C4 was detected with a FITC-labelled secondary antibody 
(section 2.9.4. materials and methods). Photographs were taken at 40X.
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DLKP DLKP-A COR-L23R
OAW42-SR OAW42-SR RZ2COR-L23S
A2780 MOP-8 Negative control
Figure 3.3.2. Immunocytochemical analysis of MDR cell lines with MAb 5/C4 
(section 3.2.2.) using the DAB/ABC method (section 2.9.5.). Negative control 
cytospin was probed with mouse IgG. Photographs were taken at 20X.
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3 3 3 Determination of molecular weight by Western Blot analysis
The molecular weight of the antigen detected by MAb 5/C4 was determined by Western 
Blotting (section 2 10 3 materials and methods)
Analysis of OAW42-SR and OAW42-S cell lysated indicate that the anti-OAW42-SR 
antibody 5/C4 recognised 2 bands with molecular weights of approximately 110 kDa and 
85 kDa, figure 3 3 3 The 2 bands appeared to be of equal intensity An anti-MVP MAb , 
1032 was included for comparison, it also detected 2 bands at 110 kDa and 85 kDa, 
figure 3 3 3 The 110 kDa band detected by MAb 1032 was more intense in the LRP 
positive control cell line, SW1573/2R120 whereas the lower 85 kDa band was more 
intense in OAW42-SR cells These results implied that the MAb 5/C4 may recognise an 
alternative form of the LRP/MVP Detection of a modified form was more likely because 
of the differences in the staining pattern between MAb 5/C4 and results previously 
observed with LRP-56 (section 3 2 3 2)
3.3 4 Western blotting studies in a panel of multidrug resistant/sensitive cell lines
A series of paired drug resistant cell lines and their sensitive counterparts were examined 
by Western Blotting with MAb 5/C4, results are illustrated in figure 3 3 4 Low 
expression of the antigen detected by MAb 5/C5 was observed in DLKP and the Pgp 
over-expression DLKP-A cell lines with 2 faint bands at 110 kDa and 85 kDa (lanes 1 
and 2) Significantly low levels were also detected in the COR-L23R cell line (lane 6) 
There did not appear to be any significant expression in the sensitive COR-L23 S cell line 
(lane 7) A2780 and the 5/C4 positive control cell line OAW42-SR appeared to strongly 
over-express the 2 bands recognised by MAb 5/C4, in the LRP/MVP transfected 
A2780/AC16 cell line, only the 110 kDa appeared to be strongly expressed (lanes 3, 4 
and 5) Expression of the 110 kDa or 85 kDa band may have some significance for the 
function of the 5/C4 and or the LRP/MVP In order to determine the specificity of the 
MAb 5/C4 further experiments were carried out
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Figure 3 3 3 Western blotting results of crude cell lysates of OAW42-SR, OAW42- 
S and SW1573/2R120 (section 3 3 3 and section 2 10 3 materials and methods) 
Blots were probed with (a) anti-MVP antibody 1032 and (b) MAb 5/C4 visualised 
with a horseradish peroxidase labelled anti-mouse secondary antibody and enhanced 
chemilummescence (section 2 10 4 materials and methods)
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116 kD
84 kD
Figure 3.3.4. Western blots of crude whole cell lysates of MDR cell lines probed 
with MAb 5/C4 (section 3.3.4.). Blots were visualised with an anti-mouse 
horseradish peroxidase-labelled secondary antibody and enhanced
chemiluminescence (section 2.10.4. materials and methods).
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3 3 5 Western Blotting studies with purified rat vaults
In this study purified rat vaults (Kedersha and Rome 1986) were probed by Western 
Blotting (section 2 10 3 materials and methods) with MAb to determine if cross 
reactivity occurred Results indicate that MAb 5/C4 does not recognise the any of the 
constituent proteins of rat vault particles The MAb 1032 (which was raised to purified 
MVP) does detect a band at 104 kDa but not at 84 kDa (Figure 3 3 5 )
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Figure 3.3.5. Western Blotting studies with purified rat vault particles (section 
2.10.3. materials and methods). Blots were probed with 1, anti-rabbit horseradish 
peroxidase-, 2-4, anti-mouse horseradish peroxidase-labelled secondary antibodies 
and enhanced chemiluminescence (section 2.10.4. materials and methods).
3 4. Characterisation of MAb 3/E3
3 4 1 Indirect immunofluorescence studies on live cells with the anti-OAW42-S 
MAb 3/E3
Live cell preparations of OAW42-S were incubated with MAb 3/E3 to determine 
whether it detected a plasma membrane associated antigen (section 2 9 3 materials and 
methods) Results show that OAW42-S cells exhibited plasma membrane staining 
characterised by a fluorescent ring around the cells which was absent from the negative 
control Results are outlined in figure 3 4 1
3 4 2 Indirect immunofluorescence on fixed cells with MAb 3/E3
Cytospins of OAW42-SR and OAW42-S cells probed with MAb 3/E3 to investigate if 
the antigen recognised by this antibody was also expressed intracellularly Results are 
illustrated in figure 3 4 2
Staining in OAW42-S cells was predominantly plasma membrane with some diffuse faint 
cytoplasmic staining In OAW42-SR cells, the staining mainly cytoplasmic and granular 
in nature In some cells, the antibody appeared to stain structures associated with the 
nuclear envelope Some plasma membrane staining was also observed, no staining was 
observed in the negative control
3 4 3 Immunocytochemical analysis of a panel of paired drug resistant/ sensitive 
cell lines
A series of multidrug resistant and sensitive cell lines were examined to determine the 
expression of the antigen detected by MAb 3/E3 Immuno-reactivity was observed on all 
cell lines tested There was no apparent differences in the number and intensity of cells 
stained There was significant difference in the cellular location of the antigen detected 
by MAb 3/E3 Typical results are illustrated in figure 3 4 3 These results suggested that
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the antigen recognised by MAb 3/E3 was a constituent plasma membrane protein in 
human cells
3 4 4 Determination of molecular weight or MAb 3/E3
MAb 3/E3 failed to recognise its antigen by Western Blotting and immunoprécipitation 
techniques It is therefore not possible to assign a molecular weight to the antigen 
detected by MAb 3/E3 This suggested that this antibody may recognise a 
conformational epitope which was destroyed by Western Blotting The inability of the 
antibody to immunoprecipitate the 3/E3 antigen suggested that the buffer constituents of 
the lysis buffer may have contributed to the destruction of the epitope
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(a)
(b)
Figure 3.4.1. Immunofluorescence studies on live OAW42-S cells. Cells were 
probed with MAb 3/E3 and detected with FITC-linked secondary antibody, (a), (b) 
is a negative control, OAW42-S cells probed with mouse IgG. All photographs were 
taken at 40X.
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OAW42-S cells probed with MAb
3/E3
OAW42-SR cells probed with MAb
3/E3
Fjgure 3.4.2. Immunofluorescence studies on fixed cells with MAb 3/E3 (section 
2.9.4. materials and methods). MAb 3/E3 was detected with a FITC-linked 
secondary antibody. Photographs were taken at 40X.
OAW42-S OAW42-SR
DLKP-A
A2780 Negative control
Figure 3.4.3. Immunocytochemical analysis of MDR cell lines with MAb 3/E3 
(section 3.4.3.). Negative control was probed with mouse IgG. Photographs were 
taken at 40X.
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Discussion
4 1 General discussion
Over the past two decades, extensive laboratory studies on the mechanisms of MDR 
have focused on drug-selected resistance cancer cell lines where a number of genetic, 
molecular and biochemical changes have been observed compared to parental cell lines 
In a number of these in vitro models, the expression of the MDR-1 gene product P- 
glycoprotein (Pgp), and the MRP gene product (MRP) appear to play a direct role in 
cytotoxic drug transport ( Coley et al, 1989 Goldstein 1992, Zaman et al, 1994) The 
search for alternative mechanisms of drug resistance led to the discovery of the 110 kDa 
protein LRP which did not appear to be co-over-expressed with Pgp (Scheper et a l, 
1993)
The subsequent discovery by Scheffer et a l, (1995) that LRP was the human homologue 
of rat and slime mould, major vault protein (MVP) and the subsequent (apparent) 
association of vault proteins with the central plug of the nuclear pore complex and 
clathnn-coated vesicles suggested some important physiological role for vault proteins 
and possibly LRP/MVP
Immunocytochemical analysis of OAW42-SR cells, the intrinsically resistant variant of 
the ovarian cell line OAW42, revealed up-regulation of the LRP/MVP associated with an 
increase in resistance to adnamycin (Moran et a l, 1997) which suggested a role in drug 
resistance A similar increase in LRP/MVP expression in the OAW42-S cell line, a drug 
sensitive clonal sub-population of the OAW42-SR, without an associated increase in 
drug resistance suggested the existence of multiple forms of the LRP/MVP These 
observations prompted the research detailed in preceding chapters and discussed below
The initial aim of this project was the isolation of monoclonal antibodies raised to the 
OAW42-SR and OAW42-S variants In achieving this aim, a total of 11 clones were 
isolated from two fusions, 3 or which were chosen for further characterisation ( see 
section 4 2)
Comprehensive characterisation of theses MAbs was the next major goal of the thesis
Immunofluorescent and immunocytochemical analysis revealed that the anti-OAW42-SR
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MAb 3/B6 displayed significant similarities in staining pattern with the anti-LRP/MVP 
monoclonal antibody LRP-56 while illustrating differences in cellular location of these 
antigens (Section 4 4 and 4 5)
These characterisation studies also suggested that 3/B6 recognised a epitope whose
;confirmation was destroyed in the course of sample preparation and Western Blotting in 
that the molecular weight could not be determined by conventional Western Blotting 
techniques (section 4 6) Immunoprécipitation of cellular antigens allows detection of 
intact antigens by a range of MAbs, which are unable to detect these antigens by 
conventional Western Blotting techniques The major goal in this phase of the project 
was to establish a reliable non-radioactive method for labelling and detecting the 3/B6 
antigen This was achieved by the modification and further development of a new cellular 
labelling and immunoprécipitation kit based on labelling protein with biotin derivatives 
(section 4 6) This improved method allowed the characterisation of the 3/B6 antigen as 
a non-glycosylated protein with an apparent molecular weight of 115 kDa Further 
immunoprécipitation studies revealed that the expression of the 3/B6 antigen appeared to 
be closely linked with that of the LRP/MVP (section 4 6 1 4 6 2 and 4 6 4) confirming 
the pattern of staining observed for these two MAbs by immunocytochemistry
LRP/MVP vs 3/B6 antibody competition experiments (outlined in sections 3 2 3 3 and 
3 2 6) were undertaken to determine if the antigen detected by 3/B6 was closely related 
to the LRP/MVP These experiments indicated that, although the 3/B6 antigen and the 
LRP/MVP had similar molecular weights and expression patterns in MDR cell lines, 
MAb 3/B6, LRP-56 and LMR-5 do not appear to recognise the same antigen (section 
47)
Protein sequence data indicated some homology with constituent proteins of the MHC 
and blood coagulation cascade the percentage homology was low within a short (14 
ammo acid) peptide (section 4 12) This observation suggested that MAb 3/B6 may 
recognise a novel antigen which might be associated with drug resistance A tissue 
survey was undertaken to establish the tissue distribution of the antigen and to determine 
whether the 3/B6 protein was associated with drug resistance in vivo (section 4 8-4 9)
155
Analysis of the results indicated that the 3/B6 antigen might be an indicator of drug 
resistance in ovarian and breast cancer (section 4 8 1) rather than playing a direct role in 
drug resistance This tissue survey data correlated with the distribution in of the 3/B6 
protein MDR cell lines which also pointed to an association with the drug resistance 
phenotype (section 4 4 and 45) Drug accumulation studies (section 4 10), data 
indicated that 3/B6 had no effect on drug accumulation
Isolation of the second anti-OAW42-SR MAb 5/C4 also revealed similarities between 
the antigen detected by this MAb and the LRP/MVP Immunocytochemical analysis 
revealed that MAb 5/C4 also stained the cytoplasm in a granular cytoplasmic fashion 
However, there was significant differences in their patterns of expression in MDR cell 
lines (4 13 1)
Western Blotting studies revealed that the 5/C4 antigen consisted of 2 protein bands 
which migrated as 110 kDa and 85 kDa which was similar to the anti MVP monoclonal 
antibody 1032 (4 13 2) However no cross-reactivity was observed with purified rat 
vault particles (4 13 4) The role, if any in drug resistance for this antigen has yet to be 
established
Increased expression of the LRP/MVP was observed in the OAW42-S without an 
associated increase in drug resistance (Moran et a l, 1997a) This observation suggests 
the existence of alternative forms of the LRP/MVP, which may also have been present in 
the OAW42-SR The final aim of the project was to raise MAbs to the OAW42-S in an 
attempt to isolate antibodies to these possible alternative forms of LRP/MVP The anti- 
OAW42-SR MAb 3/E3 did not display any characteristics in staining consistent with 
known anti-LRP/MVP antibodies (section 4 14) It was not possible to determine the 
molecular weight of this antigen by Western Blotting or immunoprecipitation suggesting 
that the 3/E3 epitope may be conformational
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4 2 Production of monoclonal antibodies
From a total of 370 clones isolated by cell fusion, supernatants from six of these clones 
consistently reacted with OAW42-SR cells while supernatants taken from five clones 
reacted with the OAW42-S cell line (Section 2 8 2) Initially the anti-OAW42-SR MAb 
3/B6 did not cross-react with OAW42-S cells but in subsequent ELISA assays cross 
reactivity was observed Similarly the anti-OAW42-S MAb 3/E3 appeared to recognise a 
sub-population of the OAW42-SR, however this was not consistently observed In order 
to ensure that the results of these studies were consistent, OAW42-SR were used 
between passage 95 and 100 and OAW42-S between 1-6 only The different expression 
patterns observed in these early studies could have been due perhaps, to different clonal 
populations within the OAW42-SR however, it is more likely that these differences were 
due to an artifact of the immunocytochemistry procedure
4.3 Purification of ascites from hybndoma clone 3/B6
The concentration of IgG (as determined by the RID method, 2 8 1) was found to be 
approximately 2 5 mg/ml, while protein concentration for punfied 3/B6 MAb was 
between 190-200 jag/ml which is a significant drop from the previous figure The 
purification columns used to purify the antibody should theoretically bind all IgG sub­
classes as sepharose beds are coated in a fusion protein of protein A and G It is 
therefore assumed that the remaining substantial quantity of IgG was lost on the column 
due to precipitation of the antibody or simply that it did not bind to the column, the 
effluent was not assayed for IgG content to confirm this
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4 4 Indirect immunofluorescence on live and fixed cells with MAb 3/B6
The initial characterisation of the antigen recognised by the anti-OAW42-SR MAb 3/B6 
was carried out by immunofluorescence on live cells A fluorescent ring around the cell 
indicates specificity for an external epitope whereas The absence of cell surface 
fluorescence indicates a cytoplasmic epitope When OAW42-SR cells were probed with 
the MAb 3/B6 a bright ring was observed around the cell indicating that the epitope 
recognised by this antibody was expressed on the cell surface MAb LRP-56, which 
recognises the LRP/MVP, (a cytoplasmic protein), gave not staining The negative 
control for all these experiments was purified mouse IgG (which also gave a negative 
result, no staining was observed, Figure 3 2 11)
The expression of the 3/B6 antigen was then assayed in a panel of MDR drug resistant 
and sensitive paired cell lines including OAW42 variants Moran et a l, (1997a) have 
investigated the expression of a number of MDR associated antigens in OAW42 patients 
Their results show the over-expression of the LRP/MVP in the OAW42-S and OAW42- 
SR with reduced expression in the OAW42-A1 and OAW42-A These variants were also 
examined during the characterisation of MAb 3/B6 (Figure 321 2, 3213)
The highest level of staining was observed in the OAW42-SR (the cell line which the 
antibody was raised to table 3 2 1) Not all of the cells were stained with equal intensity 
Similar levels of staining were observed in the OAW42-S cell line The OAW42-S 
variant was cloned from the OAW42-SR, therefore some degree of positivity would be 
expected 3/B6 staining was less intense in other OAW42 variants, the OAW42-A1 and 
OAW42-A
Low level expression of the 3/B6 antigen was also detected in the DLKP-A, a Pgp over­
expressing cell line whereas in the parental drug sensitive DLKP line 30% of cells were 
stained intensely with MAb 3/B6 The 3/B6 antigen appeared to be over-expressed 
primarily on low level resistant cell lines including the SW1573/2R120 and the sensitive 
A2780 DLKP has been shown to express low levels of MRP but little or no Pgp (Duffy 
et al, 1998) Although the OAW42-S have been shown to over-express the LRP/MVP,
no change in resistance was observed (Moran et a l, 1997a) LRP/MVP has been shown
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to be primarily associated with low level resistant drug selected and intrinsically resistant 
cell lines (Moran et a l, 1997a, Izquierdo et a l, 1996a) The MRP over-expressing cell 
line COR-L23R did not appear to be specifically stained with MAb 3/B6 in that both the 
negative control (which was probed with mouse IgG) also displayed intense plasma 
membrane staining (figure 3 2 13) This suggests that the staining observed in the COR- 
L23R was probably non-specific
Immunofluorescence on fixed cells indicated that the antigen detected by MAb 3/B6 was 
also expressed in the cytoplasm of OAW42-SR cells,(Figure 3 2 2 1 ) Plasma membrane 
staining was also evident from this experiment, the granular cytoplasmic staining 
observed did not appear to be localised to any particular region of the cytoplasm Flens 
et a l, (1997) have reported that a novel MAb, LMR-94 exhibits strong cytoplasmic 
staining close to the nucleus This group believe that this antibody may detect a 
component of the Golgi apparatus The 3/B6 antigen was located mainly on the plasma 
membrane of OAW42-S cells with some diffuse cytoplasmic staining The anti- 
LRP/MVP MAb LRP-56 was used for comparison in this study There was clear 
peripheral cytoplasmic staining with the absence of plasma membrane staining which is 
consistent with previous observations (Moran et a l, 1997a, Izquierdo et a l, 1996a, 
Scheper et a l, 1993) This differed from the 3/B6 staining pattern where the cytoplasmic 
staining was more diffuse
The optimum fixation for MAb 3/B6 was determined for this experiment It was found 
that the best results were achieved when cytospins of cells were fixed in ice cold acetone 
for 4 min A high level of background was observed in negative controls of OAW42-S 
cells This may have contributed to some of the staining with these antibodies Results 
from these initial experiments were conflicting, MAb 3/B6 recognised an antigen on a 
number of LRP/MVP over-expressing cell lines but staining was primarily plasma 
membrane in nature LRP/MVP extracellular staining has not been reported Similarly, 
vault particles appear to be confined exclusively to the cytoplasm and nuclear membrane 
(Kedersha and Rome, 1986a, Chugam et a l, 1992) This observation warranted further 
investigation
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4 5 Immunocytochemical analysis with MAb 3/B6 and LRP-56
OAW42-S and OAW42-SR cells were re-examined using the ABC/ HRP method (as 
outlined m section 2 2 3) Results from this experiment agreed with immunofluorescence 
studies on fixed cells in that MAb 3/B6 stained both the cytoplasm and plasma membrane 
of OAW42-S and OAW42-SR cells with MAb 3/B6, (figure 3 2 3 1 ) There appeared to 
be a greater expression of the 3/B6 antigen in the cytoplasm The staining also appeared 
to be more granular in nature rather than the diffuse staining observed in the previous 
experiment
A number of paired drug resistant and drug sensitive cell lines (with different expression 
levels of the LRP/MVP) were probed with MAb 3/B6 and LRP-56 to determine if the 
pattern of staining for MAb 3/B6 in this expanded panel of cell lines was similar to the 
pattern observed with immunofluorescence on live cells, (Table 3 2 2, figures 3 23 2 1 
to 3 2 3 2 4) As with the previous experiments, MAb 3/B6 and LRP-56 appeared to 
stain the low level resistant cells with a greater degree of intensity The SW1573/2R120 
drug selected cell lines are part of a larger series of variants isolated by Scheper et al 
(1993) Intense plasma membrane and cytoplasmic staining was observed m the 
LRP/MVP over-expressing 2R120 variant with less staining on the parental SW1573 
However, the level of staining in the SW1573 cell line was higher than that observed 
with MAb LRP-56 where approximately 5-10% of cells displayed LRP/MVP positivity 
Similar levels of staining were observed in the Pgp positive 2R160 variant with both 
antibodies The drug resistant GLC4/ADR cell line over-expressed both the LRP/MVP 
and MRP (Flens et a l, 1998) Staining was mainly confined to the plasma membrane of 
GLC4/ADR cells with only a small percentage of cells displaying cytoplasmic staining 
3/B6 staining (in general) appeared to be consistent with that observed for LRP-56
Drug resistant variants of the non-small cell lung carcinoma cell line DLKP (Law et a l,
1992) were established by exposure to adnamycin resulting in the isolation of the DLKP-
A, (Clynes et al 1992) and DLKP-A10 cell lines (Cleary et a l, 1997) The latter cell line
over-expresses Pgp and exhibits low level MRP (Cleary 1995, PhD thesis) It was
observed that the staining patterns of 3/B6 and LRP-56 in these variants were in general
agreement l e the highest level of staining was observed in the DLKP and DLKP-A10
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cell lines LRP/MVP and the 3/B6 over-expression was observed in a sub-population of 
the Pgp over-expressing cell line DLKP-A10 Co-expression of Pgp and LRP/MVP has 
been observed in some low level drug resistant sublines of the myeloma cell line 8226, 
the breast carcinoma cell line MCF7 and in variants of the OAW42 which have been 
descnbed here In each case it was observed that LRP/MVP was expressed at higher 
levels (Moran et a l, 1997a, Wyler et a l, 1997, Cleary et a l, 1997, Shao et a l, 1995, 
Scheper et a l , 1993,) Cleary et a l, (1997) observed novel vesicular transport 
mechanisms in this cell line by confocal laser microscopy There also appears to be a 
significant level of LRP/MVP expression which suggests that LRP/MVP may play a role 
in the observed (novel) vesicular transport mechanism These immunocytochemistry 
results did not correlate with those obtained from immunofluorescence experiments 
discussed previously Higher levels of 3/B6 expression were observed by 
immunofluorescence in the DLKP-A and A2780 cell lines(figures 3 2 12 and 3 2 13) 
The difference in results could be due to the acetone fixation method used in the 
permeabilisation procedure
There was apparent up-regulation of the 3/B6 antigen in the LRP-cDNA transfected
A2780-AC16 variant compared to the untransfected parental cell line A2780, similar
results were obtained with MAb LRP-56 However, 3/B6 staining was absent from other
cDNA transfected cells (Scheffer and Scheper, personal communication, results not
shown), whereas, these cells displayed strong cytoplasmic staining when probed with
MAb LRP-56 and the anti-vault polyclonal antibody N2 Byrne (1998) observed
increased levels of LRP/MVP expression in certain LRP/MVP nbozyme and antisense
transfected OAW42-SR clones) The increase in 3/B6 expression in the AC 16 variant
may be due simpley to the transfection procedure However, another LRP/MVP cDNA
transfected clone, the AC12 variant displays less staining with MAb 3/B6 and LRP-56 It
has been suggested that this clone did not receive the full length LRP/MVP cDNA
resulting in the reduced LRP-56 staining (Scheffer, personal communication) This
implies that the staining observed in both the AC 12 and AC 16 with MAb 3/B6 is
specific The 3/B6 antigen appeared to be expressed primarily in the plasma membrane of
the transfected variants whereas in the parental A2780 cell line, the staining was
predominantly cytoplasmic The apparent shift in the location of the 3/B6 antigen has
been observed with another anti-OAW42 MAb, Me Garry et a l, (1996) observed a
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switch in the expression of a 48 kDa antigen detected by MAb P1H10 in OAW42 
variants In OAW42-S cells staining was located mainly in the plasma membrane with no 
cytoplasmic staining while in the OAW42-SR, immunoreactivity with MAb P1H10 was 
seen mainly on the plasma membrane with some cytoplasmic/ nuclear staining
Byrne (1998) has isolated a series of stable LRP/MVP nbozyme and antisense 
transfected OAW42-SR clones Evidence from these immunocytochemical studies on 
LRP/MVP nbozyme transfectants suggests that the co-expression of LRP/MVP and the 
antigen detected by MAb 3/B6 may be influenced by LRP/MVP expression 
Immunocytochemical analysis reveals reduced expression of LRP/MVP in both LRP 
nbozyme transfectants with a significant reduction of LRP/MVP expression in the 
nbozyme 2 subline (section 3 2 3 2) A similar reduction in 3/B6 staining (compared to 
the untransfected parent) was also observed but with a greater reduction in the nbozyme 
4 transfectant (figure 3 2 3 2 1)
In this study, LRP/MVP was absent from the MRP expressing COR-L23R cell lines and 
expressed at low levels in the COR-L23S, the sensitive counterpart MAb 3/B6 also 
stained these cell lines in a similar manner indicating that their expression maybe linked
Low expression of both LRP/MVP and the antigen detected by MAb 3/B6 was observed 
in the sensitive nasal carcinoma cell line RPMI 2650 which has been confirmed by others 
(Liang, unpublished) Staining was absent from the mouse fibroblast cell line MOP-8 
which has been used for transfection and transient expression of LRP/MVP cDNA with 
no associated change in resistance (Scheffer et al 1995) Results for the OAW42 
variants, OAW42-A1 and OAW42-A are absent due to the "sticky1 nature of these cells 
This problem was also encountered by Moran et a l, (1997a), with MAb s to MRP 
Moran et al have observed that an increase in resistance is accompanied by an increase in 
the expression of cytoskeletal elements, this may have some banng on the lack of clear 
result from these sublines The increased expression of vimentin and cytokeratin may be 
accompanied by increased expression of cell adhesion molecule causing non-specific 
binding of MAb
The staining pattern of 3/B6 did not appear to correlate with resistance to any particular
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cytotoxic drug Moran et al (1997a) determined the cross-resistance profile of the 
OAW42 variants Generally, the OAW42 variants display the highest degree of resistance 
for vincristine, Adnamycin and VP-16 with lowest resistance for Cisplatin and 5-FU 
DLKP-A and DLKP-A10 had a similar pattern (Cleary, 1995 PhD thesis) The majonty 
of other cell lines tested had similar drug resistance profiles Flens et a l, (1998) have 
demonstrated that within a range of rat MAb raised to the SW1573/2R120 cell line, 
some antibodies have a greater affinity for vincristine selected cell lines Staining was 
absent from single step, low dose doxorubicin-selected SW1573 sublmes
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4 6 Development of an immunoprécipitation protocol for the characterisation of 
the 3/B6 antigen
In order to characterise and quantitate cellular proteins, the molecules are usually 
labelled with radioisotopes, immunoprecipitated and analysed by SDS-PAGE and 
autoradiography Membrane proteins are most often labelled by îodmation while 
intracellular antigens are usually labelled metabolically with radiolabelled amino acids 
such as [35S] Methionine (Harlow and Lane, 1988)
Attempts have been made to use biotin labelling, initially for the labelling of cell surface 
proteins (Meier et a l, 1992), coupled with enhanced chemiluminescence (Nesbitt et a l, 
1992) As described in section 2 10 5 , biotin labelling is based on the principle of 
covalent binding of biotin-7-NSH to amino groups, mainly on lysine residues Proteins 
are then immunoprecipitated Biotin labelling does not appear to interfere significantly 
with antibody binding (Levy-Toledano et a l, 1993)
Conventional Western Blotting techniques failed to allow the estimation of the molecular 
weight of the 3/B6 antigen Furthermore, non-reducing and non-denaturing loading 
buffers failed to give a positive result This suggested that the 3/B6 MAb recognised an 
epitope which was destroyed by conditions for preparation for Western Blotting
A biotin labelling and precipitation kit was extensively modified in order to allow
successful immunoprécipitation of the 3/B6 antigen and subsequent determination of the
molecular weight (Masterson, Moran, Scheper and Clynes, 1998) The detergents
provided (Nomdet-P40 and sodium deoxycholate), were gentle enough to allow
detection of the antigen by MAb 3/B6 antigen but not to solubilise the background
protein to too high a degree This was particularly important since 3/B6 is expressed in
the cytoplasm and the plasma membrane Preclearmg (incubation of the cell lysate with
protein A or G labelled sepharose to remove any protein which may non-specifically bind
to them) and test antibody incubation times were increased in order to improve
immunoprécipitation Scheper et al (1993) and Flens et al (1998) have reported
preclearmg and antibody incubation times in the range of 1 -2 hours Observations in this
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laboratory for a number of non-MDR related MAb found that pre-clearing steps of up to 
8 hours were required to reduce non-specific background in the development of Western 
Blots by ECL Test antibody incubation times were earned out overnight on a belly 
dancer which appeared to improve the results (Figure 3 2 4 1 1 ) A minimum of 4 hours 
immunoprecipitation with Protein-G coated sepharose beads gave optimal results for this 
these antibodies Other researchers in this laboratory have used longer incubation times 
with other monoclonal antibodies (Walsh and Meledy, personal communication) It was 
found that repeated washing steps with high salt buffers reduced the quantity of protein 
obtained from immunoprecipitation experiments with a range of antibodies Antibodies 
with low affinities for their target proteins tend to dissociate in high salt buffers (Harlow 
and Lane, 1988)
Procedure guidelines included with the kit suggested streptavidin-biotin/HRP complex as 
method for the detection of biotin labelled protein bands which was based on the 
protocols of Levy-Toledano et a l, 1993, and Meier et a l, 1992) However, significant 
background staining was observed when Western Blots of 3/B6 immunoprecipitates 
were developed by ECL (Figure 3 2 4 1 2) This high degree of background staining was 
due to endogenous biotin present in non-fat milk used as blocking buffer Chu et a l, 
(1989) reported similar background in blot development with ABC/HRP complex 
Further experimentation revealed that the combination of an anti-biotin secondary 
labelled coupled with biotin free BSA significantly reduced the background staining 
levels It was found that antibody dilutions of the secondary antibody of 1/4000 to 
1/6000 in TBS 0 1% (v/v) Tween 20 reduced the levels of background staining without 
compromising antigen detection
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4 6 1 Determination of the molecular weight of the 3/B6 antigen
A biotin labelled band at approximately 115 kDa was detected in 3/B6 
immunoprecipitates of OAW42-SR cell lysates This band was absent from the negative 
control lane consisting of OAW42-SR cell lysate precipitated with mouse IgGl antibody 
(Figure 3 2 4 2) A series of bands at 95 kDa and 55-45 kDa were detected in the 
majority of immunoprécipitation samples These bands were detected non-specifically by 
the secondary antibody Izquierdo et al (1996b) observed similar bands in 
immunoprécipitation preparations from fresh tissue samples They have assigned these 
bands to (a) precipitation of mouse IgG at 90 kDa and (b) breakdown of IgG molecules 
at 55-45 kDa Mouse IgG was subjected to SDS-PAGE and formed a similar pattern of 
bands
4 6.2. Determination of protein glycosylation of the 3/B6 antigen
Proteins destined for secretion, incorporation into membranes or localisation inside 
membranous organelles, usually contain carbohydrate moitiés (Lodish et a l, 1988) 
Glycosylation appears to play an important role in the sorting and distribution of these 
proteins to their correct cellular destinations (Pfeifer et a l, 1987) The oligosaccharide 
portion is usually classified as being N-linked where sugar groups are linked by a p-N- 
glycoside bond to an Asn residue in the sequence Asn-X-Ser or Asn-XThr where X may 
be any amino acid except Pro or Asp They may also be classified as O-linked where
j
oligosaccharides are attached to their polypeptide chain through an ot-O- glycoside bond 
to Ser or Thr (Voet and Voet, 1990) Inhibitors of N-glycosylation include tumcamycin 
which specifically inhibits synthesis of intermediaries in N-linked synthesis by binding 
irraversably to glycosyl transferase Similarly PNAG binds O glycosyl trnsferase 
Therefore the presence of these compounds in the growth medium of cultured cells 
should inhibit the glycosylation in a population of cells
Analysis of the results from this experiment reveals that there were no extraneous bands 
visible in Western Blots of 3B6 immunoprecipitates from OAW42-SR when treated with
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tumcamycin or PNAG (Figure 3 2 5 1 (a) Scheper et a l, (1993) have established that 
the LRP/MVP is unglycosylated therefore this protein was used a negative control, no 
extra bands were visible on Western Blots of LRP/MVP immunoprecipitates The lower 
band visible in immunoprécipitation preparations is due to non-specific binding of the 
secondary antibody to IgG A clear shift in the molecular weight and the appearance of a 
second band at approximately 140 kDa is apparent in the positive control, DLKP-A cell 
lysated treated with tumcamycin and detected using the anti-Pgp MAb C219 (Figure
3 2 5 1 (b)
The ovarian carcinoma-associated antigens listed in section 14 6 have been 
characterised as glycoproteins therefore it is possible to conclude that 3/B6 is probably 
not one of these proteins or a segment thereof
4 6 3 Immunoprécipitation of MDR cell lines
Analysis of a series of drug resistant and sensitive cell lines was undertaken to confirm 
the levels of expression of the 3/B6 antigen and LRP/MVP observed previously by 
immunocytochemistry
A faint band was detected in DLKP, compared to the positive control, OAW42-SR cells 
precipitated with MAb 3/B6 (figure 3 2 7 1 ) There was no band detected in 
preparations of DLKP-A cells suggesting that the staining detected by immuno-analysis 
may have been non-specific A large band at 115 kDa was observed in A2780/AC16 cells 
confirming the îmmunocytochemical results discussed earlier This also indicates that the 
3/B6 staining observed previously was specific
A 110 kDa band (LRP/MVP) was also absent in the DLKP-A LRP-56 
immunoprecipitates (Figure 3 2 7 2) Surprisingly, high levels of LRP/MVP expression 
was observed in the A2780, COR-L23S and COR-L23R cell lines These results do not 
correlate with those obtained by immunocytochemistry The lack of correlation may be 
due to fixation of the protein which may destroy some of the epitope sites whereas 
immunoprécipitation theoretically allows detection of the entire protein although this has 
not been observed in this laboratory before
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4 6.4. Analysis of LRP nbozyme-transfected OAW42-SR sublines by 
lmmunoprecipitation
Byrne (1998) have isolated a number of LRP/MVP cDNA nbozyme and antisense 
transfected sublines of OAW42-SR to determine whether this protein plays a direct role 
in the MDR phenotype In the course of characterising the MAb 3/B6 the three selected 
clones, one antisense and two nbozyme transfectants were investigated further in order 
to determine if LRP/MVP expression influences that of the 115 kDa antigen recognised 
by 3/B6
Reduced LRP/MVP expression was observed in all 3 clones compared to the positive 
control, untransfected OAW42-SR cells (figure 3 2 8 1 ) Immunocytochemical analysis 
had shown that the expression of LRP/MVP was down regulated in the nbozyme 2 and 4 
sublines with the greatest reduction observed in the nbozyme 2 line A faint band at 110 
kDa was observed for OAW42-SR RZ2 compared to the positive control, OAW42-SR 
cells precipitated with LRP-56 Densitometry analysis by Byrne (1998) has indicated a 10 
fold reduction in the expression of LRP/MVP in the nbozyme 2 clone compared to the 
untransfected control with no significant change in cells transfected with the pH0 
plasmid This indicates that these results are not simply an artefact of the transfection 
procedure Reduced 3/B6 antigen expression was observed in 1 clone only, the nbozyme 
4 clone (when compared to the untransfected control) These results are consistent with 
the immunocytochemical results discussed earlier
Drug toxicity profiles of these transfected OAW42-SR clones show a marked decrease in 
resistance to adnamycin compared to the parental untransfected OAW42-SR cells with 
the nbozyme 2 transfectant showing the greatest reduction in resistance (10 fold) This 
clone also showed a 70 fold decrease in resistance to vincristine and 71 fold reduction in 
Taxol resistance (Byrne 1998, PhD thesis) Byrne did not observe a significant reduction 
in LRP/MVP mRNA in the nbozyme 4 clone whereas in the nbozyme 2 clone, significant 
reduction was observed
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It appears from these results that 3/B6 expression in the OAW42-SR is closely linked to 
that of the LRP/MVP This observation can be made from both the 
immunocytochemistry and immunoprécipitation results which appear to be consistent for 
3/B6 antigen expression
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4 7 Cross-reactivity studies with anti-MVP and anti-LRP/MVP antibodies
SchefFer et a l, (1995) demonstrated that the LRP is the human homologue of the rat 
major vault protein (MVP) Flens et al (1997) also confirmed that the rat MAb LMR-5 
recognises the LRP/MVP Evidence from immunofluorescence and immunocytochemical 
studies have indicated a distinct similarity in the staining patterns of MAbs 3/B6 and 
LRP-56 Immunoprécipitation of OAW42-SR cell lysates have shown similarities in 
molecular weight and glycosylation pattern (Section 3 2 4 and 3 2 5 )
These studies were concerned with determining whether the MAb 3/B6 cross-reacted 
with the LRP/MVP Two experiments were undertaken In the first experiment 3/B6 and 
LRP-56 immunoprecipitates from OAW42-SR and SW1573/2R120 cells were probed by 
Western Blotting with the anti-rat vault polyclonal antiserum Supernatants from these 
overnight precipitations ( i e following the addition of protein A or G coated sepharose 
beads to cell lysates containing the antibody antigen complex, the suspension is spun 
down and supernatant concentrated) were subjected to SDS PAGE If 3/B6 is an anti 
vault antibody then there would be a significant reduction in the levels of MVP detected 
in the supernatants of these immunoprecipitates The second part of the experiment 
involved competition studies with the anti-vault MAb LMR-5, the anti-vault polyclonal 
antibody N2 and MAb 3/B6
Results indicate that although there are similarities between the two proteins, MAb 3/B6
does not recognise the MVP (Figure 3 2 6 1 ) The N2 polyclonal antibody detected a
104-110 kDa band in LRP-56 immunoprecipitates OAW42-SR and SW1573/2R120
only In 3/B6 immunoprecipitates this band was absent There appeared to be a reduction
in the level of 3/B6 expression in the 2R120 variant compared to immunocytochemical
results (Section 3 2 6 2) There is as yet no explanation for these results The
supernatants taken from the previous immunoprécipitation experiments were also probed
with the anti-rat vault polyclonal antibody to determine the specificity of MAb 3/B6
Immunoprécipitation effectively clears most or all of the target antigen from the
supernatant (cell lysates) Probing the supernatants from 3/B6 immunoprecipitates with
the N2 antibody determines whether the LRP/MVP expression is affected (Figure
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3 2 6 2) There was a significant reduction in LRP/MVP expression in supernatants form 
LRP-56 immunoprecipitates compared to the control, SW1573/2R120 whole cell 
lysates No such reduction was observed in the 3/B6 immunoprecipitates
The second part of this expenment involved competition experiments with anti-vault 
antibodies and the MAb 3/B6 (as outlined in materials and methods section 2 9 5 ) No 
apparent reduction in 3/B6 MAb staining was observed when OAW42-SR cells were 
pre-incubated with LMR-5 or N2 (Figure 3 2 3 3 2 and 32333) As a polyclonal 
antibody, N2 would normally contain antibodies that which bind to multiple sites on the 
antigen thereby blocking more binding sites than a MAb Whereas, pre-incubation of 
OAW42-SR cells with N2 resulted in significant reduction in LMR-5 staining (Figure 
3 2 3 3 4) Taken with the immunoprecipitation results it is possible to conclude that the 
MAb 3/B6 probably does not cross react with the LRP/MVP It is also possible to 
conclude that MAb 3/B6 probably does not detect an alternative form of the LRP/MVP
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4.8. Studies on the expression of the 3/B6 antigen in normal adult and foetal tissue
Antigen expression in vitro is usually a good indicator of expression in vivo. However in 
some cases, continuous culture can cause changes in the expression of some antigens 
therefore it is important to determine the expression in vivo. A limited panel of normal 
adult and foetal tissue of different histological origins were probed with MAb 3/B6 and 
LRP-56.
The 3/B6 antigen was found to have high expression in the adult kidney, localised to the 
distal collecting tubules (Figure 3.2.10.1.). The staining appeared to cytoplasmic in 
nature; no plasma membrane staining was evident. No specific staining was observed in 
the adult thyroid. Izquierdo et al., (1996b) have reported absence of LRP-56 staining in 
the adult thyroid and granular cytoplasmic staining in the adult kidney. LRP/MVP 
appears to be primarily expressed in the proximal tubules differing from that of 3/B6. 
Scheper et al, (1993) also observed this pattern of LRP-56 staining. Thiebault et al., 
(1987) have reported that Pgp expression is localised to the proximal tubules of the adult 
kidney. Flens et al, (1996) reported positive MRP staining in both the distal and proximal 
tubules of the adult kidney whereas no staining was observed in adult thyroid. The 
expression of the LRP/MVP and the 3/B6 antigen in the adult kidney may reflect 
differences in the function of these proteins. The primary function of the distal tubules is 
to aid the reabsorption (into the blood) of sodium and calcium ions. Similar functions are 
carried out in the proximal tubules however, their functions also include reabsorption of 
amino acids and glucose (Tortora and Reynolds-Grabowski 1996). These results may 
give some insight into the functions of the LRP/MVP (and possibly 3/B6 ) in vivo.
3/B6 expression was also screened in a series of foetal tissues (Figure 3.2.10.2.). 3/B6
staining was similar to that observed in adult tissues; primarily localised in the distal
tubules of the foetal kidney. Some low level staining was also observed in the proximal
tubules. Low level staining was also observed in the trophoblasts of the placenta and
enterocytes of the small intestine. Staining was found to be absent from the liver and
adrenal gland. LRP/MVP expression was found primarily in the proximal tubules of the
kidney with some low level staining in the distal tubules (Figure 3.2.10.3. The staining
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pattern of LRP-56 was similar to that observed with of 3/B6, low level staining was 
observed m the trophoblasts of the placenta and entreocytes of the small intestine No 
staining was observed in the adrenal gland Low level staining was observed in the bile 
ducts of foetal liver with MAb LRP-56 which differed from the results observed with 
MAb 3/B6 There did not appear to be the same level of correlation in LRP-56 and 3/B6 
staining which was previously observed in cultures cell lines Me Garry et al (1996) 
have report absence of P1H10 (an anti-OAW42 MAb) staining in normal lymphocytes 
and low level staining in normal buccal cells, other human tissues were not screened 
therefore it is not possible to draw comparisons between these two anti-OAW42 MAbs
4 8 1. Studies on the expression of the 3/B6 antigen in archival breast and ovarian 
material
Two normal ovary, ten pre-chemotherapy tissue blocks and one post-chemotherapy 
tissue block were probed with MAb 3/B6 and LRP-56 to compare the staining patterns 
in these tissue types and to determine the association, if any with drug resistance in 
ovarian carcinoma The 10 pre-chemotherapy blocks were also examined for Pgp, and 
MRP expression using a number of MAbs (section 2 9 2 materials and methods, 3 2 11 
results)
Analysis of the results from these studies revealed that the 3/B6 antigen was not 
expressed in normal ovarian tissue or in pre-chemotherapy tissue blocks (figure 3 111) 
These results indicated that the 3/B6 antigen may only be associated with drug resistance 
phenotype in this tissues Analysis of the expression of the LRP/MVP in normal and pre­
chemotherapy ovarian tissue revealed that there was low-level expression in normal 
tissue but an absence of expression in the pre-chemotherapy tissue sections (figure 
3 2 11 1 ) Izquierdo et a l, (1996b) reported LRP/MVP expression in normal ovary 
They also reported high-level expression of the LRP/MVP in ovarian carcinoma but they 
did not indicate whether these tumour samples were from pre- or post-chemotherapy 
patients It would appear from the results discussed here, that there does not appear to 
be a significant association of the LRP/MVP with untreated ovarian carcinoma
Thiebault et al (1987) did not find any significant Pgp expression in untreated ovarian
173
tumour tissue Similarly, Flens et al (1994) observed only low level expression of MRP 
in ovarian neoplasms These findings appear to be consistent with the results outlined 
here There did not appear to be any significant Pgp expression and only low level MRP 
expression (1/10 tumours, figure 3 111) These results indicated that the 3/B6 antigen 
was not co-expressed with other MDR associated markers which was observed in 
immunocytochemical analysis of MDR cell lines (section 4 5)
Izquierdo et al (1995) have shown that, in tumours treated with platinum- or alkylating- 
based treatment LRP/MVP expression was significant and this expression correlated with 
poor prognosis and reduced disease free period One post-chemotherapy tumour sample 
(from a patient who received 3 cycles of cisplatinum and adriamycin treatments) was 
investigated with MAb 3/B6 and LRP-56 The results from this study were inconclusive 
There appeared to be a high level of (apparently non-specific) nuclear staining, this type 
of staining has not been observed with these MAbs in previous studies Therefore it was 
not possible to draw any conclusions from this study Repeating this experiment with a 
larger number of samples may give a better indication of the association of the 3/B6 
antigen ,if any, with drug resistance in ovarian cancer
Two paired pre- and post-chemotherapy breast tumour samples (infiltrating and ductal 
carcinoma in situ) were investigated with MAb 3/B6 These tissue blocks had been 
previously examined with MAb LRP-56 (Larkin et al, 1998b), therefore this experiment 
was undertaken to compare 3/B6 staining with that of LRP-56 to determine if there was 
any association in expression between these two antigens
There did not appear to be any significant staining with MAb 3/B6 in the pre­
chemotherapy tissue blocks (1423/92 and 1418/86) 3/B6 staining was observed in the 
tumour cells of both of the post-chemotherapy tissue blocks (1664/94 and 9987/86) 
Results from the study by Larkin et a l, (1998b) showed low level LRP/MVP expression 
in 1 of this set of tumour blocks (the post-chemotherapy block 1664/94) Although this 
was a limited study, these results indicated that the 3/B6 antigen was associated primarily 
with the MDR phenotype in breast cancer whereas, LRP/MVP expression was not 
significant which appears to concur with findings by Linn et al (1997) The treatment
regimes for the two patients examined in this study consisted of 9 cycles of CMF
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(cyclophosphomide, methotrexate and 5-fluoruracil) adnamycin and tamoxifen Patient 
1418/86 also received CMF and tamoxifen The expression of the 3/B6 antigen may be 
linked to the administration of one or more of these drugs although there did not appear 
to be any association between 3/B6 expression and the choice of drug used in the 
selection procedure in in vitro cell lines (section 4 5) There appeared to be correlation 
with the expression of the 3/B6 antigen expression in both breast and ovarian cancer in 
that 3/B6 staimng was absent from untreated/pre-chemotherapy tumour tissue The
s
apparent co-expression of the 3/B6 antigen and LRP/MVP was not evident in this study 
A larger survey of breast tissue samples may show an association does exist between the 
expression of the 3/B6 antigen and the MDR phenotype
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4 9 Detection of the 3/B6 antigen in spent medium
Ovarian cancer-associated antigens have been used as markers for the progression of 
ovarian cancer for a number of years Table 1 4 6 lists a number of common tumour 
markers which have been used in the management of patients with ovarian cancer These 
antigens share a common feature in that they are shed into serum Quantification of these 
proteins allow an estimation tumour progression
In these studies, growth medium from cultures of OAW42-SR were concentrated 
(section 2 10 6 materials and methods) and immunoprecipitated with MAb 3/B6 
Analysis of these results show that the 3/B6 antigen was not secreted from OAW42-SR 
cells when compared to immunoprecipitates of whole cell lysates of the same cell 
line(Figure 3 2 9 1) The negative control consisted of media from OAW42-SR cells 
immunoprecipitated with LRP-56 As expected, there was no band at 110 kDa
Since it was first reported by Bast et aly (1981), CA125 (recogmsed by MAb OC125 and
OC125 Mil) has been one of the primary tools in the diagnosis and monitoring of
epithelial ovarian cancer The secretion of this molecule into the serum has allowed the
development of a range of sensitive radioimmunoassay kits which can readily detect
serum levels of CA125 The MDR associated marker, P-glycoprotein has also been
detected in spent medium or MDR cell lines Chu and Kawinski (1994) detected soluble
Pgp in the spent medium drug resistant A2780AD cells while Pgp was absent from the
drug sensitive parental A2780 cells This specificity was mirrored in vivo, soluble Pgp
was observed in the extracellular fluids of cancer patients such as ascites and serum),but
not in the serum of healthy individuals There did not appear to be any difference in the
molecular weight or other characteristics of this soluble Pgp McGarry et a l, (1997)
have also demonstrated that the cell surface associated P1H10 antigen (recognised by
MAb P1H10) was absent from spent medium of the HepG2 cell line In this study,
HMFG2 was used as positive control was detected in the spent medium by ELISA This
suggests that, although the 3/B6 antigen may be associated with cellular organelles which
merge with the plasma membrane but do not shed its components It has been
demonstrated that elements of clathrin coated pits are expressed in the cell surface during
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vesicular transport (Goldstein et a l, 1985) Further investigation possibly with 
fluorescent labelled antibody fragments may give some insight into the function and of 
the 3/B6 protein
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4.10 Drug accumulation studies with MAb 3/B6
Evidence from immunocytochemical and immunoprecipitation expenments in this study 
have indicated that the 3/B6 antigen and the LRP/MVP may be co-expressed It has also 
been suggested that the LRP/MVP may play a direct role in drug resistance, possibly as a 
transport molecule (Section 1 3 3 13 ) In an effort to determine whether the 3/B6 
antigen influenced the accumulation of adnamycin , OAW42-SR cells were incubated 
with this MAb prior to exposure to adnamycin Drug accumulation was then measured at 
a number of time points to determine the cellular concentration for the cytotoxic drug
There was no observable effect on drug accumulation when OAW42-SR cells were 
incubated with MAb 3/B6 compared to cells incubated in adnamycin only (Figure 
3 2 14) In the positive control samples (OAW42-SR cells incubated with adnamycin 
and the Pgp circumvention agent cyclosporin A) there was a significant increase in drug 
accumulation to a maximum concentration of 995 pmoles Moran et a l , (1997) have 
shown previously that cyclosponn A is a potent circumvention agent in the OAW42-SR 
cell line The ability of MAbs to modulate to accumulation of cytotoxic drugs has been 
demonstrated previously for Pgp MAb MRK-16 raised to the external portion of Pgp 
increased the accumulation of vincristine in K562/ADM cells (Hamada and Tsuro, 1986) 
Merchetner and Romnson (1992) demonstrated a similar effect on vincnstine, 
vinblastine, VP-16 and taxol with MAb UIC-2 as have Shi et a l, (1995) with 2 MAbs 
raised to an external epitope of adnamycin resistant cell lines
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4 11. Studies on the possible anti-proliferative effects of MAb 3/B6
Yang and Page (1997) have reported on the anti-proliferative effects of a MAb raised to 
an MDR ovarian cell line A MAb raised to a 7 kDa membrane protein specifically 
inhibited the proliferation of drug resistant variants of the SKOV3 and OVCAR4 cell 
lines but did not inhibit the drug sensitive parental cell line In the process of 
characterising the effects if any 3/B6 exerted on the cellular processes of OAW42-SR 
cells
No anti-proliferative effects were observed when these cells were incubated with MAb 
3/B6 when these readings were compared to (a) cells grown in the presence of mouse 
IgGl or (b) cells grown in the absence of MAb The negative control consisted of 
OAW42-SR cells grown in the presence of MAb LRP-56
4 12 Studies on distribution and species cross reactivity with MAb 3/B6 and LRP- 
56
A series of rodent, primate, canine and bovine cell lines were investigated for 3/B6 and 
LRP-56 expression by immunoprecipitation (section 2 10 5 materials and methods, 
3 2 12 results) This was carried out to determine the distribution and species cross- 
reactivity of MAbs 3/B6 LRP-56
Results indicated that the 3/B6 antigen was not widely expressed amongst the cell lines
tested Low level expression was confined to green African monkey kidney cells
LRP/MVP expression was limited to two cell lines High level expression was observed
in the bovine kidney cell line NDBK and also in the African monkey cell line BS-C-1
Analysis of these results indicated that the MAb 3/B6 did not cross react significantly
with kidney cells from other species It also indicated limited distribution of the antigen
amongst other mammals This suggested that the 3/B6 antigen may be a human
homologue of a protein, sharing homology with the primate protein but differing
significantly from antigens which may be expressed other mammals and lower
eukaryotes Alternatively, it may also suggest that the epitope recognised by MAb 3/B6
is not found in the 3/B6 protein expressed in the lower mammals
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The limited expression of the LRP/MVP amongst these cell lines is unusual Kedersha et 
al (1990) demonstrated that vault particles (recognised by an anti-vault polyclonal 
antibody) are wide spread amongst a wide variety of prokaryotic and eukaryotic cell 
types These results indicate that there is limited antibody cross reactivity with MAb 
LRP-56 This suggests that this MAb recognises an epitope which is found in the major 
vault protein on the higher mammals only
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4 13 Micro-sequencing of 3/B6 protein sample
The isolation and subsequent sequencing of short peptides by proteolytic cleavage are 
important in the characterisation of unknown/novel proteins In this experiment, 3/B6 
immunoprecipitates of OAW42-SR were separated on polyacrylamide gels and the band 
of interest at 115 kDa was excised, exposed to trypsin digestion and sequenced on a 
pulsed liquid sequencer (section 2 10 7)
Results from this experiment indicated that the 14 amino acid peptide sequence (which 
had a high serine and threonine content) had 67% homology with blood coagulation 
factor Xlla inhibitor It also shared 43% with peptide sequences derived from MHC class 
I after 2 peptide (section 3 2 15, table 3215)
Isolation of proteins by immunoprecipitation and Western Blotting can lead to problems 
of purity Multiple proteins may have similar molecular weights and therefore migrate on 
polyacrylamide gels at similar positions In this case, protein coated sepharose beads 
were added to cell lysates to remove any proteins which may have bound non-specifically 
to this protein (discussed in section 4 6) SDS-PAGE of 3/B6 immunoprecipitates 
produced a single band at 115 kDa when gels were stained with Coomassie Brilliant Blue 
(section 210 7) which was consistent with biotin labelled bands detected by enhanced 
chemiluminescence of Western Blots (section 3 242) Finally, if the 115 kDa band 
contained more than 1 protein, there have been a series of variables (ammo acids) 
assigned to each position of the peptide Analysis of the chromatographs in Appendix 2 
reveals a series of peaks corresponding to all major amino acids During the sequencing 
procedure, residues from proteolytic cleavage invariably lead to some background 
however, as in this case, they rarely contribute significantly to the results of each cycle 
Background levels of Glycine appear to contribute significantly to the results in the first 
3-5 cycles These levels are reduced in subsequent cycles Similarly, levels of break down 
products from reagents used in the formation of amino acid derivatives (Dmp, dptu, 
dpu,and mptc) and ammonia (which is used in the reagent buffers)are apparent in the 
chromatographs but do not interfere with the overall result (Appendix 2)
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The homology of the 115 kDa 3/B6 protein with elements of such diverse proteins from 
the coagulation and immune system suggested possible functions for the 3/B6 protein 
The blood coagulation factor XII (Hageman) is an 80 kDa involved in a complex series 
of reactions which leads to the eventual conversion of fibrinogen to fibrin (Voet Voet 
1990) Bovine Factor Xlla inhibitor is one of a number of control mechanisms employed 
in the control of blood coagulation The inhibitor has been isolated and characterised as 
an 88Kda glycoprotein which is expressed exclusively in the cytoplasm (Thorton and 
Krkby 1987) N-terminal sequencing (14 a a) was completed by Muldbjerg et a l, 1993 
and the sequence deposited in the protein bank
MHC (Major Histocompatability Complex) proteins are expressed on the cell surface of 
nearly all nucleated invertebrate cells (Voet and Voet 1990) The MHC class I consist of 
polypeptide chains, the a or heavy chain of about 44 kDa and a 12 kDa polypeptide 
forming the core of the (3 chain Both chains have a series of N-linked polysaccharides 
(Alberts et a l, 1994) Analysis of these two proteins suggest that the 3/B6 protein is not 
a constituent peptide of either of these proteins In both cases the 3/B6 protein has a 
greater molecular weight 3/B6 has been shown to be un-glycosylated (section 3 2 5) 
Analysis of evidence from this experiment although encouraging, suggests that 3/B6 
proteins is not MHC or Factor XII
Therefore, the evidence from protein sequencing indicates that the 3/B6 antigen may be a 
novel drug resistance associated protein Analysis of the results from this project appear 
to confirm this observation Immunocytochemical studies on a panel of drug resistant 
cells lines indicated that, in general, the 3/B6 antigen was co-expressed with LRP/MVP 
The question then arose whether these two proteins shared homology The glycosylation 
pattern of the 3/B6 antigen and LRP/MVP were similar however, studies also showed 
that these MAbs raised to these antigens recognised different proteins, 3/B6, expressed 
primarily on the plasma membrane and LRP/MVP which was expressed exclusively in 
the cytoplasm
Immunohistochemical analysis of normal and malignant tissue of different histological 
origin revealed that the 3/B6 antigen was widely distributed in foetal tissues and was also
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expressed in the distal collecting tubules of adult kidney, suggesting a role in transport of 
biomolecules. The strongest evidence that 3/B6 may be associated with the MDR 
phenotype came for studies on pre- and post-chemotherapy tumour tissue where 3/B6 
was expressed in the post-chemotherapy tissue blocks only. No expression of the 3/B6 
antigen was found in normal and pre-chemotherapy ovarian tissue sections. These results 
were in agreement with immunocytochemical studies on cultured cells where low-level 
expression of the 3/B6 antigen was observed in drug-sensitive cell lines. Is there then, a 
direct role for the 3/B6 antigen in drug resistance? Evidence from drug accumulation 
studies would suggest that this is not the case. The 3/B6 antigen may simply be an 
indicator of the MDR phenotype.
The question remains as to the identity of the 3/B6 antigen. The observation that the 
3/B6 protein stained the cytoplasm of some MDR cell lines and tissue sections suggested 
an association with subcellular organelles or vesicles which interacted with the plasma 
membrane. The apparent co-expression of the 3/B6 protein with LRP/MVP suggested 
that the protein may be associated with clathrin coated pits and vesicles. Vault proteins 
are also known to be associated with clathrin coated pits (Kedersha and Rome, 1986 a, 
b). The observation that the 3/B6 protein stained the cytoplasm of some MDR cell lines 
and tissue sections suggested an association with subcellular organelles or vesicles which 
interacted with the plasma membrane
Clathrin coated pits and coated vesicles are associated, at plasma membrane, with the 
early stages of receptor-mediated endocytosis (Goldstein et a l, 1985, Robinson et al., 
1987) and in the Golgi region with organisation of the non-constitutive pathway of 
exocytosis (Ahel et al., 1988). The major structural components of the coat are the light 
and heavy chains of clathrin assembly proteins (Ungewickell 1993). AP2 is a complex 
made up of several kinds of polypeptide chains large (100-115KDa), medium (45- 
50KDa) and small (17-20Kda) (Kirchhausen et al., 1989), medium and small chains are 
designated AP50 and AP20 respectively.
However, data base searches with the 14 a.a. peptide derived from 3/B6 did not reveal 
any sequence homology with the subunits of this complex. The 3 aC2 species (115 kDa)
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yet to be sequenced may contain this 14 a a sequence The data so far suggests that 
3/B6 and LRP/MVP are closely expressed in cell lines and tissues Coupled with the 
reduced expression of the 3/B6 antigen in the LRP nbozyme and antisense transfected 
OAW42-SR cells and the increase in the expression in the LRP/MVP cDNA transfected 
A2780 cells it appears that the 3/B6 antigen may constitute part of the clathrin adapter 
protein complex Similarly, the major subunits of the AP2 complex are also un­
glycosylated If clathnn associated vault particles are up-regulated in multidrug resistant 
cell lines than it would be expected that the expression of other clathrin associated 
proteins may also be up regulated
Further sequence and possibly cDNA sequence data will be necessary to determine 
whether the 3/B6 antigen forms part of the clathnn transport pathway For the moment 
however, evidence suggests that this protein is a novel MDR associated antigen
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4.14. Immunofluorescence studies with MAb 5/C4
Analysis of OAW42-SR cells by immunofluorescence with the anti-OAW42-SR MAb 
5/C4 revealed that this antibody recognised a cytoplasmic antigen The absence of a 
fluorescent ring around OAW42-SR cells confirmed this observation This antigen was 
revealed following fixation of OAW42-SR cells with a glutaraldehyde fixative (Becton 
Dickinson facslyse solution, (Figure 3 3 11)
4 14 1 Immunocytochemical studies with MAb 5/C4
Immunocytochemical analysis indicated that this antibody stained the cytoplasm of all the 
cell lines assayed (section 3 3 2) Generally, a large majority of cell lines displayed low 
level cytoplasmic staining The highest level of staining was observed in the OAW42 
vanants, OAW42-SR and OAW42-S with approximately 90% of cells exhibiting 
granular cytoplasmic staining with MAb 5/C4 Staining was also observed in the LRP 
cDNA transfected vanants A2780/AC12 and AC 16 However these cell lines were 
stained with less intensity than the OAW42 variants There was some variation in the 
staining in the LRP nbozyme and antisense transfected variants There did not appear to 
be any significant down regulation in 5/C4 antigen expression in these vanants compared 
to that observed with MAb 3/B6 in preceding sections Low level staining was observed 
in the GLC4 and COR-L23 senes of cell lines and the mouse fibroblast line MOP-8 with 
negligible staining observed in the DLKP vanants
Analysis of these results indicates that this antibody appears to have a slightly higher 
specificity for the OAW42 variants than for the majority of other cell lines tested 
Generally, this antibody appeared to have a low specificity for lung tumour cell lines with 
low level staining observed in the COR-L23 and DLKP series The differences in staining 
between these two groups of variants may suggest that the antibody is more specific for 
large-cell lung tumour cell lines (COR-L23) rather that non-small cell (DLKP) 
Expression of the 5/C4 protein did not appear to be associated with resistance to any 
particular cytotoxic drug In fact these results suggest that this antigen is probably a 
constituent protein in most cell types
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4 14 2 Determination of molecular weight by western blotting with MAb 5/C4
The molecular weight of the antigen/s recognised by MAb 5/C4 were determined by 
western blotting The doublet with M w  of approximately 110 kDa and 85 kDa were 
consistently detected in a number of OAW42-SR and OAW42-S preparations, (figure
3 3 3 1 ) A new MAb which was raised to the human MVP was included for comparison 
purposes (Abbandonza et al, unpublished) This antibody also appears to detect a 
doublet by western blotting m OAW42-SR and SW1573/2R120 The lower 85 kDa band 
appeared to be intense in the OAW42-SR while the 110 kDa band was stronger in the 
SW1573/2R120 line with MAb 1032 There did not appeared to be difference in the 
expression of the bands detected by MAb 5/C4
4 14 3 Investigation of a panel of MDR cell lines with MAb 5/C4
A panel of drug resistance/sensitive cell line pairs was also assayed for the expression of 
the 5/C4 antigen These results appeared to correlate with those obtained for by 
immunocytochemistry except for the A2780 line Immunocytochemical analysis revealed 
that approximately 10% of cells exhibited immunoreactivity with MAb 5/C4 whereas 
investigation by Western Blotting shows an intense doublet The different results may be 
due in part to fixation of the cells for immunocytochemistry i e fixation may have 
reduced the number of sights available to the MAb Western Blotting may have allowed 
more epitopes to be recognised by this MAb
4 14 4 Cross reactivity studies with purified rat vaults
Purified rat vaults were probed by Western Blotting MAb 5/C4 failed to detect a band at 
104 kDa This strongly suggests that MAb 5/C4 is not an anti-MVP antibody It also 
suggests that this antibody does not detect an LRP/MVP-like protein or cross-react with 
the LRP/MVP
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4 14 5 General discussion for MAb 5/C4
The possibility that MAbs 5/C4 and 1032 (a MAb raised to the MVP by Abbadonza et 
al, personal communication) detected the same antigen then this information would 
conflict with the previous staining pattern observed for anti-MVP antibodies, LRP-56 
and LMR-5 (Flens et al 1997 (a) and Schroeijers et al 1998) Granular outer cytoplasmic 
staining was observed with 1032 in SW1573/2R120 and A2780-AC16 cytospins while 
the A2780 were only slightly positive and the MOP-8 cells were negative (Rome et a l, 
personal communication) This is consistent with staining observed for LRP-56 MAb 
5/C4 stained A2780 and MOP-8 cell lines but in a similar cytoplasmic fashion Rome et 
al have also, on occasion, observed a second band at approximately 85 kDa when 
probing preparations of multidrug resistant cells by Western Blotting with the anti-rat 
vault polyclonal antibody, N2, which may be due to a previously unidentified breakdown 
product of the MVP or alternatively this band could simply be due to non-specific 
staining (Rome et al, personal communication) This second band was observed when 
OAW42-SR cells were probed with the N2 polyclonal antibody in experiments with 
MAb 3/B6 (Figure 3 2 6 2)
MAb 5/C4 may recognise a vault associated protein It has been shown that vault 
proteins associate with coated vesicles (and ferritin) in rat liver (Kedersha and Rome 
1986a, b) It is possible that MAb 5/C4 could recognise a constituent protein of coated 
vesicles Fractions collected from agarose gel electrophoresis purified rat microsomes 
and separated by SDS-PAGE revealed a series of protein species between 38-180 kDa 
including the 104 kDa rat MVP If MAb 5/C4 recognises a protein from this range then 
this may account for the presence of peripheral granular cytoplasmic staining in the 
MOP-8 and A2780 lines
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4 15 Characterisation of the anti-OAW42-S MAb 3/E3
Immunofluorescence studies indicated that this MAb detected a cell surface epitope on 
OAW42-S cells Investigation of cytospins of OAW42-S and OAW42-SR cells revealed 
that the staining was predominantly localised to the plasma membrane in OAW42-S cells 
while it appeared that this MAb detected discrete cytoplasmic structures in OAW42-SR 
cells (figure 3 4 2 1 ) however immunocytochemical analysis revealed no difference in the 
staining pattern or intensity of staining among drug resistant and drug sensitive cell lines 
(figure3 4 3 1 ) It was not possible to determine the molecular weight of this antigen by 
western blotting or immunoprécipitation From the evidence obtained so far with this 
MAb it is probable that the antigen detected by MAb 3/E3 is a constituent protein found 
in all cells and therefore is unconnected with drug resistance The protein is probably not 
useful as a marker in ovarian cancer
It is evident from the work outlined here that there is a complex series of interactions 
which lead to the development of the MDR phenotype Investigation of the antigenic 
expression in in vitro cell culture models and in vivo will allow a greater understanding 
of the processes involved in chemotherapeutic drug resistance
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Conclusions and Future Work
Conclusions and future work
Monoclonal antibodies were raised to drug resistant and sensitive variants of the ovanan 
carcinoma cell line OAW42 From a series of positive clones, 3 were chosen on the 
basis strong immuno-reactivity to these cell lines by ELISA for further characterisation 
The anti-OAW42-SR monoclonal antibodies 3/B6 and 5/C4 and the anti-OAW42-S 
MAb 3/E3 were characterised by a range of immunological and biochemical methods 
The results of these experiments are summarised below
Immunofluorescence studies, initially carried out on the OAW42-SR cell line with MAb 
3/B6, revealed that this antibody recognised a cell surface antigen This was confirmed 
by further immunofluorescent studies on acetone fixed OAW42-SR cells which also 
showed that the 3/B6 antigen was expressed mtracellularly Expression of this antigen 
was also apparent on a number of drug multidrug resistant cell lines
Immunocytochemical analysis of an expanded series of MDR cell lines which included 
a number LRP/MVP over-expressing cells lines indicated that the 3/B6 antigen was 
predominantly associated with LRP/MVP over-expressing cell lines Staining with this 
antibody was both plasma membrane and cytoplasmic Close co-expression was 
observed in the LRP/MVP cDNA transfected A2780 and LRP/MVP nbozyme and 
antisense transfected OAW42-SR cell lines
A series of studies were initiated to determine the expression of the 3/B6 antigen in a 
range of normal adult and foetal tissues Expression was compared with that of the 
LRP/MVP smce our previous results from studies in MDR cell lines suggested some 
degree of co-expression of these two antigens These studies concluded that the 3/B6 
antigen and the LRP/MVP were probably differentially regulated in normal tissue 
Expression of the 3/B6 antigen was confined to the distal collecting tubules of adult 
kidney while LRP/MVP expression was found mainly in the proximal tubules Neither 
antigen was expressed in the adult thyroid Foetal expression of the 3/B6 antigen was 
observed in the distal tubules of the kidney, placenta and small intestine while LRP-56 
staming was observed in the proximal and distal tubules of the kidney LRP-56 staining 
was also observed in the liver, placenta and small intestine Staining was absent from 
the foetal adrenal gland with this antibody
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In further tissue surveys, co-expression of these two antigens was observed in a limited 
study of 2 paired pre-and post-chemotherapy breast samples This mdicated that the 
3/B6 antigen might be a indicator of drug resistance Staining was absent from the pre­
chemotherapy tissue blocks while over expression was observed m  the post­
chemotherapy samples Staining was also absent from 2 normal ovarian and 10 pre­
chemotherapy samples indicating that the 3/B6 antigen may not play a major role in the 
normal ovary or in untreated tumours Analysis of 1 post-chemotherapy tumour block 
gave inconclusive results In order to fully understand the role of the 3/B6 antigen as a 
possible indicator of drug resistance it would be necessary to complete a more detailed 
tissue survey using a greater panel of archival tissue samples Izquierdo et al ,(1995) 
have shown that the LRP/MVP is a negative indicator of survival in ovarian tumours 
treated with platinum based and alkylating drugs which are more commonly used in the 
treatment of ovarian cancer It would be necessary to evaluate 3/B6 expression in 
relation to tumours treated with these drugs Similarly, it would be useful to determine 
whether 3/B6 is associated with more recently developed drug such as taxol The 
preliminary results from the pre-and post-chemotherapy breast tumour samples 
mdicated a role for 3/B6 an indicator of drug resistance in breast cancer Given that 
these two malignancies are sometimes linked (through the expression of the BRCA1 
gene in familial ovarian cancer), it would also be useful to determine the importance of 
3/B6 expression in this tumour type
The inability to detect the 3/B6 by Western Blotting suggested that this antibody 
recognised a conformational epitope The development of an immunoprecipitation 
protocol for MAb 3/B6 and LRP-56 based on biotin labelling of protein allowed the 
characterisation of the 3/B6 antigen as an un-glycosylated protein with a molecular 
weight of 115 kDa which was similar but not identical in molecular weight the that of 
the LRP/MVP Further immunoprecipitation confirmed pervious observations that this 
antigen was closely co-expressed with the LRP/MVP in MDR cell lines
Cross-reactivity studies with anti-LRP/MVP monoclonal antibodies, and-rat vault 
polyclonal antibody and purified rat vault indicate that MAb 3 B6 did not recognise the 
LRP/MVP It was also possible to conclude from these studies that the 3/B6 antigen was 
probably not an alternative form of the LRP/MVP
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It was found that incubation of OAW42-SR cells with MAb 3/B6 did not have any 
effect on drug accumulation. Therefore the antigen recognised by MAb 3/B6 does not 
appear to play a direct role in drug resistance in this cell line.
This MAb does not appear to play any significant role in cellular proliferation in the 
OAW42-SR. It has been observed that some MAb can affect cellular proliferation of 
MDR cells (Yang and Page 1995).
Protein sequencing results showed that the 3/B6 antigen shared low percentage 
homology with the blood coagulation factor XII a inhibitor and the MHC class 1 alpha 2 
protein.. These proteins however, have significant glycosylation. Their molecular 
weights are also lower than the 3/B6 antigen. In view of this information and the 
relatively low homology, it is possible to conclude that the 3/B6 antigen is probably not 
a member of the coagulation cascade family of proteins or an element of the MHC. The 
3/B6 protein does however, share some similarities (particularly molecular weight i.e. 
major subunits are 115 kDa) with the alpha and beta subunit of the clathrin adapter 
protein 2 complex which is a multi-subunit protein expressed in association with 
clathrin coated pits. In view of the apparent frequent co-expression between the 3/B6 
protein and the coated pit associated vault proteins, it is possible that the 3/B6 protein 
might be a subunit of this complex. In order to confirm this hypothesis it would be 
necessary to conduct studies with available anti-AP-2 antibodies to determine the 
expression of this protein complex in MDR cell lines. Isolation of purified coated pits 
(Kedersha and Rome 1986) and analysis by immunoprécipitation or dot blots with MAb 
3/B6 would indicate whether the 3/B6 antigen is associated with coated pits.
Micro-sequencing of the 3/B6 protein did not reveal homology with any of the large 
subunits, however, the occl subunit (115 kDa) has yet to be sequenced and is therefore a 
possible candidate. Further work on cDNA libraries may give some insight into the 
identity of the 3/B6 antigen. Preliminary investigation of a cDNA library derived from a 
normal human kidney cell line has already been carried out.. Lifts taken from phage 
infected E. coli .Y1090 colonies have been probed with MAb 3/B6. Initial results
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indicate some possible positive colonies Sequence data from isolated clones would 
allow comparisons with sequence data already obtained for the (3 heavy cham (115 kDa) 
and may suggest the identity of the protein rather than comparisons of short peptide 
sequences
Coated pits are known to be quickly recycled Labelling experiments, where F(ab) 
fragments or whole IgG molecular of 3/B6 could be labelled with gold particles (1-5 
nm) might allow the subcellular location of the 3/B6 antigen identified Similarly this 
process could also be carried out with fluorescent labelled dyes and the process assayed 
by confocal laser microscopy
Immunofluorescence studies with the anti-OAW42-SR MAb 5/C4 indicated that this 
antibody recognised a cytoplasmic antigen which was not expressed on the cell surface
immunocytochemistry results revealed that the antigen recognised by this antibody was 
expressed in all of the cell lines tested with little degree in variation of staining It is 
possible to conclude from these studies that the expression of this antigen is not 
associated with any particular drug resistance mechanism (by comparing it to the 
predominant mechanisms which are expressed in these cell lmes)
Western Blotting results revealed that this antibody detected 2 bands at 110 kDa and 85 
kDa which was similar to the anti-MVP antibody 1032 This suggested that the MAb 
5/C4 might recognise the MVP However further studies with purified rat vault particles 
showed no cross-reactivity The 2 protein bands at 110 kDa and 85 kDa suggest that the 
MAb 5/C4 might also detect elements of clathnn coated pits Further work with isolated 
coated pits (Kedersha and Rome 1996) would confirm this hypothesis
The MAb 3/E3 was raised to the OAW42-S cell line which also over-expressed the 
LRP/MVP In characterising this antibody it was found that the 3/E3 antigen appears to 
be expressed on the cell surface of all the cell lines tested save for the OAW42-SR 
where it appeared to be associated with particular cytoplasmic bodies It was not
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possible to obtain a molecular weight for this antigen It is probable that this antigen is a 
common cell surface antigen which is ubiquitously expressed on all cell types
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Appendix 1
Abbreviations
5-FU 5-Flurouracil
ABC/HRP Streptavidin/biotin-horseradish peroxidase conjugate
Adr Adnamycin
ATCC American Tissue Culture Collection
BCA Bicmchonmic acid
Biotin-7-NHS D-biotmyl-s-aminocaproic acid-N-hydroxysuccmimide
BSA Bovine serum albumin
CMF cyclophosphamide, methatrexate, 5-fluoruracil
DAB Diaminobenzidine
DDSA Dodecenylsuccimc anhydrate
dH20 Deionised water/glass distilled water
DMEM Dulbeccos Modified Eagles Medium
DMSO Dimethyl sulfoximide
DNA Deoxyribonucleic acid
DOX Doxorubicin( Adnamycin)
ECL Enhanced chemiluminescence
ECACC European Collectionof Animal Cell Culture
EDTA Ethylene diamino tetra-acetic acid
ELISA Enzyme-linked immunosorbent assay
FCS Foetal calf serum
FIGO Federation of Gynaecology and Obstetncs
FITC Fluorescein-isocyanate
HAT Hypoxanthme, aminopterin, thymidme
HC1 Hydrochloric acid
HEPES 4-(2-hydroxethyl-)-piperazine ethane sulphonic acid
RPHPLC Reverse phase High performance liquid chromatography
HT Hypoxanthme, thymadine
IC50 Inhibitory concentration 50%
Ig Immunoglobulin
IMS Industrial methylated spirits
KDa KiloDalton
LRP Lung resistance related protein
MAb/s Monoclonal antibody/monoclonal antibodies
MDR Multidrug resistance
M E M Minimum Essential Medium
MgCl2 Magnesium chloride
MHC Major histocompatibility complex
mRNA Messenger RNA
MRP Multidrug resistance protein
MVP Major vault protein
M w Molecular weight
NaCl Sodium chloride
NaHC03 Sodium bicarbonate
NaOH Sodium hydroxide
NCTCC National Cell and Tissue Culture Centre
ND Not done
NEAA Non-essential amino acids
NSCLC Non-small cell lung carcinoma
OD Optical density
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PEG Polyethylene glycol
P-gp P-glycoprotein
PMSF Phenylmethyl sulfonyl fluoride
PNAG Phenyl-N-acetyl-a-D-galactosamimde
PNPP P-mtrophenyl phosphate
PVDF polyvinyidifluoride (blotting membrane)
RID Radial-immunodiffusion
RNA Ribonucleic acid
SDS Sodium dodecyl sulphate
TBS Tns buffered saline
TEMED N,N,N,N-tetramethyl-ethylenediamme
Tns Tris(hydroxymethyl)aminomethane
TV Trypsin /versene
UV Ultra violet
11
VP-16
v/v
w/v
Etoposide (Vepesid) 
Volume to volume ratio 
weight to volume ratio
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Appendix 2
09-1998 08 48 98C444-980613~fr41-100%
2 Standard 1, Interpolated baseline
Peak No RT Peak ID Type Height Pmol Ht
1 3 78 D c 25966 10 00
2 4 24 N c 28521 10 00
3 4 91 S c 18314 10 00
4 5 15 Q c 23723 10 00
5 5 45 T c 17942 10 00
6 5 72 G c 19320 10 00
7 6 15 E c 25483 10 00
8 6 47 dmp 8005 10 00
9 « 7 54 H , C 16841 10 00- -10 8 07 A - c — 19197 - « 10 00
14 ~ 9 40 S' 2409 10 00
15 9 74 R c 14921 10 00
16 10 34 Y c 19200 10 00
20 12 65 P c 17503 10 00
21 13 35 M c 18564 10 00
22 13 66 V c 19132 10 00
24 14 86 dptu 16871 10 0025 15 05 mptc r 6167 10 00
26 15 87 W c 23497 10 00
27 16 17 dpu 10796 10 00
28 16 51 F c 19169 10 00
29 16 95 I c 13982 10 00
30 17 23 K c 28640 10 0031 17 49 L c 19246 10 00
I
Applied Biosystems Procise - PROCISE
-09-1998 08 48 98C444-980613-fr41-100%
98C444-980613-fr41-100% 3 Residue 1
3 Residue 1, Interpolated baseline
Peak No RT Peak ID, Type Height Pmol Ht
2 3 91 p c 11026 4 254 4 37 N c 1723 0 605 4 90 S c 12619 6 896 5 14 Q c 1146 0 487 5 45 T c 1849 1 038 5 72 G c 5075 2 639 6 15 E c 2479 0 9710 6 57 dmp 395 0 4911 7 50 H c 731 0 4312 8 06 A c 6108 3 1815 9 40 S ' 2949 12 2416 9 75 R c 815 0 5518 10 35 y c 1780 0 9322 12 7 0 p c 937 0 5424 13 38 M c 279 0 1525 13 68 V c 2442 1 2828 14 88 dp tu 143723 85 1929 15 07 mptc r 287792 466 6631 15 88 W c 264 0 1132 16 20 dpu 2580 2 3933 16 54 F c 460 0 2434 16 99 I c 1180 0 8435 17 24 K c 1897 0 6636 17 51 L c 2702 1 40
II
Applied Biosystems Procise - PROCISE
-09-1998 08 48 98C444-980613-fr41-100%
98C444-980613-fr41-100% 4 Residue 2
4 Residue 2, Interpolated baseline
Peak No RT Peak ID Type Height Pmol Ht
2 3 95 c 7781 3 00
3 4 28 N c 768 0 27
5 4 94 S c 1749 0 96
6 5 19 Q c 2080 0 887 5 50 T c 12855 7 16
8 5 77 G c 4953 2 56
10 6 20 E c 1412 0 55
11 6 63 dmp 833 1 0413 8 13 A c 1379 0 72
14 9 45 S 1 533 2 21
15 9 83 R c 527 0 35
18 10 41 Y c 1729 0 9023 12 70 P c 725 0 41
25 13 42 M c 192 0 10
26 13 72 V c 1118 0 5828 14 91 dp tu 106857 63 3429 15 10 mptc r 210768 341 7731 15 91 W c 231 0 1032 16 22 dpu 882 0 8233 16 67 F c 154 0 0834 17 00 I c 315 0 2335 17 26 K c 1396 0 4936 17 54 L c 1132 0 59
I I I
Applied Biosystems Procise - PROCISE
98C444-980613-fr41-100% 5 Residue 3
28-09-1998 08 48 98C444-980613-fr41-100%
5 Residue 3 Interpolated baseline
Peak No RT Peak Type Height Pmol Ht
2 3 95 c 7602 2 93
3 4 28 N c 1814 0 64
6 4 96 S c 949 0 52
7 5 19 Q c 915 0 398 5 49 T c 1058 0 59
9 5 78 G c 4174 2 16
10 6 22 E c 2544 1 00
11 6 69 dmp 448 0 5612 8 12 A c 836 0 44
13 9 48 S' 297 1 2314 9 80 R c 403 0 2715 10 42 Y c 1194 0 6217 12 71 P c 1099 0 6318 13 73 V c 16796 8 7821 14 93 dp tu 91520 54 2522 15 12 mptc r 204241 331 1824 16 26 dpu 351 0 3325 16 55 F c 557 0 2926 17 01 I c 280 0 2027 17 30 K c 618 0 2228 17 55 L c 1526 0 79
IV
A p p l i e d  B i o s y s t e m s  P r o c i s e  -  P R O C I S E
-09-1998 08 48 98C444-980613-fr41-100%
98C444-980613-fr41-100% 6 Residue 4
6 Residue 4, Interpolated baseline
Peak No RT Peak ID Type Height Pmol Ht
2 3 95 c 7152 2 75
3 4 27 N c 844 0 30
5 4 95 S c 6337 3 46
6 5 20 Q c 1631 0 697 5 50 T c 935 0 52
8 5 78 G c 2931 1 52
9 6 21 E c 1566 0 61
11 6 66 dmp 320 0 40
13 7 60 H c 389 0 23---14 8 14 ^  A ~ c 848-- ‘ 0 44
16 9 46 S' 1413 5 87
17 9 80 R c 534 0 36
18 10 41 Y c 1315 0 68
21 12 72 P c 1483 0 85
22 13 72 V c 1986 1 04
26 14 92 dp tu 79264 46 98
27 15 11 mptc r 202789 328 8328 16 23 dpu 604 0 5629 16 55 F c 588 0 3130 17 54 L c 1630 0 85
V
Applied Biosystems Procise - PROCISE
-09-1998 08 48 98C444-980613-fr41-100%
98C444~980613-fr41-100% 7 Residue 5
7 Residue 5, Interpolated baseline
Peak No RT Peak ID Type Height Pmol Ht
2 3 95 c 6008 2 313 4 28 N c 1810 0 63
5 4 95 S c 1421 0 786 5 20 Q c 786 0 337 5 50 T c 907 0 518 5 77 G c 3402 1 76
9 6 22 E c 1050 0 4110 7 56 H c 262 0 1611 8 13 A c 1499 0 7815 9 45 S' 563 2 3416 9 77 R c 228 0 1517 10 42 Y c 1022 0 5318 12 73 P c 810 0 4620 13 39 M c 328 0 1821 13 72 V c 1220 0 6423 14 92 dptu 69712 41 3224 15 11 mptc r 196120 318 0225 16 24 dpu 380 0 3526 17 02 I c 801 0 5727 17 54 L c 13189 6 85
V|
Applied Biosystems Procise - PROCISE
98C444-980613-fr41-100% 8 Residue 6
-09-1998 08 48 98C444-980613-fr41-100%
8 Residue 6, Interpolated baseline
No RT Peak ID Type Height Pmol Ht
2 3 95 X c 5775 2 223 4 28 N c 1126 0 39
5 4 96 S c 1272 0 69
6 5 20 Q c 1105 0 477 5 51 T c 8556 4 77
8 5 78 G c 2846 1 47
9 6 22 E c 1667 0 65
10 6 68 dmp 609 0 76
12 8 13 A c 1257 - 0 65
13 9 80 R c 755 * 0 51
15 10 42 Y c 1297 0 68
22 12 73 P c 913 0 52
25 13 44 M c 327 0 18
26 13 72 V c 1291 0 67
28 14 93 dptu 70906 42 03
29 15 12 mptc r 208055 337 37
30 16 00 W c 254 0 1131 16 25 dpu 550 0 5132 16 58 F c 880 0 4633 17 01 I c 1143 0 8235 17 27 K c 393 0 1436 17 55 L c 3089 1 61
/
V||
A p p l i e d  B i o s y s t e m s  P r o c i s e  -  P R O C I S E
-09-1998 08 48 98C444-980613-fr41-100%
98C444-980613-fr41-100% 9 Residue 7
9 Residue 7, Interpolated baseline
Peak No RT Peak ID
y
Type Height Pmol Ht
2 3 96 c 6299 2 43
3 4 29 N c 1110 0 39
6 4 96 S c 1228 0 67
7 5 22 Q c 826 0 358 5 52 T c 1782 0 99
9 5 79 G c 3637 1 8810 6 23 E c 1801 0 7111 6 43 dmp 318 0 4012 7 73 H c 170 0 1013 8 15 A c 984 0 5116 9 50 S' 771 3 2017 9 80 R c 386 0 2619 10 45 Y c 1673 0 8722 12 75 P c 908 0 5224 13 74 V c 1214 0 6327 14 95 dp tu 67439 39 9728 15 14 mptc r 182650 296 1729 15 86 W c 217 0 0930 16 23 dpu 312 0 2931 16 60 F c 880 0 4632 17 06 I c 1110 0 7933 17 56 L c 1645 0 85
VIII
Applied Biosystems Procise - PROCISE
-09-1998 08 48 98C444-980613-fr41-100%
98C444-980613-fr41-100% 10 Residue 8
1 00
0 00
-1 00
•2 00
4 0 6 0 8 0 10 0 12 0 14 0
Residue 8, Interpolated baseline
Peak No RT Peak ID ^ Type Height Pmol Ht
2 3 95 j r c 5651 2 18
3 4 27 N c 1010 0 35
5 4 95 S c 842 0 46
6 5 19 Q c 912 0 387 5 52 T c 1015 0 57
8 5 78 G c 3095 1 60
9 6 22 E c 1387 0 54
10 7 82 H c 197 0 12
11 8 12 A c 1560 0 81
12 9 47 S' 347 1 44
13 10 40 Y c 1228 0 64
17 12 73 P c 1183 0 68
18 13 42 M c 7272 3 92
19 13 73 V c 1757 0 92
24 14 93 dptu 63802 37 82
25 15 12 mptc r 203769 330 42
27 16 26 dpu 421 0 3928 16 58 F c 445 0 23
29 17 04 I c 612 0 44
30 17 28 K c 496 0 1731 17 55 L c 1433 0 74
16 0 18 0
/ PC
Applied Biosystems Procise - PROCISE
98C444-980613-fr41-100% 11 Residue 9
28-09-1998 08 48 98C444-980613-fr41-100%
11 Residue 9, Interpolated baseline
Peak No RT Peak ID ^ Type Height Pmol Ht
2 3 95 c 5853 2 25
3 4 30 N c 1057 0 375 4 95 S c 935 0 516 5 20 Q c 1376 0 587 5 50 T c 734 0 41
8 5 78 G c 2957 1 539 6 22 E c 1057 0 4110 7 62 H c 116 0 07
11 8 13 A c 1250- 0 6512 10 42“ y c 1675 0 8715 13 43 M c 2519 1 3616 13 73 V c 7984 4 1718 14 93 dp tu 63790 37.81
19 15 12 mptc r 196533 318 6821 16 23 dpu 474 0 4423 16 56 F c 759 0 4024 17 04 I c 672 0 4825 17 55 L c 1746 0 91
X
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09-1998 08 48 98C444-980613-fr41-100%
98C444-9B0613-fr41-100% 12 Residue 10
12 Residue 10, Interpolated baseline
No RT Peak ID . Type Height Pmol Ht
2 3 96 J r c 5045 1 94
3 4 30 N c 686 0 24
6 4 97 S c 925 0 51
7 5 21 Q c 985 0 428 5 51 T c 4996 2 78
9 5 78 G c 2986 1 55
10 6 22 E c 2139 0 84
11 6 64 dmp 284 0 35
14 - 8 13 “ =- « i, A c 1181 0 62
16 "9 50~ S' 214 0 89
17 9 80 R c 168 0 11
18 10 44 y c 1611 0 84
20 12 73 p c 1010 0 58
22 13 43 M c 866 0 47
23 13 74 V c 4216 2 20
27 14 94 dptu 64854 38 44
28 15 13 mptc r 181640 294 54
31 16 04 w c 230 0 10
32 16 26 dpu 456 0 42
34 16 60 F c 730 0 38
35 17 03 I c 381 0 27
36 17 30 K c 494 0 1737 17 57 L c 1721 0 89
XI
Applied Biosystems Procise - PROCISE
-09-1998 08 48 98C444-980613-fr41-100%
98C444-980613-fr41-100% 13 Residue 11
13 Residue 11, Interpolated baseline
Peak No RT Peak ID Type Height Pmol Ht2 3 96
yXN
c 5167 1 99
3 4 51 c 475 0 17
4 4 97 S c 2738 1 505 5 22 Q c 1303 0 556 5 52 T c 2346 1 317 5 79 G c 3608 1 878 6 23 E c 1790 0 70
11 8 15 A c 1487 0 7712 9 48 S' 472 1 9613 9 79 R c 333 0 2214 10 43 Y c 1792 0 9315 12 73 P c 816 0 4717 13 43 M c 524 0 2818 13 74 V c 2193 1 1520 14 94 dptu 68315 40 4921 15 14 mptc r 163787 265 5923 16 26 dpu 408 0 3824 16 58 F c 721 0 3826 17 06 I c 642 0 4627 17 29 K c 523 0 1828 17 57 L c 1489 0 77
XII
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-09-1998 08 48 98C444-980613-fr41-100%
98C444-960613-fr41-100% 14 Residue 12
14 Residue 12, Interpolated baseline
Peak No RT Peak ID / Type Height Pmol Ht
2 3 95 Y c 5986 2 313 4 28 c 1414 0 50
4 4 95 S c 1675 0 91
5 5 20 Q c 1233 0 526 5 50 T c 1409 0 79
7 5 78 G c 3354 1 74
8 6 22 E c 1667 0 65
10 8 13 A c 1274 0 66
15 10 42 Y c 1313 0 68
16 12 71 P c 826 0 47
17 13 42 M c 338 0 18
18 13 74 V c 2027 1 06
19 14 93 dptu 63194 37 46
20 15 12 mptc r 176901 286 85
22 16 26 dpu 574 0 53
23 16 57 F c 5109 2 67
24 17 04 I c 659 0 47
25 17 28 K c 498 0 1726 17 55 L c 1313 0 68
XIII
Applied Biosystems Procise - PROCISE
-09-1998 08 48 98C444-980613-fr41-100%
98C444-980613-£r41-100% 15 Residue 13
15 Residue 13, Interpolated baseline
Peak No RT Peak ID Type Height Pmol Ht2 3 95 X c 4767 1 843 4 28 N c 1089 0 38
4 4 96 S c 1223 0 67
5 5 20 Q c 1128 0 486 5 52 T c 937 0 527 5 78 G c 3377 1 758 6 22 E c 1859 0 739 6 68 dmp 307 0 3811 8 14 A c 1054 0 5513 9 80 R c 287 0 1914 10 43 Y c 5334 2 7818 12 75 P c 508 0 2920 13 43 M c 186 0 1021 13 73 V c 1285 0 6723 14 94 dp tu 55846 33 1024 15 13 mptc r 165800 268 8526 15 87 W c 149 0 0627 16 58 F c 2696 1 4128 17 02 I c 342 0 2429 17 55 L c 1873 0 97
XIV
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\  EUROSEQUENCE*
synthesis and analysis of peptides, proteins and oligonucleotides
INTERPRETATION PROTEIN SEQUENCE ANALYSIS RESULTS
See also 'Product Information Protein Sequence Analysis' for explanation of 
'Initial Yield' and amino acids in parentheses.
Our order number »  980613 
Product code »  98C444 Sample* 980613-(I+III)-T-fr. 41
Sample amount 
Date of analysis 
Performed
Date of interpretation report 
Interpreted by
100%
September 25, 1998 
14 cycles 
October 30, 1998 
Dr. Wicher J Weiner
MAIN SEQUENCE
Position # 1  5 10 14
Amino Acid Ser-Thr-Val-Ser-Leu-Thr-(Cys?)-Met-Val-Thr-Ser-Phe-Tyr-Pro
Initial Yield appr 10 pmol
Remarks
1. Fraction 41 of HPLC 98E178 was analyzed
2 At position 7 there are some indirect indications for the presence of a 
cysteine
Signature Signature
(’investigator’) {•verifier1)
XV|
Appendix 3
3 Standard protocols
The lysis of cells disintegration of isolated ccll membranes and solubilization of 
proteins is a crucial step for subsequent immunoprécipitation 1 he method should 
ensure solubilization of the target protein m a form that is immunoro'icUve undeg 
n ded  and ideally biologically active Variables influencing the efficicncy of solu 
bihzahon and subséquent immunoprécipitation of proteins arc the ionic sttenglh 
and pH of the lysis buffer type and concentration of dcteigents used piesence ol 
divalent cations and other factors (3 4)
In the following protocols are given for biotinylation of sut face proteins on intact 
cells {3 2 ) or membrane preparations (3 3 ) and for total cell homogenates (3 4 ) 
These standard protocols serve as general guidelines and first choice protocols but 
may be varied to meet special needs
Note Biotin 7 NHS reacts with free amino groups Do not use Tns buffers or bui 
fers containing ammonium ions or sodium azide for the biotin labeling reaction In 
case of contamination with these substances extensive dnlyzing or desalting on 
appropriate columns is recommended
3 1 Buffers required
Phosphate buffered saline (PBS)
Dissolve 8 g of NaCI 0 2 g of KCI 1 44 g of Na2H P 0 4 and 0 24 g of KHt P 0 5 in 
800 ml of redist H?0  Adjust the pH to 7 4 with HCI Add H O to 1 I Dispense 
the solution into aliquots and autoclave Store at room temperature
- NaCI 1 M, 100 ml
Dissolve 5 04 g of NaCI m 80 ml of redist water Adjust the volume to 100 ml 
with redist water Dispense into aliquots and steulize by auloclaving
Buffers listed in table 1 (Note not all buffers are needed for particular 
applications amounts were calculated for at least 10 labeling réactions) 
Prepare the daily requirements only
Tab 1 Preparation ol bullers
Stock
solutions
Biotmy-
lation
buffer
Final
conc
Lysis
buffer
Final
conc
Homogeni 
zmg buffer
Final con­
centration
Core buffer 4 0 ml 50 mM 4 ml 50 mM 12 m! 50 mM
NaCI 1 R nil 150 mM 1 8 ml 150 mM 5 4 ml 150 mM
PMSF 0 12 ml 0 1 mg/ml 0 36 ml 0 1 mg/ml
Aprolinin 1 2 pi 1 |ig/ml 3 6 (il 1 il g/ml
Leupeptm 1 2 Ml 1 Mg/nrt 3 6 pi 1 (.ig/ml
Nonidet’ P 40 1 2 ml 1%
Sodium
deoxycholate 0 6 ml 0 5%
Redist water 6 2 ml 4 3 ml 18 2 ml
Final volume 12 0 ml 12 0 ml 36 0 ml
3 2 Biotin-labeling of cell surface proteins on intact cells, preparation for immuno 
precipitation
Wash cells at least twice with ice cold PBS to remove any remaining serum 
proteins from the culture medium Adherent cells should be washed by addition 
of PBS to the monolayer and the supernatant discarded Cells in suspension 
should be washed by centrifugation and the pellet resuspended Carefuliy 
remove PBS from ceils after the last w ish
Add biotmylation buffer to the washed cell monolayers (volumes as indicated in 
tabic 2) or lo the cell sediment at a concentration of 10G 107 cells/ml suspend 
pelleted cells
Note A ccll concentration no higher than 1 x 107 cells per ml should be used to 
ensure optimal vectorial labeling and cell recovery
T ib  2 C o n d ition  between cell number in d  biotinyhtion buffer
Volume of biotmylation  
buffer (ml)
Size of petri dish or well 
diam eter (mm)
Approxim ate num ber of 
cells
1 0 90 106 107
0 5 60 5 x 105 5 x 10°
0 25 35 105 105
0 25 30 105 106
Add 5 j.il of biotin 7 NHS slock solution lo 1 ml of suspension mix and incubati 
for 15 mm at room temperature
Stop the reaction by adding 50 pi of stop solution per ml (final concentration 
50 inM NH4CI) ind  incubale for 15 mm at room temperature or on ice 
Wash the cells in PBS
Extract cells in lysis buffer (up to 106 cells 0 5 ml and 105 107 cells 1 ml c 
lysis buffer) for 30 min on ice If suspension cells are used proceed with som 
cation of the suspension (three steps ahead)
Scrape the cells to one side of the dish with a suitable device 
Transfer lo a chilled microfuge tube
Sonicate the suspension (3 pulses 30 s each) on ice and extract for a furthc 
30 nun on ice
Centrifuge the lysate at 12 000 g for 10 mm at 4°C  in a table top microfuge 
Transfer the supernatant to a fresh microfuge tube and store it on ice ( 
at 70°C depending on the sensitivity ol the target antigen lo freezing an 
thawing
Continue with the immunoprécipitation procedure (3 5 )
3 3 Isolation of m em branes, biotm labeling of m em brane proteins and their pr 
paration for im m unoprécipitation
Wash cells at least twice with ice cold PBS to remove any remaining seru 
proteins from the culture medium Adherent cells should be washed by additx 
of PBS to the monolayer and the supernatant discarded Cells m suspensi 
should be washed by centrifugation and the pellet resuspended 
Add homogenizing buffer (cooled to 4 ‘ C) to the chilled washed cell mor 
layers or to the cell sediment at a concentration of 106 107 cells/ml (see tat 
2) to give a total volume of 1 3 ml If suspension cells are used proceed w 
ultrasonic treatment of suspension (three steps ahead)
Scrape the cells to one side of Ihe dish with a suitable device 
Transfer the suspension to a chilled microfuge tube 
Homogenize cells by ultrasonic treatment
7 B0EHR1NGER MANNHE
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Centrifuge the homogenized suspension at 12^000^ 12 min 4°C m,a table ^  
top microiuge to remove debris ¿ -A / -f  ^ ^
Separate the supernatant and transfer Jo a tube for ultracentnfugTlion , 
Centrifuge the solution at 100 000 g 45 nun 4 C (o*pellet the ceil mcm bnnc 
fraction
Resuspend ihe membrane pellet in 1 ini of lysis buffer Sonicate and incubate 
30 mm at 4 C j
Add 5 }il of bioltn /  NHS slock olulion mix and incubate foi 15 mm on ice 
Slop the reaction by adding 50 jii of olop.solulion pc^mt (fin il concenti ilion 
50 m M N H ,C I) u  , ,l\$ 1
Store sample on ice or at 70 C depending1 on tthe sensitivity of tnrget antigen 
to freezing and thawing i * f j  1 I !■»' /
/ - O v  Continue with immunoprecipitation procedure 1(3 5) J t
( V 1 f " I\ 3  4 Biotin labeling of total proteins and recom birnnt proteins from cucaryotic  
'expression systems and their preparation for im m unoprecipitation
The basic protocol provided heic may be used with minor modifications lor other 
expression systems like yeast or bacteria ;
Wash cells at leist twice with ice cold PBS to remove nny icm tuninq sr rum 
proteins from the culture medium Adherent cells should be washed by the 
addition ot PBS to the monolayer and the supernatant discarded Cells in sus 
pension should be washed by centrifugation 'ind the pellet lesuspended 
Add lysis bufler (cooled to A C) to the chilled washed ccll monohyeio (appiox 
cell number per volume sec table 2 ) or lo the enll sediment it i eoncentr ition 
of 10' 10 cells/ml If suspension cells arc used proceed with somcation of the 
suspension (1 2 ml) (three steps ihead)
Srr ipp thn cell0 to one side of the di h with n suitable device 
Transfer 1 2 ml to i ehilled mictofuge lube
Sonicate (3 pulses 30 s each) on ire and incubate for 30 nun at 4 C 
Centrifuge the iysnte at 12 000 g (or 10 min at 4 C in a tnble lop microiuge 
Transfer the supernatant to a fresh microiuge tube
Add 25 pi of biotin 7 NHS stock solution to 1,'ml of the sample mix and incu 
bate for 15 nun at A°C '
Slop Ihe icnction by ndding 50 of slop solution per ml (fin ii conccntr Uioii 
50 mM NH4CI) and incubate lor 15 nun at 4 C 
Continue with the immunoprecipitation procedure (3 5)
3 5 Imm unoprecipitation of the target protein
3 5 1 Solutions required 1 ‘ .
I
1 M Tris buffer, pH 7 5, 50 ml ! *
Dissolve 12 1 g of Tris base in 80 ml of redist water Adjust lo pH 7 5 by 
adding about 6 5 ml of conc HCI Adjust the; volume of the solution to 100 ml 
with redist water Dispense into aliquots and sterilize by autoclaving Store at 
room temperature •'
- NaCI, 1 M, 100 ml
Dissolve 5 84 g of NaCI in 80 ml of redist water Adjust the volume to 100 ml 
with redist water Dispense into aliquots and sterilize by autoclaving Store at 
room temperature i
Buffers listed in table 3 (amounts were calculated for at least 10 labeling 
reactions) Prepare the daily requirements only , ,
Tab 3 Preparation of buffers
Stock
s o lu t io n
Dilution
buffer
Final
conc
Wash  
buffer 1
Final
conc
W ash  
buffer 2
Final
conc
Wash 1 
buffer 3
Fmal,1^  
conc *
fns buffer 0 6 ml 50 niM 2 A ml 50 mM 2 4 ml 50 mM 0 24 ml 10 mM
NaCl 1  0 ml 150 mM 7 2 ml 150 mM 24 0 ml 500 mM * /
Nonidct 
P 40 0 12 ml 0 1 0 4fi ml 0 1% 0 40 ml 0 1%
, i
Aprolinm 1 2 jil 1 jig/ml
Leupeptin 1 2 (il 1 ng/mi ji / e >
PMSF 0 12 ml 100 pg/ml l *- *i
Rodisi wnler 7 8 ml 30 0 ml 21 1 ml 23 8 mli *  (<**
Final
volume 12 0 ml 48 0 ml 40 0 ml 24 0 ml!
J ftT ,‘u  
* »?IV- I ,
Not provided With the Kit s
ContioJ mlibody (preimmune st. ruin or mo!cv<int monoclonal antibody) , ^
3 5 2 Assay procedure <
Divide Ihc preparations oi antigen (1 ml) into two or more equally sized aliquots 
and pi icc in microfuqe tubes Adjust the volume ol each aliquot to 1 0 ml with 
dilution buffer Add 50 jil ol ptoloin A agarose suspension (50 n1 beads pei 
I ml of o imple) to two ol those aliquots Gcntiy rock both aliquots lor 1 3 h a4 C I i,
Pf liel be ids by gravity s< dimcntition or alternatively by centnlugation a 
1? 000 q  for >0 s in i microfuye Transfer supernatants to fresh tubes 
Note In oO inc e ioc on e  or iw o  iddilionai lb^orption steps may be noccssar 
to completely remove proteins that may bind to protein A agarose (e g ant 
bodies contained in the culture medium and bound to the cell surface)
To one aliquot add antibody directed against the target protein To the o th e  
add the same volume of a control antibody (preimmune serum or an irrelevar 
monoclon il antibody) GenlJy rock both aliquots for 1 h at 4"C 
Note 1 lie antibody should be titrated m pilot experiments in which increasm 
quantities of antibody arc used to precipitate a fixed amount of andger 
Usually between 0 5 fil and 5 |tl of polyclonal antiserum 5 pi and 100 pi ( 
hybridoma tissue culture medium 0 1 and 1 0 ¿il of ascitic fluid or 1 pg an
5 ng of purified monoclonal or polyclonal antibodies are sufficient for comple' 
fmmunoprccipitation
Add protein A agarose to the mixture and incubate for at least 3 h (or ove 
night) at 4 ’C on a rocking platform 50 of the homogeneous protein A-ag 
rose suspension are usually sufficient the amount of protein A agarose! shou 
at least result in a visible pellet after sedimentation i 'U
Note 1 ml of protein A agarose binds about 20 mg of IgG equivalent to abc 
2 ml of serum 200 ml of supernatant from cultured hybridoma cells 'a n d  1 
ascites fluid , ’’
Pioiem A binds the Fc parts of most m a m m a lia n  JgGs with high 'affinity by 
non immune mechanism (4) The binding capacity depends on the'amrr 
spccies and the IgG subclass (see table 4) Protein A does not bind olf" 
immunoglobulins like IgM IgA etc and bovine serum albumin In the case tf 
the primary antibody in use is not compatible with the protein A a g a ro s e  p 
vided with this kit switch to protein G agarose or immobilized anti Ig antibc 
(4) Cut the pipette tip for pipetting the bead suspension
RnFHRiNfiFR MANNHE
Tab 4 Binding specificities of protein A i  i
Species/subclass Affinity for 
protein A
Species/
subclass
Affinity for 
protein A
Human IgG, ++++ 1 Horse ++
lgG2 ++++ Cow ++'
ig c , ' Pig +++
igG, ++++ b Sheep , +/
Rat IgG, s ,Goat i
igG2a iRabbit +++1-
igGib ,Chicken
igG2c + Hamster +
Mouse IgG, + f Guinea pig J-+++
igG2a ++++
IgG;* +++
igG3 ++ (
t  f
j
Collect complexes by gravity sedimentation or alternatively by ce n trifu g a tio n  at 
12 000 g for 20 s »n a microfuge v
Remove supernatant carefully i
Add 1 ml of wash buffer 1 resuspend the beadsiand incubate for 20 min at 4 C
on a rocking platform
Repeat the preceding three steps once
Collect complexes as described add 1 ml of wash buffer 2 to the pellet resus 
pend incubate for 20 min at 4cC on a rocking platform pellet the beads again 
and remove the supernatant
Note Different buffers are commonly used to wash protein A antigen antibody
complexes The tighter the binding between antibody and antigen the more
stringent the washing buffer conditions can bo The washing buffers described 
are used if low stringency conditions are appropriate If higher stringency is 
needed increase the salt concenliation and tonic strength by using 0 5  M NaCI 
or 0 5  M LiC) lor Ihe firsl wash Addjlionally SDS (final conccnlratjon 0 1% 
(w/v)) may be applied in the second wash 
Repeat previous step
Add 1 ml of wash buffer 3 to the pellet resuspend incubate for 20 min at 4JC 
on a rocking platform pellet the beads again and remove the supernatant 
Remove the last traces of the final wash from the agarose pellet and from the 
wall and lid of the microfuge tube !!
Add 25 75 Ml of gel loading buffer i ,
Denature proteins by heating to 100°C for 3 min Remove protein A agarose by 
centrifugation at 12 000 g for 20 s at room temperature in a microfuge Transfer 
supernatant to a fresh tube
Analyze an aliquot by SDS polyacrylamide gel electrophoresis
i3 6 Gel electrophoresis
The biotin labeled and immunoprecipitated proteins can be separated by any type 
of one and two dimensional eloctrophoresis system providing sufficient protein 
resolution (5 6 7)
For a detailed protocol for SDS polyacrylamide gel electrophoresis or two dimen 
sional electrophoresis please refer to one of the standard textbooks or to manuals 
from manufacturers of electrophoresis equipments
3 7 Western blotting ,
After electrophoresis blot the gel onto a nitrocellulose or PVDF membrane using a 
standard Western blot protocol (8 9) 1 (
Note To avoid damage or contamination of the membrane always wear g lo v e s
when handling 1 *
•  Hydrophobic membranes such as PVDF must be pre wetted prior to protein 
transfer moisten the membrane with methanol for a few seconds then soak in 
transfer buffer for at least 5 mm Nitrocellulose should be briefly soaked in 
water and then for at least 5 mm in transfer buffer i
0 It is essential to thoroughly equilibrate the gel in transfer buffer for 5 10 min 
prior to transfer
•  Blot according to standard protocols 1 < >
O The blot can be stored dry for several months in a refrigerator if necessary but^ 
must be re wetted before starting immunodetection PVDF membranes should 
be re wetted in methanol or in 5% Tween 20 (v/v)
3 8 Visualization of biotm labeled proteins on mem branes (
There are a number of reagents and kits available which can be used for the visua 
lization of biotm labeled proteins on membranes (table 5)
Tab 5 Suitable products lor the detection of biotm labeled proteins on Western blots
Product Pack size Cat No
BM Chemiluminescence Western 
Blotting Kit (Biotm/Streptavidm) For 1000 cm2 of membrane 1559 460
BM Chcmilummescence Western 
Blotting Reagents
For 1000 c m 2 of m e m b ra n e  
For 4000 cm2 of membrane
1500 708 
1500 694
Streptavidm POD conjugate 500 U 1089 153
Streptavidm AP conjugate 1000 U 1089 161
BM Teton POD substrate precipitating 200 mg 1544 845
BM blue POD substrate precipitating 100 ml 1442 066
BM purple AP substrate precipitating 100 ml 1442 074
4 Nitro blue tetrazolium chloride (NBT) 3 ml (300 mg) 1383 213
5 Bromo 4 chloro 3 indolyl phosphate 
(X phosphate) 3 ml (150 mg) 1383 221
Blocking reagent for n u c le ic  acid 
hybridization and detection 50 g 1096 176
In principle the membrane is first incubated in a suitable blocking reagent to pre 
vent non specific binding of conjugate or substrate The biotin labeled proteins are 
then reacted with a streptavidm enzyme conjugate Excess conjugate is removed 
by washing and bands are visualized by a suitable substrate
nrtrunwiOCD MAMMUCIM
